<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        449-212-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BANORIV 2.5MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RIVAROXABAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        190.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AF01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have been diagnosed with a high risk of getting a blood clot due to a coronary artery disease or peripheral artery disease which causes symptoms.Banoriv reduces the risk in adults of getting blot clots (atherothrombotic events). Banoriv will not be given to you on its own. Your doctor will also tell you to take acetylsalicylic acid.</p><p>&nbsp;</p><p>Banoriv contains the active substance rivaroxaban and belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Banoriv</strong></p><ul><li>if you are allergic to rivaroxaban or any of the other ingredients of this medicine (listed in section 6)</li><li>if you are bleeding excessively</li><li>if you have a disease or condition in an organ of the body that increases the risk of serious bleeding (e.g., stomach ulcer, injury or bleeding in the brain, recent surgery of the brain or eyes)</li><li>if you are taking medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), except when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open</li><li>if you have an acute coronary syndrome and previously had a bleeding or a blood clot in your brain (stroke)</li><li>if you have coronary artery disease or peripheral artery disease and previously had a bleeding in your brain (stroke) or where there was a blockage of the small arteries providing blood to the brain&rsquo;s deep tissues (lacunar stroke) or if you had a blood clot in your brain (ischaemic, non-lacunar stroke) in the previous month</li><li>if you have a liver disease which leads to an increased risk of bleeding</li><li>if you are pregnant or breast feeding</li></ul><p><strong>Do not take Banoriv and tell your doctor</strong>&nbsp;if any of these apply to you.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Banoriv.</p><p>Banoriv should not be used in combination with certain other medicines which reduce blood clotting such as prasugrel or ticagrelor other than aspirin and clopidogrel/ticlopidine.</p><p><strong>Take special care with Banoriv</strong></p><ul><li>If you have an increased risk of bleeding, as could be the case in situations such as:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe kidney disease, since your kidney function may affect the amount of medicine that works in your body</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking other medicines to prevent blood clotting (e.g. Warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section &ldquo;other medicines and banoriv&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding disorders</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very high blood pressure, not controlled by medical treatment</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diseases of your stomach or bowel that might result in bleeding, e.g. Inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet) e.g. Due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A problem with the blood vessels in the back of your eyes (retinopathy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are older than 75 years</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You weigh 60 kg or less</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have a coronary artery disease with severe symptomatic heart failure</p><ul><li>If you have a prosthetic heart valve</li><li>If you know that you have a disease called antiphospholipid syndrome (a disorder of the immune system that causes an increased risk of blood clots), tell your doctor who will decide if the treatment may need to be changed.</li></ul><p><strong>If any of the above apply to you, tell your doctor</strong>&nbsp;before you take Banoriv. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.</p><p><strong>If you need to have an operation:</strong></p><ul><li>It is very important to take Banoriv before and after the operation exactly at the times you have been told by your doctor.</li><li>If your operation involves a catheter or injection into your spinal column (e.g. For epidural or spinal anaesthesia or pain reduction):<ul><li>It is very important to take Banoriv before and after the injection or removal of the catheter exactly at the times you have been told by your doctor</li><li>Tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.</li></ul></li></ul><p><strong>Children and adolescents</strong></p><p>Banoriv is&nbsp;<strong>not recommended for people under 18 years of age.</strong>&nbsp;There is not enough information on its use in children and adolescents.</p><p><strong>Other medicines and Banoriv</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><ul><li><strong>If you are taking:</strong><ul><li>Some medicines for fungal infections (e.g. Fluoconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin.</li><li>Ketoconazole tablets (used to treat cushing&rsquo;s syndrome - when the body produces an excess of cortisol)</li><li>Some medicines for bacterial infections (e.g. Clarithromycin, erythromycin)</li><li>Some anti-viral medicines for hiv / aids (e.g. Ritonavir)</li><li>Other medicines to reduce blood clotting (e.g. Enoxaparin, clopidogrel or vitamin k antagonists such as warfarin and acenocoumarol, prasugrel and ticagrelor (see section &ldquo;warnings and precautions&rdquo;))</li><li>Anti-inflammatory and pain relieving medicines (e.g. Naproxen or acetylsalicylic acid)</li><li>Dronedarone, a medicine to treat abnormal heart beat</li><li>Some medicines to treat depression (selective serotonin reuptake inhibitors (ssris) or serotonin norepinephrine reuptake inhibitors (snris))</li></ul></li></ul><p><strong>If any of the above apply to you, tell your doctor</strong>&nbsp;before taking Banoriv, because the effect of Banoriv may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.<br />If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.</p><ul><li><strong>If you are taking:</strong><ul><li>some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)</li><li>St John&rsquo;s Wort (<em>Hypericum perforatum</em>), a herbal product used for depression</li><li>rifampicin, an antibiotic</li></ul></li></ul><p><strong>If any of the above apply to you, tell your doctor</strong>&nbsp;before taking Banoriv, because the effect of Banoriv may be reduced. Your doctor will decide, if you should be treated with Banoriv and if you should be kept under closer observation.</p><p><strong>Pregnancy and breast feeding</strong></p><p>Do not take Banoriv if you are pregnant or breast feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Banoriv. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.</p><p><strong>Driving and using machines</strong></p><p>Banoriv may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, &lsquo;Possible side effects&rsquo;). You should not drive or use machines if you are affected by these symptoms.</p><p><strong>Banoriv contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p>The recommended dose is one 2.5 mg tablet twice a day.</p><p>Take Banoriv around the same time every day (for example, one tablet in the morning and one in the evening).</p><p>This medicine can be taken with or without food.</p><p>If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Banoriv. The tablet may be crushed and mixed with water or apple puree immediately before you take it.</p><p>If necessary, your doctor may also give you the crushed Banoriv tablet through a stomach tube.</p><p>Banoriv will not be given to you on its own. Your doctor will also tell you to take either:</p><ul><li>acetylsalicylic acid (also known as aspirin) or</li><li>acetylsalicylic acid plus clopidogrel or ticlopidine.</li></ul><p>Your doctor will tell you how much of these to take (usually between 75 to 100 mg acetylsalicylic acid daily or a daily dose of 75 to 100 mg acetylsalicylic acid plus a daily dose of either 75 mg clopidogrel or a standard daily dose of ticlopidine).</p><p><strong>When to start Banoriv</strong></p><p>Your doctor will tell you when to start treatment with Banoriv if you have been diagnosed with coronary artery disease or peripheral artery disease.</p><p>Your doctor will decide how long you must continue treatment.</p><p><strong>If you take more Banoriv than you should</strong></p><p>Contact your doctor immediately if you have taken too many Banoriv tablets. Taking too much Banoriv increases the risk of bleeding.</p><p><strong>If you forget to take Banoriv</strong></p><p>Do not take a double dose to make up for a missed dose. If you miss a dose, take your next dose at the usual time.</p><p><strong>If you stop taking Banoriv</strong></p><p>Take Banoriv on a regular basis and for as long as your doctor keeps prescribing it.</p><p>Do not stop taking Banoriv without talking to your doctor first. If you stop taking this medicine, it may increase your risk of having another heart attack or stroke or dying from a disease related to your heart or your blood vessels.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Banoriv can cause side effects, although not everybody gets them.</p><p>Like other similar medicines (antithrombotic agents), Banoriv may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.</p><p><strong>Possible side effects which may be a sign of bleeding:</strong></p><p><strong>Tell your doctor immediately</strong>&nbsp;if you experience any of the following side effects:</p><ul><li>long or excessive bleeding</li><li>exceptional weakness, tiredness, paleness, dizziness, headache, unexplained swelling, breathlessness, chest pain or angina pectoris, which may be signs of bleeding.</li></ul><p>Your doctor may decide to keep you under closer observation or change how you should be treated.</p><p><strong>Possible side effects which may be a sign of severe skin reaction:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>Tell your doctor immediately if you experience</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin reactions such as spreading intense skin rash, blisters or mucosal lesions, e.g. in the mouth or eyes (Stevens-Johnson syndrome/Toxic Epidermal Necrolysis). The frequency of this side effect is very rare (Up to 1 in 10,000).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS syndrome). The frequency of this side effect is very rare (up to 1 in 10,000).</p><p><strong>Possible side effects which may be a sign of severe allergic reactions</strong></p><p><strong>Tell your doctor immediately</strong>&nbsp;if you experience any of the following side effects:</p><ul><li>swelling of the face, lips, mouth, tongue or throat; difficulty swallowing; hives and breathing difficulties; sudden drop in blood pressure. The frequencies of these side effects are very rare (anaphylactic reactions, including anaphylactic shock; may affect up to 1 in 10,000 people) and uncommon (angioedema and allergic oedema; may affect up to 1 in 100 people).</li></ul><p>&nbsp;</p><p><strong>Overall list of possible side effects:</strong></p><p><strong>Common</strong>&nbsp;(may affect up to 1 in 10 people):</p><ul><li>Bleeding in the stomach or bowel, urogenital bleeding (including blood in the urine and heavy menstrual bleeding), nose bleed, bleeding in the gum</li><li>Bleeding into the eye (including bleeding from the whites of the eyes)</li><li>Bleeding into tissue or a cavity of the body (haematoma, bruising)</li><li>Coughing up blood</li><li>Bleeding from the skin or under the skin</li><li>Bleeding following an operation</li><li>Oozing of blood or fluid from surgical wound</li><li>Swelling in the limbs</li><li>Pain in the limbs</li><li>Fever</li><li>Reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</li><li>Stomach ache, indigestion, feeling or being sick, constipation, diarrhoea</li><li>Low blood pressure (symptoms may be feeling dizzy or fainting when standing up)</li><li>Decreased general strength and energy (weakness, tiredness), headache, dizziness</li><li>Rash, itchy skin</li><li>Impaired function of the kidneys (may be seen in tests performed by your doctor)</li><li>Blood tests may show an increase in some liver enzymes</li></ul><p><strong>Uncommon</strong>&nbsp;(may affect up to 1 in 100 people):</p><ul><li>Bleeding into the brain or inside the skull</li><li>Bleeding into a joint causing pain and swelling</li><li>Thrombocytopenia (low number of platelets, which are cells that help blood to clot)</li><li>Fainting</li><li>Feeling unwell</li><li>Dry mouth</li><li>Faster heartbeat</li><li>Allergic reactions, including allergic skin reactions</li><li>Hives</li><li>Impaired function of the liver (may be seen in tests performed by your doctor)</li><li>Blood tests may show an increase in bilirubin, some pancreatic or liver enzymes or in the number of platelets</li></ul><p><strong>Rare</strong>&nbsp;(may affect up to 1 in 1,000 people):</p><ul><li>Bleeding into a muscle</li><li>Cholestasis (decreased bile flow), Hepatitits incl. hepatocellular injury (inflamed liver incl. liver injury)</li><li>Localised swelling</li><li>Yellowing of the skin and eye (jaundice)</li><li>Collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)</li></ul><p><strong>Not known</strong>&nbsp;(frequency cannot be estimated from the available data):</p><ul><li>increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)</li><li>kidney failure after a severe bleeding</li></ul><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is rivaroxaban. Each tablet contains 2.5 mg of rivaroxaban.</li><li>The other ingredients are:<br />Tablet core:</li></ul><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactose BP 200,Avicel PH 101,Hydroxypropyl Methylcellulose,Sodium Lauryl Sulphate,Croscarmellose Sodium Type-A,Magnesium Stearate.</p><p><br />Tablet film coat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydroxypropyl Methyl Cellulose,Titanium Dioxide Pharma Grade,Purified Talc,Polyethylene Glycol MW 6000,Iron Oxide Red,Purified Water BP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink to dark pink coloured, round, biconvex, film-coated tablet, engraved with “261” on one side and plain on the other side.
Each pack contains 10 or 60 film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation.</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb 2020.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&bull; يوصف بانوريڤ أيضا إذا تم تشخيصك بزيادة خطورة الإصابة بجلطة دموية بسبب مرض الشريان التاجي أو مرض الشريان المحيطي الذي يسبب الأعراض. يقلل بانوريڤ من خطر الإصابة بالجلطات (أمراض تصلب الشرايين). لن يوصف لك بانوريڤ وحده. سيخبرك طبيبك أيضًا بتناول حمض استيل ساليسيلات (المعروف أيضا باسم الأسبرين).</p><p dir="RTL">بانوريڤ يحتوي على المادة الفعالة ريفاروكسيبان والتى تنتمي إلى مجموعة من الأدوية تسمى مضادات التجلطات.&nbsp;وهو يعمل عن طريق منع عامل تخثر الدم (عامل رقم عشرة)، وبالتالي الحد من ميل الدم إلى تشكيل جلطات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول بانوريڤ </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من ريفاروكسيبان أو أي من المكونات الأخرى من هذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تنزف بشكل مفرط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض أو حالة في أحد أجهزة الجسم الذي يزيد من خطر النزيف الشديد (مثل قرحة المعدة أو إصابة أو نزيف في الدماغ، جراحة حديثة في الدماغ أو العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية لمنع تخثر الدم (مثل الوارفارين، دابيجاتران، ابيكسابان أو الهيبارين)، إلا في حالة تغيير العلاج المضاد للتخثر أو في حالة اعطاء الهيبارين من خلال الوريد أو الشريان لإبقائها مفتوحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك متلازمة الشريان التاجي الحادة وسبق أن تعرضت لنزيف أو جلطة دموية في الدماغ (السكتة الدماغية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض الشريان التاجي أو أمراض الشريان المحيطي وكان لديك في السابق نزيف في المخ (السكتة الدماغية) أو حيث كان هناك انسداد في الشرايين الصغيرة التي توفر الدم لأنسجة المخ العميقة (السكتة الدماغية الجوبية) أو إذا كان لديك جلطة دموية في المخ (السكتة الدماغية غير الجوبية الناجمة عن نقص التروية) في الشهر السابق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض في الكبد مما يؤدي إلى زيادة خطر النزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من الحوامل أو المرضعات.</p><p dir="RTL"><strong>لا تأخذ بانوريڤ وأخبر طبيبك</strong>&nbsp;إذا كان أي من هذه تنطبق عليك.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني قبل تناول بانوريڤ .</p><p dir="RTL">بانوريڤ لا يجب أن يوصف مع الأدوية الأخرى التي تقلل من تجلط الدم مثل براسوجريل أوتيكاجريلول أو أي آخرين بخلاف الأسبرين وكلبيدوجريل وتيكلوبيدين.</p><p dir="RTL"><strong>أعطي عناية خاصة مع بانوريڤ </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك زيادة خطر النزيف، كما يمكن أن يكون هذا هو الحال في حالات مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الكلى الحادة ، حيث أن وظيفة الكلى الخاصة بك قد تؤثر على كمية الدواء التي تعمل في جسمك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ أدوية أخرى لمنع تخثر الدم (مثل الوارفارين، دابيجاتران، ابيكسيبان أو الهيبارين)، عند تغيير العلاج المضاد للتخثر أو في حالة اعطاء الهيبارين من خلال الوريد أو الشريان لإبقائها مفتوحة. (انظر فقرة &nbsp;&quot;الأدوية الأخرى وبانوريڤ &quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النزيف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع شديد في ضغط الدم، الغير مستجيب للعلاج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض المعدة أو الأمعاء التي قد تؤدي إلى نزيف، مثل التهاب الأمعاء أو المعدة، أو التهاب في المريء على سبيل المثال بسبب مرض الارتجاع المعدي المريئي (حيث يرتد حمض المعدة صعودا إلى المريء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة في الأوعية الدموية في الجزء الخلفي من العين (اعتلال الشبكية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احد أمراض الرئة حيث تتسع القصبات و تمتلئ بالقيح، أو نزيف سابق من الرئة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أكبر من 75 عاما</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تزن 60 كجم أو أكثر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أمراض الشرايين التاجية مع فشل في عضلة القلب المصاحب له أعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك صمام قلب صناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أن لديك مرضًا يسمى متلازمة الفوسفوليبيد (اضطراب في الجهاز المناعي الذي يسبب زيادة خطر جلطات الدم) ، أخبر طبيبك الذي سيقرر ما إذا كان العلاج قد يحتاج إلى تغيير.</p><p dir="RTL"><strong>إذا كان أي من أعلاه ينطبق عليك، أخبر طبيبك</strong>&nbsp;قبل أن تتناول بانوريڤ .&nbsp;سوف يقرر الطبيب، إذا كان يجب أن تتناول هذا الدواء أم لا، وإذا كان يجب أن تبقى تحت الملاحظة الأدق.</p><p dir="RTL">إذا كنت بحاجة إلى عملية جراحية:</p><p dir="RTL">من المهم للغاية أن تتناول بانوريڤ قبل وبعد العملية بالضبط في المرات التى أخبرك بها الطبيب.</p><p dir="RTL">إذا تضمنت العملية الخاصة بك قسطرة أو الحقن في العمود الفقري الخاص بك (على سبيل المثال للتخدير فوق الجافية أو العمود الفقري أو الحد من الألم):</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من المهم جدا أن تأخذ بانوريڤ قبل وبعد الحقن أو إزالة القسطرة تماما في الأوقات التي أخبرك بها الطبيب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك فورا إذا كان لديك خدر أو ضعف الساقين أو مشاكل في الأمعاء أو المثانة بعد انتهاء التخدير الخاص بك، لأن الرعاية العاجلة في هذه الحالة أمر ضروري.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL"><strong>لا ينصح</strong>&nbsp;<strong>بتناول</strong> <strong>بانوريڤ</strong> <strong>لمن هم دون 18 سنة من العمر.</strong>&nbsp;ليست هناك معلومات كافية عن استخدامه في الأطفال والمراهقين.</p><p dir="RTL"><strong>الأدوية الأخرى وبانوريڤ </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تتناول:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للأمراض الفطرية (مثل الفلوكونازول، الايتراكونازول، فوريكونازول، بوساكونازول)، ما لم يتم وضعها على الجلد فقط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الكيتوكونازول (تستخدم لعلاج متلازمة كوشينغ - عندما يزيد إنتاج الجسم من الكورتيزول)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية للعدوى البكتيرية (مثل كلاريثروميسين ، إريثروميسين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المضادة للفيروسات لعلاج فيروس نقص المناعة البشرية / الإيدز (على سبيل المثال ريتونافير)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لتقليل تخثر الدم (مثل اينوكسابارين، كلوبيدوجرل أو مضادات فيتامين K مثل الوارفارين وأسينوكومارول وبراسوجريل و تيكاجريلول( انظر قسم التحذيرات والاحتياطات))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للالتهابات وتخفيف الألم (مثل نابروكسين أو حمض استل ساليسلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دروندارون ، وهو دواء لعلاج ضربات القلب الغير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الاكتئاب (مثبطات إعادة امتصاص السيروتونين الانتقائية ،مثبطات إعادة إمتصاص السيروتونين والنورإيبنفرين).</p><p dir="RTL"><strong>إذا كان أي من أعلاه ينطبق عليك، أخبر طبيبك</strong>&nbsp;قبل تناول بانوريڤ ، لأن تأثير بانوريڤ قد يزيد.&nbsp;سوف يقرر الطبيب، إذا كان يجب أن تتناول هذا الدواء، وإذا كان يجب أن تبقى تحت الملاحظة الأدق.</p><p dir="RTL">وإذا كان الطبيب يعتقد انك في خطر متزايد لحدوث قرحة المعدة أو الأمعاء، يمكن أيضا أن ينصحك باستخدام علاج قرحة وقائية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تتناول:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية لعلاج الصرع (الفينيتوين، كاربامازيبين، الفينوباربيتال)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سانت جون ورت <em>،</em>&nbsp;وهو منتج عشبي يستخدم لعلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، وهو مضاد حيوي</p><p dir="RTL"><strong>إذا كان أي من أعلاه ينطبق عليك، أخبر طبيبك</strong>&nbsp;قبل تناول بانوريڤ ، لأن تأثير بانوريڤ ربما ينخفض.&nbsp;سوف يقرر الطبيب، إذا كان يجب أن تتناول بانوريڤ وإذا كان يجب أن تبقى تحت الملاحظة الأدق.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تتناولي بانوريڤ إذا كنت من الحوامل أو المرضعات.&nbsp;إذا كان هناك فرصة أن تصبحي حاملا، استخدمي وسائل منع الحمل يمكن الاعتماد عليها أثناء العلاج ب بانوريڤ .&nbsp;إذا أصبحت حاملا في أثناء تناول هذا الدواء، أخبري طبيبك فورا، سيقرر كيف يجب أن تتم معالجتك.</p><p dir="RTL"><strong>القيادة واستخدام آلات </strong></p><p dir="RTL">بانوريڤ قد يسبب دوخة (عرض جانبي شائع) أو الإغماء (عرض جانبي غير شائع) (انظر القسم 4. &quot;الأعراض الجانبية المحتملة &quot;).&nbsp;يجب أن لا تقود أو تستخدم الآلات إذا كنت تعاني من هذه الأعراض.</p><p dir="RTL"><strong>يحتوي بانوريڤ على اللاكتوز</strong></p><p dir="RTL">إذا قيل لك من قبل الطبيب أن لديك عدم تحمل لبعض السكريات، اخبر الطبيب قبل تناول هذا الدواء.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائما تناول هذا الدواء تماما كما أخبرك طبيبك.&nbsp;استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>الجرعة</strong><br />الجرعة الموصى بها هي قرص واحد 2.5 ملجم مرتين يوميا.&nbsp;</p><p dir="RTL">تناول القرص تقريبا في نفس الموعد كل يوم ( على سبيل المثال قرص صباحا وقرص في المساء)</p><p dir="RTL">يمكن تناول بانوريڤ مع أو بدون الطعام.</p><p dir="RTL">إذا كان لديك صعوبة في بلع قرص بأكمله، أخبر طبيبك حول طرق أخرى لتناول بانوريڤ .&nbsp;يمكن سحق الحبوب وخلطها مع الماء أو هريس التفاح على الفور قبل التناول.</p><p dir="RTL">إذا لزم الأمر، فإن طبيبك قد يعطيك أيضا قرص بانوريڤ مسحوق من خلال أنبوب في المعدة.</p><p dir="RTL">لن يوصف لك بانوريڤ وحده. طبيبك سوف يصف لك أيضا:</p><p dir="RTL">&bull; حمض استيل ساليسيلات (المعروف أيضا باسم الأسبرين) أو</p><p dir="RTL">&bull; حمض استيل ساليسيلات بالإضافة إلى كلوبيدوجرل أو تيكلوبيدين.</p><p dir="RTL">طبيبك سوف يخبرك بجرعة الأدوية السابقة (عادة ما بين 75 إلى 100 ملجم حمض استيل ساليسيلات يوميا أو جرعة يومية من 75 إلى 100 ملجم حمض استيل ساليسيلات بالإضافة إلى جرعة يومية من إما 75 ملجم كلوبيدوجرل أو جرعة يومية قياسية من تيكلوبيدين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تبدأ تناول بانوريڤ </strong></p><p dir="RTL">سيخبرك طبيبك متى تبدأ العلاج ب بانوريڤ إذا تم تشخيصك بمرض الشريان التاجي أو مرض الشريان المحيطي.</p><p dir="RTL">طبيبك سوف يقرر إلى متى يجب مواصلة العلاج.</p><p dir="RTL"><strong>إذا تناولت بانوريڤ أكثر مما يجب</strong></p><p dir="RTL">اتصل بطبيبك على الفور إذا كنت قد تناولت الكثير من أقراص بانوريڤ .&nbsp;أخذ الكثير من أقراص بانوريڤ يزيد من خطر النزيف.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناول بانوريڤ </strong></p><p dir="RTL">لا تتناول قرصين معا لتعويض القرص المنسي. إذا نسيت تناول قرص، تناول القرص التالي في موعده</p><p dir="RTL"><strong>إذا توقفت عن تناول بانوريڤ </strong></p><p dir="RTL">تناول بانوريڤ بانتظام طالما يخبرك الطبيب بذلك .لا توقف العلاج ب بانوريڤ دون التحدث مع طبيبك أولا، لأن وقف العلاج ب بانوريڤ قد يؤدي إلى زيادة خطورة حدوث نوبة قلبية أو سكتة دماغية أخرى أو حتى الموت من مرض متعلق بالقلب أو الأوعية الدموية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب بانوريڤ في أعراض جانبية، على الرغم من أن الجميع لا يتعرض لها.</p><p dir="RTL">مثل أدوية أخرى مماثلة (مضادات التجلط)، قد يسبب بانوريڤ النزيف الذي من المحتمل أن يكون مهدد للحياة.&nbsp;النزيف الحاد قد يؤدي إلى انخفاض مفاجئ في ضغط الدم (صدمة).&nbsp;في بعض الحالات قد لا يكون نزيف واضح.</p><p dir="RTL"><strong>الأعراض الجانبية المحتملة التي قد تكون علامة على حدوث نزيف:</strong></p><p dir="RTL"><strong>أخبر طبيبك فورا</strong>&nbsp;إذا كنت تواجه أي من الأعراض الجانبية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف الطويل أو المفرط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف استثنائي، والتعب، وشحوب، والدوخة، والصداع، والتورم الغير مبرر، وضيق في التنفس، ألم في الصدر أو الذبحة الصدرية، والتي قد تكون علامات النزيف.</p><p dir="RTL">طبيبك قد يقرر إبقائك تحت الملاحظة الدقيقة أو تغيير طريقة العلاج.</p><p dir="RTL">الأعراض الجانبية المحتملة التي قد تكون علامة على رد فعل جلدي تحسسي خطير:</p><p dir="RTL">أخبر طبيبك فورا إذا تعرضت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لأعراض جلدية مثل انتشار الطفح الجلدي الشديد، البثور أو جروح في الأغشية المخاطية، على سبيل المثال. في الفم أو العينين (متلازمة ستيفنز جونسون / انحلال البشرة النخري السمي). نسبة حدوث هذا العرض الجانبي نادر جدا (يصل إلى 1 في 10000).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل دوائي يسبب طفح ، حمى ، التهاب في الأعضاء الداخلية ، تشوهات دموية وأمراض جهازيه (متلازمة دريس). نسبة حدوث هذا العرض الجانبي نادر جدا (يصل إلى 1 من كل 10000).</p><p dir="RTL"><strong>القائمة الشاملة للأعراض الجانبية المحتملة:</strong></p><p dir="RTL"><strong>شائع</strong>&nbsp;(قد يؤثر على ما يصل إلى 1 في كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المعدة أو الأمعاء، نزيف في الجهاز البولي التناسلي (بما في ذلك الدم في البول ونزيف الحيض الشديد)، نزيف الأنف، ونزيف في اللثة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين (بما في ذلك نزيف من بياض العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأنسجة أو تجويف في الجسم (ورم دموي، وكدمات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الجلد أو تحت الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بعد العملية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رشح الدم أو السوائل من الجروح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل الجلد شاحب وتسبب ضعف أو ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة، عسر الهضم، والشعور بالغثيان، والإمساك، والإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (الأعراض: قد تشمل الشعور بالدوار أو الإغماء عند الوقوف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض القوة العامة والطاقة (الضعف، التعب)، والصداع، والدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في وظائف الكلى (يمكن أن ينظر إليها في الاختبارات التي يقوم بها الطبيب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر اختبارات الدم زيادة في بعض إنزيمات الكبد.</p><p dir="RTL"><strong>غير شائع</strong>&nbsp;(قد يؤثر على ما يصل إلى 1 في كل 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الدماغ أو داخل الجمجمة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المفاصل مما يسبب الألم والتورم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الصفيحات (انخفاض عدد الصفائح الدموية، وهي الخلايا التي تساعد على تجلط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إغماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بشعور المرض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع نبضات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الحساسية، بما في ذلك ردود فعل حساسية الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في وظائف الكبد (يمكن أن ينظر إليها في الاختبارات التي يقوم بها الطبيب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر اختبارات الدم زيادة في البيليروبين، وبعض انزيمات البنكرياس أو الكبد أو في عدد الصفائح الدموية.</p><p dir="RTL"><strong>نادر</strong>&nbsp;(قد يؤثر على ما يصل إلى 1 في كل 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العضل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ركود صفراوي (انخفض تدفق الصفراء)، التهاب الكبد نتيجة&nbsp;إصابة الخلايا الكبدية (التهاب الكبد بما في ذلك إصابة الكبد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد والعين (اليرقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع الدم (ورم دموي) في الفخذ نتيجة مضاعفات عمليات القلب حيث يتم إدخال قسطرة في شريان ساقك.</p><p dir="RTL"><strong>غير معروف</strong>&nbsp;(لا يمكن تقدير مدي حدوثها من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط داخل عضلات الساقين والذراعين بعد النزيف، الأمر الذي يؤدي إلى الألم، وتورم، وتغير الإحساس أو التنميل أو الشلل (متلازمة الحيز بعد النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي بعد نزيف حاد.</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا كان لديك أي أعراض جانبية، أخبر طبيبك أو الصيدلي.&nbsp;ويشمل ذلك أي أعراض جانبية محتملة غير المدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">حافظ على هذا الدواء بعيدا عن نظر ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المطبوع على الكرتون وعلى كل شريط بعد كلمة EXP.</p><p dir="RTL">تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.&nbsp;اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدم.&nbsp;ومن شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي ريفاروكسيبان.&nbsp;كل قرص يحتوي على 2.5 ملجم من ريفاروكسيبان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:&nbsp;<br />نواة القرص: لاكتوز 200، افيسيل بي اتش 101، هيدروكسي بروبيل ميثيل السيليلوز، صوديوم لوريل سلفيت، كروس كارميلوز صوديو نوع A ، ماغنسيوم ستيرات.</p><p dir="RTL">الغلاف الرقيق: هيدروكسي بروبيل ميثيل السيليلوز، تيتانيوم ثنائي الأكسدة ، تلك منقي، بولي ايثيلين جليكول ام دبليو 6000 ، أكسيد الحديد الأحمر، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص وردية إلى وردية داكنة، مستديرة، محدبة الوجهين، مغلفة بطبقة رقيقة، منقوش عليها رقم &quot; 261 &quot; من احدي الجوانب وجلية السطح على الجانب الأخر.</p><p dir="RTL">تحتوي كل عبوة على 10 أو 60 قرص مغلفة بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الدوائية</p><p dir="RTL">مصنع الأدوية بالقصيم،</p><p dir="RTL">الشركة السعودية للصناعات الدوائية والمستلزمات الطبية،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            فبراير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Banoriv 2.5 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 2.5 mg rivaroxaban.
Excipient with known effect:
Each film-coated tablet contains 96.5 mg lactose, see section 4.4.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pink to dark pink coloured, round, biconvex, film-coated tablet, engraved with “261” on one side and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Banoriv, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose is 2.5 mg twice daily.</p><p>&bull;&nbsp;<em><u>CAD/PAD</u></em></p><p>Patients taking Banoriv 2.5 mg twice daily should also take a daily dose of 75 - 100 mg ASA.</p><p>Duration of treatment should be determined for each individual patient based on regular evaluations and should consider the risk for thrombotic events versus the bleeding risks.</p><p>In patients with an acute thrombotic event or vascular procedure and a need for dual antiplatelet therapy, the continuation of Banoriv 2.5 mg twice daily should be evaluated depending on the type of event or procedure and antiplatelet regimen. Safety and efficacy of Banoriv 2.5 mg twice daily in combination with ASA plus clopidogrel/ticlopidine has only been studied in patients with recent ACS (see section 4.1). Dual antiplatelet therapy has not been studied in combination with Banoriv 2.5 mg twice daily in patients with CAD/PAD (see sections 4.4 and 5.1).</p><p>If a dose is missed the patient should continue with the regular dose as recommended at the next scheduled time. The dose should not be doubled to make up for a missed dose.</p><p><em>Converting from Vitamin K Antagonists (VKA) to Banoriv</em></p><p>When converting patients from VKAs to Banoriv, International Normalised Ratio (INR) values could be falsely elevated after the intake of Banoriv. The INR is not valid to measure the anticoagulant activity of Banoriv, and therefore should not be used (see section 4.5).</p><p><em>Converting from Banoriv to Vitamin K antagonists (VKA)</em></p><p>There is a potential for inadequate anticoagulation during the transition from Banoriv to VKA. Continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant. It should be noted that Banoriv can contribute to an elevated INR.</p><p>In patients converting from Banoriv to VKA, VKA should be given concurrently until the INR is &ge; 2.0. For the first two days of the conversion period, standard initial dosing of VKA should be used followed by VKA dosing, as guided by INR testing. While patients are on both Banoriv and VKA the INR should not be tested earlier than 24 hours after the previous dose but prior to the next dose of Banoriv. Once Banoriv is discontinued INR testing may be done reliably at least 24 hours after the last dose (see sections 4.5 and 5.2).</p><p><em>Converting from parenteral anticoagulants to Banoriv</em></p><p>For patients currently receiving a parenteral anticoagulant, discontinue the parenteral anticoagulant and start Banoriv 0 to 2 hours before the time that the next scheduled administration of the parenteral medicinal product (e.g. low molecular weight heparins) would be due or at the time of discontinuation of a continuously administered parenteral medicinal product (e.g. intravenous unfractionated heparin).</p><p><em>Converting from Banoriv to parenteral anticoagulants</em></p><p>Give the first dose of parenteral anticoagulant at the time the next Banoriv dose would be taken.</p><p><em><u>Special populations</u></em></p><p><em>Renal impairment</em></p><p>Limited clinical data for patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) indicate that rivaroxaban plasma concentrations are significantly increased. Therefore, Banoriv is to be used with caution in these patients. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.4 and 5.2).</p><p>No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance 50 - 80 ml/min) or moderate renal impairment (creatinine clearance 30 - 49 ml/min) (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>Banoriv is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see sections 4.3 and 5.2).</p><p><em>Elderly population</em></p><p>No dose adjustment (see sections 4.4 and 5.2)</p><p>The risk of bleeding increases with increasing age (see section 4.4).</p><p><em>Body weight</em></p><p>No dose adjustment (see sections 4.4 and 5.2)</p><p><em>Gender</em></p><p>No dose adjustment (see section 5.2)</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Banoriv in children aged 0 to 18 years have not been established. No data are available. Therefore, Banoriv is not recommended for use in children below 18 years of age.</p><p><u>Method of administration</u></p><p>Banoriv is for oral use.</p><p>The tablets can be taken with or without food (see sections 4.5 and 5.2).</p><p>For patients who are unable to swallow whole tablets, Banoriv tablet may be crushed and mixed with water or apple puree immediately prior to use and administered orally.</p><p>The crushed Banoriv tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active clinically significant bleeding.

Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities.

Concomitant treatment with any other anticoagulants, e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy (see section 4.2) or when UFH is given at doses necessary to maintain an open central venous or arterial catheter (see section 4.5).

Concomitant treatment of ACS with antiplatelet therapy in patients with a prior stroke or a transient ischaemic attack (TIA) (see section 4.4).

Concomitant treatment of CAD/PAD with ASA in patients with previous haemorrhagic or lacunar stroke, or any stroke within a month (see section 4.4).

Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C (see section 5.2).

Pregnancy and breast-feeding (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In ACS patients, efficacy and safety of Banoriv 2.5 mg have been investigated in combination with the antiplatelet agents ASA alone or ASA plus clopidogrel/ticlopidine. Treatment in combination with other antiplatelet agents, e.g. prasugrel or ticagrelor, has not been studied and is not recommended.</p><p>In patients at high risk of ischaemic events with CAD/PAD, efficacy and safety of Banoriv 2.5 mg have only been investigated in combination with ASA.</p><p>Clinical surveillance in line with anticoagulation practice is recommended throughout the treatment period.</p><p><u>Haemorrhagic risk</u></p><p>As with other anticoagulants, patients taking Banoriv are to be carefully observed for signs of bleeding. It is recommended to be used with caution in conditions with increased risk of haemorrhage. Banoriv administration should be discontinued if severe haemorrhage occurs.</p><p>In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment on top of single or dual anti-platelet therapy. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate.</p><p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. Therefore, the use of Banoriv in combination with dual antiplatelet therapy in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events. In addition these patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment (see section 4.8).</p><p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p><p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g. overdose and emergency surgery (see sections 5.1 and 5.2).</p><p><u>Renal impairment</u></p><p>In patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6 fold on average) which may lead to an increased bleeding risk. Banoriv is to be used with caution in patients with creatinine clearance 15 - 29 ml/min. Use is not recommended in patients with creatinine clearance &lt; 15 ml/min (see sections 4.2 and 5.2).</p><p>In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations Banoriv is to be used with caution (see section 4.5).</p><p><u>Interaction with other medicinal products</u></p><p>The use of Banoriv is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6 fold on average) which may lead to an increased bleeding risk (see section 4.5).</p><p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors or selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered (see section 4.5).</p><p>Patients on treatment with Banoriv and ASA or with Banoriv and ASA plus clopidogrel/ticlopidine should only receive concomitant treatment with NSAIDs if the benefit outweighs the bleeding risk.</p><p><u>Other haemorrhagic risk factors</u></p><p>As with other antithrombotics, rivaroxaban is not recommended in patients with an increased bleeding risk such as:</p><p>&bull; congenital or acquired bleeding disorders</p><p>&bull; uncontrolled severe arterial hypertension</p><p>&bull; other gastrointestinal disease without active ulceration that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease)</p><p>&bull; vascular retinopathy</p><p>&bull; bronchiectasis or history of pulmonary bleeding</p><p>It should be used with caution in ACS and CAD/PAD patients:</p><p>&bull; &ge; 75 years of age if co-administered with ASA alone or with ASA plus clopidogrel or ticlopidine. The benefit-risk of the treatment should be individually assessed on a regular basis.</p><p>&bull; with lower body weight (&lt; 60 kg) if co-administered with ASA alone or with ASA plus clopidogrel or ticlopidine.</p><p>&bull; CAD patients with severe symptomatic heart failure. Study data indicate that such patients may benefit less from treatment with rivaroxaban (see section 5.1).</p><p><u>Patients with prosthetic valves</u></p><p>Rivaroxaban should not be used for thromboprophylaxis in patients having recently undergone transcatheter aortic valve replacement (TAVR). Safety and efficacy of Banoriv have not been studied in patients with prosthetic heart valves; therefore, there are no data to support that Banoriv provides adequate anticoagulation in this patient population. Treatment with Banoriv is not recommended for these patients.</p><p><u>Patients with antiphospholipid syndrome</u></p><p>Direct acting Oral Anticoagulants (DOACs) including rivaroxaban are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies), treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.</p><p><u>Patients with prior stroke and/or TIA</u></p><p><em><u>Patients with ACS</u></em></p><p>Banoriv 2.5 mg is contraindicated for the treatment of ACS in patients with a prior stroke or TIA (see section 4.3). Few ACS patients with a prior stroke or TIA have been studied but the limited efficacy data available indicate that these patients do not benefit from treatment.</p><p><em><u>Patients with CAD/PAD</u></em></p><p>CAD/PAD patients with previous haemorrhagic or lacunar stroke, or an ischaemic, non-lacunar stroke with in the previous month were not studied (see section 4.3).</p><p><u>Spinal/epidural anaesthesia or puncture</u></p><p>When neuraxial anaesthesia (spinal/epidural anaesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal haematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the post-operative use of indwelling epidural catheters or the concomitant use of medicinal products affecting haemostasis. The risk may also be increased by traumatic or repeated epidural or spinal puncture. Patients are to be frequently monitored for signs and symptoms of neurological impairment (e.g. numbness or weakness of the legs, bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. There is no clinical experience with the use of Banoriv 2.5 mg with ASA alone or with ASA plus clopidogrel or ticlopidine in these situations.</p><p>To reduce the potential risk of bleeding associated with the concurrent use of rivaroxaban and neuraxial (epidural/spinal) anaesthesia or spinal puncture, consider the pharmacokinetic profile of rivaroxaban. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is estimated to be low (see section 5.2). However, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</p><p>Platelet aggregation inhibitors should be discontinued as suggested by the manufacturer&#39;s prescribing information.</p><p><u>Dosing recommendations before and after invasive procedures and surgical intervention</u></p><p>If an invasive procedure or surgical intervention is required, Banoriv 2.5 mg should be stopped at least 12 hours before the intervention, if possible and based on the clinical judgement of the physician. If a patient is to undergo elective surgery and anti-platelet effect is not desired, platelet aggregation inhibitors should be discontinued as directed by the manufacturer&#39;s prescribing information.</p><p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p><p>Banoriv should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician (see section 5.2).</p><p><u>Elderly population</u></p><p>Increasing age may increase haemorrhagic risk (see sections 5.1 and 5.2).</p><p><u>Dermatological reactions</u></p><p>Serious skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis and DRESS syndrome, have been reported during post-marketing surveillance in association with the use of rivaroxaban (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first weeks of treatment. Rivaroxaban should be discontinued at the first appearance of a severe skin rash (e.g. spreading, intense and/or blistering), or any other sign of hypersensitivity in conjunction with mucosal lesions.</p><p><u>Information about excipients</u></p><p>Banoriv contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CYP3A4 and P-gp inhibitors</u></p><p>Co-administration of rivaroxaban with ketoconazole (400 mg once a day) or ritonavir (600 mg twice a day) led to a 2.6 fold / 2.5 fold increase in mean rivaroxaban AUC and a 1.7 fold / 1.6 fold increase in mean rivaroxaban C<sub>max</sub>, with significant increases in pharmacodynamic effects which may lead to an increased bleeding risk. Therefore, the use of Banoriv is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics such as ketoconazole, itraconazole, voriconazole and posaconazole or HIV protease inhibitors. These active substances are strong inhibitors of both CYP3A4 and P-gp (see section 4.4).</p><p>Active substances strongly inhibiting only one of the rivaroxaban elimination pathways, either CYP3A4 or P-gp, are expected to increase rivaroxaban plasma concentrations to a lesser extent. Clarithromycin (500 mg twice a day), for instance, considered as a strong CYP3A4 inhibitor and moderate P-gp inhibitor, led to a 1.5 fold increase in mean rivaroxaban AUC and a 1.4 fold increase in C<sub>max</sub>. The interaction with clarithromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Erythromycin (500 mg three times a day), which inhibits CYP3A4 and P-gp moderately, led to a 1.3 fold increase in mean rivaroxaban AUC and C<sub>max</sub>. The interaction with erythromycin is likely not clinically relevant in most patients but can be potentially significant in high-risk patients.</p><p>In subjects with mild renal impairment erythromycin (500 mg three times a day) led to a 1.8 fold increase in mean rivaroxaban AUC and 1.6 fold increase in CR<sub>max</sub>&nbsp;when compared to subjects with normal renal function. In subjects with moderate renal impairment, erythromycin led to a 2.0 fold increase in mean rivaroxaban AUC and 1.6 fold increase in CR<sub>max</sub>&nbsp;when compared to subjects with normal renal function. The effect of erythromycin is additive to that of renal impairment (see section 4.4).</p><p>Fluconazole (400 mg once daily), considered as a moderate CYP3A4 inhibitor, led to a 1.4 fold increase in mean rivaroxaban AUC and a 1.3 fold increase in mean C<sub>max</sub>. The interaction with fluconazole is likely not clinically relevant in most patients but can be potentially significant in high-risk patients. (For patients with renal impairment: see section 4.4).</p><p>Given the limited clinical data available with dronedarone, co-administration with rivaroxaban should be avoided.</p><p><u>Anticoagulants</u></p><p>After combined administration of enoxaparin (40 mg single dose) with rivaroxaban (10 mg single dose) an additive effect on anti-factor Xa activity was observed without any additional effects on clotting tests (PT, aPTT). Enoxaparin did not affect the pharmacokinetics of rivaroxaban.</p><p>Due to the increased bleeding risk care is to be taken if patients are treated concomitantly with any other anticoagulants (see sections 4.3 and 4.4).</p><p><u>NSAIDs/platelet aggregation inhibitors</u></p><p>No clinically relevant prolongation of bleeding time was observed after concomitant administration of rivaroxaban (15 mg) and 500 mg naproxen. Nevertheless, there may be individuals with a more pronounced pharmacodynamic response.</p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with 500 mg acetylsalicylic acid.</p><p>Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.</p><p>Care is to be taken if patients are treated concomitantly with NSAIDs (including acetylsalicylic acid) and platelet aggregation inhibitors because these medicinal products typically increase the bleeding risk (see section 4.4).</p><p><u>SSRIs/SNRIs</u></p><p>As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets. When concomitantly used in the rivaroxaban clinical programme, numerically higher rates of major or non-major clinically relevant bleeding were observed in all treatment groups.</p><p><u>Warfarin</u></p><p>Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin) more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT, inhibition of factor Xa activity and endogenous thrombin potential were additive.</p><p>If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity and ETP) reflected only the effect of rivaroxaban.</p><p>If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR measurement can be used at the C<sub>trough</sub>&nbsp;of rivaroxaban (24 hours after the previous intake of rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.</p><p>No pharmacokinetic interaction was observed between warfarin and rivaroxaban.</p><p><u>CYP3A4 inducers</u></p><p>Co-administration of rivaroxaban with the strong CYP3A4 inducer rifampicin led to an approximate 50% decrease in mean rivaroxaban AUC, with parallel decreases in its pharmacodynamic effects. The concomitant use of rivaroxaban with other strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbital or St. John&#39;s Wort (<em>Hypericum perforatum</em>)) may also lead to reduced rivaroxaban plasma concentrations. Therefore, concomitant administration of strong CYP3A4 inducers should be avoided unless the patient is closely observed for signs and symptoms of thrombosis.</p><p><u>Other concomitant therapies</u></p><p>No clinically significant pharmacokinetic or pharmacodynamic interactions were observed when rivaroxaban was co-administered with midazolam (substrate of CYP3A4), digoxin (substrate of P-gp), atorvastatin (substrate of CYP3A4 and P-gp) or omeprazole (proton pump inhibitor). Rivaroxaban neither inhibits nor induces any major CYP isoforms like CYP3A4.</p><p>No clinically relevant interaction with food was observed (see section 4.2).</p><p><u>Laboratory parameters</u></p><p>Clotting parameters (e.g. PT, aPTT, HepTest) are affected as expected by the mode of action of rivaroxaban (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Safety and efficacy of Banoriv have not been established in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Banoriv is contraindicated during pregnancy (see section 4.3).</p><p>Women of child-bearing potential should avoid becoming pregnant during treatment with rivaroxaban.</p><p><u>Breast-feeding</u></p><p>Safety and efficacy of Banoriv have not been established in breast-feeding women. Data from animals indicate that rivaroxaban is secreted into milk. Therefore Banoriv is contraindicated during breast-feeding (see section 4.3). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.</p><p><u>Fertility</u></p><p>No specific studies with rivaroxaban in humans have been conducted to evaluate effects on fertility. In a study on male and female fertility in rats no effects were seen (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Banoriv has minor influence on the ability to drive and use machines. Adverse reactions like syncope (frequency: uncommon) and dizziness (frequency: common) have been reported (see section 4.8). Patients experiencing these adverse reactions should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety of rivaroxaban has been evaluated in thirteen phase III studies including 53,103 patients exposed to rivaroxaban (see Table 1).</p><p><strong>Table 1: Number of patients studied, total daily dose and maximum treatment duration in phase III studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Number of patients*</strong></p></td><td><p><strong>Total daily dose</strong></p></td><td><p><strong>Maximum treatment duration</strong></p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6,097</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Prevention of VTE in medically ill patients</p></td><td><p>3,997</p></td><td><p>10 mg</p></td><td><p>39 days</p></td></tr><tr><td><p>Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE) and prevention of recurrence</p></td><td><p>6,790</p></td><td><p>Day 1 - 21: 30 mg</p><p>Day 22 and onwards: 20 mg</p><p>After at least 6 months: 10 mg or 20 mg</p></td><td><p>21 months</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td><p>7,750</p></td><td><p>20 mg</p></td><td><p>41 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td><p>10,225</p></td><td><p>5 mg or 10 mg respectively, co-administered with either ASA or ASA plus clopidogrel or ticlopidine</p></td><td><p>31 months</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>18,244</p></td><td><p>5 mg co-administered with ASA or 10 mg alone</p></td><td><p>47 months</p></td></tr><tr><td colspan="4"><p>* Patients exposed to at least one dose of rivaroxaban</p></td></tr></tbody></table><p>The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and &#39;Description of selected adverse reactions&#39; below) (Table 2). The most commonly reported bleedings were epistaxis (4.5 %) and gastrointestinal tract haemorrhage (3.8 %).</p><p><strong>Table 2: Bleeding* and anaemia events rates in patients exposed to rivaroxaban across the completed phase III studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Indication</strong></p></td><td><p><strong>Any bleeding</strong></p></td><td><p><strong>Anaemia</strong></p></td></tr><tr><td><p>Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery</p></td><td><p>6.8% of patients</p></td><td><p>5.9% of patients</p></td></tr><tr><td><p>Prevention of venous thromboembolism in medically ill patients</p></td><td><p>12.6% of patients</p></td><td><p>2.1% of patients</p></td></tr><tr><td><p>Treatment of DVT, PE and prevention of recurrence</p></td><td><p>23% of patients</p></td><td><p>1.6% of patients</p></td></tr><tr><td><p>Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation</p></td><td><p>28 per 100 patient years</p></td><td><p>2.5 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients after an ACS</p></td><td><p>22 per 100 patient years</p></td><td><p>1.4 per 100 patient years</p></td></tr><tr><td><p>Prevention of atherothrombotic events in patients with CAD/PAD</p></td><td><p>6.7 per 100 patient years</p></td><td><p>0.15 per 100 patient years**</p></td></tr><tr><td colspan="3"><p>* For all rivaroxaban studies all bleeding events are collected, reported and adjudicated.</p><p>** In the COMPASS study, there is a low anaemia incidence as a selective approach to adverse event collection was applied</p></td></tr></tbody></table><p><u>Tabulated list of adverse reactions</u></p><p>The frequencies of adverse reactions reported with Banoriv are summarised in Table 3 below by system organ class (in MedDRA) and by frequency.</p><p>Frequencies are defined as:</p><p>very common (&ge; 1/10)</p><p>common (&ge; 1/100 to &lt; 1/10)</p><p>uncommon (&ge; 1/1,000 to &lt; 1/100)</p><p>rare (&ge; 1/10,000 to &lt; 1/1,000)</p><p>very rare ( &lt; 1/10,000)</p><p>not known (cannot be estimated from the available data)</p><p><strong>Table 3: All adverse reactions reported in patients in phase III clinical trials or through post-marketing use*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Common</strong></p></td><td><p><strong>Uncommon</strong></p></td><td><p><strong>Rare</strong></p></td><td><p><strong>Very rare</strong></p></td><td><p><strong>Not known</strong></p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Anaemia (incl. respective laboratory parameters)</p></td><td><p>Thrombocytosis (incl. platelet count increased)<sup>A</sup>, Thrombocytopenia</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Immune system disorders</strong></p></td></tr><tr><td>&nbsp;</td><td><p>Allergic reaction, dermatitis allergic, Angioedema and allergic oedema</p></td><td>&nbsp;</td><td><p>Anaphylactic reactions including anaphylactic shock</p></td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Dizziness, headache</p></td><td><p>Cerebral and intracranial haemorrhage, syncope</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Eye haemorrhage (incl. conjunctival haemorrhage)</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td>&nbsp;</td><td><p>Tachycardia</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p>Hypotension, haematoma</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Epistaxis, haemoptysis</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td><p>Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipation<sup>A</sup>, diarrhoea, vomiting<sup>A</sup></p></td><td><p>Dry mouth</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td><p>Increase in transaminases</p></td><td><p>Hepatic impairment, Increased bilirubin, increased blood alkaline phosphatase<sup>A</sup>, increased GGT<sup>A</sup></p></td><td><p>Jaundice, Bilirubin conjugated increased (with or without concomitant increase of ALT), Cholestasis, Hepatitis (incl. hepatocellular injury)</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>Pruritus (incl. uncommon cases of generalised pruritus), rash, ecchymosis, cutaneous and subcutaneous haemorrhage</p></td><td><p>Urticaria</p></td><td>&nbsp;</td><td><p>Stevens-Johnson syndrome/ Toxic Epidermal Necrolysis , DRESS syndrome</p></td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td><p>Pain in extremity<sup>A</sup></p></td><td><p>Haemarthrosis</p></td><td><p>Muscle haemorrhage</p></td><td>&nbsp;</td><td><p>Compartment syndrome secondary to a bleeding</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td><p>Urogenital tract haemorrhage (incl. haematuria and menorrhagia<sup>B</sup>), renal impairment (incl. blood creatinine increased, blood urea increased)</p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td><p>Renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td><p>Fever<sup>A</sup>, peripheral oedema, decreased general strength and energy (incl. fatigue and asthenia)</p></td><td><p>Feeling unwell (incl. malaise)</p></td><td><p>Localised oedema<sup>A</sup></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Investigations</strong></p></td></tr><tr><td>&nbsp;</td><td><p>Increased LDH<sup>A</sup>, increased lipase<sup>A</sup>, increased amylase<sup>A</sup></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td><p>Postprocedural haemorrhage (incl. postoperative anaemia, and wound haemorrhage), contusion, wound secretion<sup>A</sup></p></td><td>&nbsp;</td><td><p>Vascular pseudoaneurysm<sup>C</sup></p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="5"><p>A: observed in prevention of VTE in adult patients undergoing elective hip or knee replacement surgery</p><p>B: observed in treatment of DVT, PE and prevention of recurrence as very common in women &lt; 55 years</p><p>C: observed as uncommon in prevention of atherothrombotic events in patients after an ACS (following percutaneous coronary intervention)</p><p>* A pre-specified selective approach to adverse event collection was applied. As incidence of adverse reactions did not increase and no new adverse reaction was identified, COMPASS study data were not included for frequency calculation in this table.</p></td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p>Due to the pharmacological mode of action, the use of Banoriv may be associated with an increased risk of occult or overt bleeding from any tissue or organ which may result in post haemorrhagic anaemia. The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anaemia (see section 4.9 &ldquo;Management of bleeding&rdquo;). In the clinical studies mucosal bleedings (i.e. epistaxis, gingival, gastrointestinal, genito urinary including abnormal vaginal or increased menstrual bleeding) and anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment. Thus, in addition to adequate clinical surveillance, laboratory testing of haemoglobin/haematocrit could be of value to detect occult bleeding and quantify the clinical relevance of overt bleeding, as judged to be appropriate. The risk of bleedings may be increased in certain patient groups, e.g. those patients with uncontrolled severe arterial hypertension and/or on concomitant treatment affecting haemostasis (see section 4.4 &ldquo;Haemorrhagic risk&rdquo;). Menstrual bleeding may be intensified and/or prolonged. Haemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnoea and unexplained shock. In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.</p><p>Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for Banoriv. Therefore, the possibility of haemorrhage is to be considered in evaluating the condition in any anticoagulated patient.</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; +966-11-2038222&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exts: 2317-2356-2340.</p><p>Toll free phone: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p><strong>For UAE</strong></p><p>&middot; Pharmacovigilance &amp; Medical Device section</p><p>&middot; P.O.Box: 1853</p><p>&middot; Tel: 80011111</p><p>&middot; Email: pv@moh.gov.ae</p><p>&middot; Drug Department, Ministry of Health &amp; Prevention, Dubai</p><p><strong>For Oman</strong></p><p>&middot; Department of Pharmacovigilance &amp; Drug Information</p><p>&middot; Directorate General of Pharmaceutical Affairs &amp; Drug Control</p><p>&middot; Ministry of Health, Sultanate of Oman</p><p>&middot; Phone Nos. 22357687 / 22357686</p><p>&middot; Fax: 22358489</p><p>&middot; Email: dg-padc@moh.gov.om</p><p>&middot; Website: www.moh.gov.om</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rare cases of overdose up to 600 mg have been reported without bleeding complications or other<br />adverse reactions. Due to limited absorption a ceiling effect with no further increase in average plasma<br />exposure is expected at supratherapeutic doses of 50 mg rivaroxaban or above.<br />A specific antidote antagonising the pharmacodynamic effect of rivaroxaban is not available.<br />The use of activated charcoal to reduce absorption in case of rivaroxaban overdose may be considered.<br />Management of bleeding<br />Should a bleeding complication arise in a patient receiving rivaroxaban, the next rivaroxaban<br />administration should be delayed or treatment should be discontinued as appropriate. Rivaroxaban has a<br />half-life of approximately 5 to 13 hours (see section 5.2). Management should be individualised<br />according to the severity and location of the haemorrhage. Appropriate symptomatic treatment could be<br />used as needed, such as mechanical compression (e.g. for severe epistaxis), surgical haemostasis with<br />bleeding control procedures, fluid replacement and haemodynamic support, blood products (packed red<br />cells or fresh frozen plasma, depending on associated anaemia or coagulopathy) or platelets.<br />If bleeding cannot be controlled by the above measures, administration of a specific procoagulant<br />reversal agent should be considered, such as prothrombin complex concentrate (PCC), activated<br />prothrombin complex concentrate (APCC) or recombinant factor VIIa (r-FVIIa). However, there is<br />currently very limited clinical experience with the use of these medicinal products in individuals<br />receiving rivaroxaban. The recommendation is also based on limited non-clinical data. Re-dosing of<br />recombinant factor VIIa shall be considered and titrated depending on improvement of bleeding.<br />Depending on local availability, a consultation with a coagulation expert should be considered in case<br />of major bleedings (see section 5.1).<br />Protamine sulphate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban.<br />There is limited experience with tranexamic acid and no experience with aminocaproic acid and<br />aprotinin in individuals receiving rivaroxaban. There is neither scientific rationale for benefit nor<br />experience with the use of the systemic haemostatic desmopressin in individuals receiving rivaroxaban.<br />Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, direct factor Xa inhibitors, ATC code: B01AF01</p><p><u>Mechanism of action</u></p><p>Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.</p><p><u>Pharmacodynamic effects</u></p><p>Dose-dependent inhibition of factor Xa activity was observed in humans. Prothrombin time (PT) is influenced by rivaroxaban in a dose dependent way with a close correlation to plasma concentrations (r value equals 0.98) if Neoplastin is used for the assay. Other reagents would provide different results. The readout for PT is to be done in seconds, because the INR is only calibrated and validated for coumarins and cannot be used for any other anticoagulant.</p><p>In a clinical pharmacology study on the reversal of rivaroxaban pharmacodynamics in healthy adult subjects (n=22), the effects of single doses (50 IU/kg) of two different types of PCCs, a 3-factor PCC (Factors II, IX and X) and a 4-factor PCC (Factors II, VII, IX and X) were assessed. The 3-factor PCC reduced mean Neoplastin PT values by approximately 1.0 second within 30 minutes, compared to reductions of approximately 3.5 seconds observed with the 4-factor PCC. In contrast, the 3-factor PCC had a greater and more rapid overall effect on reversing changes in endogenous thrombin generation than the 4-factor PCC (see section 4.9).</p><p>The activated partial thomboplastin time (aPTT) and HepTest are also prolonged dose-dependently; however, they are not recommended to assess the pharmacodynamic effect of rivaroxaban. There is no need for monitoring of coagulation parameters during treatment with rivaroxaban in clinical routine. However, if clinically indicated, rivaroxaban levels can be measured by calibrated quantitative anti-factor-Xa tests (see section 5.2).</p><p><u>Clinical efficacy and safety</u></p><p><em><u>CAD/PAD</u></em></p><p>The phase III COMPASS study (27,395 patients, 78.0% male, 22.0% female) demonstrated the efficacy and safety of Banoriv for the prevention of a composite of CV death, MI, stroke in patients with CAD or symptomatic PAD at high risk of ischaemic events. Patients were followed for a median of 23 months and maximum of 3.9 years.</p><p>Subjects without a continuous need for treatment with a proton pump inhibitor were randomized to pantoprazole or placebo. All patients were then randomized 1:1:1 to rivaroxaban 2.5 mg twice daily/ASA 100 mg once daily, to rivaroxaban 5 mg twice daily, or ASA 100 mg once daily alone, and their matching placebos.</p><p>CAD patients had multivessel CAD and/or prior MI. For patients &lt; 65 years of age atherosclerosis involving at least two vascular beds or at least two additional cardiovascular risk factors were required.</p><p>PAD patients had previous interventions such as bypass surgery or percutaneous transluminal angioplasty or limb or foot amputation for arterial vascular disease or intermittent claudication with ankle/arm blood pressure ratio &lt; 0.90 and/ or significant peripheral artery stenosis or previous carotid revascularization or asymptomatic carotid artery stenosis &ge; 50%.</p><p>Exclusion criteria included the need for dual antiplatelet or other non-ASA antiplatelet or oral anticoagulant therapy and patients with high bleeding risk, or heart failure with ejection fraction &lt; 30% or New York Heart Association class III or IV, or any ischaemic, non-lacunar stroke within 1 month or any history of haemorrhagic or lacunar stroke.</p><p>Banoriv 2.5 mg twice daily in combination with ASA 100 mg once daily was superior to ASA 100 mg, in the reduction of the primary composite outcome of CV death, MI, stroke (see Table 7 and Figure 2).</p><p>There was a significant increase of the primary safety outcome (modified ISTH major bleeding events) in patients treated with Banoriv 2.5 mg twice daily in combination with ASA 100 mg once daily compared to patients who received ASA 100 mg (see Table 8).</p><p>For the primary efficacy outcome, the observed benefit of Banoriv 2.5 mg twice daily plus ASA 100 mg once daily compared with ASA 100 mg once daily was HR=0.89 (95% CI 0.7-1.1) in patients&nbsp;<strong>&ge;</strong>75 years (incidence: 6.3% vs 7.0%) and HR=0.70 (95% CI 0.6-0.8) in patients &lt;75 years (3.6% vs 5.0%). For modified ISTH major bleeding, the observed risk increase was HR=2.12 (95% CI 1.5-3.0) in patients&nbsp;<strong>&ge;</strong>75 years (5.2% vs 2.5%) and HR=1.53 (95% CI 1.2-1.9) in patients &lt;75 years (2.6% vs 1.7%).</p><p><strong>Table 7: Efficacy results from phase III COMPASS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study Population</strong></p></td><td colspan="6"><p><strong>Patients with CAD/PAD&nbsp;<sup>a)</sup></strong></p></td></tr><tr><td><p><strong>Treatment Dosage</strong></p></td><td colspan="2"><p><strong>Banoriv 2.5 mg bid in combination with ASA 100 mg od</strong></p><p><strong>N=9152</strong></p></td><td colspan="2"><p><strong>ASA 100 mg od</strong></p><p>&nbsp;</p><p><strong>N=9126</strong></p></td><td colspan="2">&nbsp;</td></tr><tr><td>&nbsp;</td><td><p><strong>Patients with events</strong></p></td><td><p><strong>KM %</strong></p></td><td><p><strong>Patients with events</strong></p></td><td><p><strong>KM %</strong></p></td><td><p><strong>HR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>p-value&nbsp;<sup>b)</sup></strong></p></td></tr><tr><td><p>Stroke, MI or CV death</p></td><td><p>379 (4.1%)</p></td><td><p>5.20%</p></td><td><p>496 (5.4%)</p></td><td><p>7.17%</p></td><td><p>0.76</p><p>(0.66;0.86)</p></td><td><p>p = 0.00004*</p></td></tr><tr><td><p>- Stroke</p></td><td><p>83 (0.9%)</p></td><td><p>1.17%</p></td><td><p>142 (1.6%)</p></td><td><p>2.23%</p></td><td><p>0.58</p><p>(0.44;0.76)</p></td><td><p>p = 0.00006</p></td></tr><tr><td><p>- MI</p></td><td><p>178 (1.9%)</p></td><td><p>2.46%</p></td><td><p>205 (2.2%)</p></td><td><p>2.94%</p></td><td><p>0.86</p><p>(0.70;1.05)</p></td><td><p>p = 0.14458</p></td></tr><tr><td><p>- CV death</p></td><td><p>160 (1.7%)</p></td><td><p>2.19%</p></td><td><p>203 (2.2%)</p></td><td><p>2.88%</p></td><td><p>0.78</p><p>(0.64;0.96)</p></td><td><p>p = 0.02053</p></td></tr><tr><td><p>All-cause mortality</p></td><td><p>313 (3.4%)</p></td><td><p>4.50%</p></td><td><p>378 (4.1%)</p></td><td><p>5.57%</p></td><td><p>0.82</p><p>(0.71;0.96)</p></td><td>&nbsp;</td></tr><tr><td><p>Acute limb ischaemia</p></td><td><p>22 (0.2%)</p></td><td><p>0.27%</p></td><td><p>40 (0.4%)</p></td><td><p>0.60%</p></td><td><p>0.55</p><p>(0.32;0.92)</p></td><td>&nbsp;</td></tr><tr><td colspan="7"><p>a) intention to treat analysis set, primary analyses</p><p>b) vs. ASA 100 mg; Log-Rank p-value</p><p>* The reduction in the primary efficacy outcome was statistically superior.</p><p>bid: twice daily; CI: confidence interval; KM %: Kaplan-Meier estimates of cumulative incidence risk calculated at 900 days; CV: cardiovascular; MI: myocardial infarction; od: once daily</p></td></tr></tbody></table><p><strong>Table 8: Safety results from phase III COMPASS</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>Study population</strong></p></td><td colspan="3"><p><strong>Patients with CAD/PAD&nbsp;<sup>a)</sup></strong></p></td></tr><tr><td><p><strong>Treatment Dose</strong></p></td><td><p><strong>Banoriv 2.5 mg bid in combination with ASA 100 mg od,</strong></p><p><strong>N=9152</strong></p><p><strong>n (Cum. risk %)</strong></p></td><td><p><strong>ASA 100 mg od</strong></p><p><strong>N=9126</strong></p><p><strong>n (Cum.risk %)</strong></p></td><td><p><strong>Hazard Ratio (95 % CI)</strong></p><p><strong>p-value&nbsp;<sup>b)</sup></strong></p></td></tr><tr><td><p>Modified ISTH major bleeding</p></td><td><p>288 (3.9%)</p></td><td><p>170 (2.5%)</p></td><td><p>1.70 (1.40;2.05)</p><p>p &lt; 0.00001</p></td></tr><tr><td><p>- Fatal bleeding event</p></td><td><p>15 (0.2%)</p></td><td><p>10 (0.2%)</p></td><td><p>1.49 (0.67;3.33)</p><p>p = 0.32164</p></td></tr><tr><td><p>- Symptomatic bleeding in critical organ (non-fatal)</p></td><td><p>63 (0.9%)</p></td><td><p>49 (0.7%)</p></td><td><p>1.28 (0.88;1.86)</p><p>p = 0.19679</p></td></tr><tr><td><p>- Bleeding into the surgical site requiring reoperation (non-fatal, not in critical organ)</p></td><td><p>10 (0.1%)</p></td><td><p>8 (0.1%)</p></td><td><p>1.24 (0.49;3.14)</p><p>p = 0.65119</p></td></tr><tr><td><p>- Bleeding leading to hospitalisation (non-fatal, not in critical organ, not requiring reoperation)</p></td><td><p>208 (2.9%)</p></td><td><p>109 (1.6%)</p></td><td><p>1.91 (1.51;2.41)</p><p>p &lt; 0.00001</p></td></tr><tr><td><p>- With overnight stay</p></td><td><p>172 (2.3%)</p></td><td><p>90 (1.3%)</p></td><td><p>1.91 (1.48;2.46)</p><p>p &lt; 0.00001</p></td></tr><tr><td><p>- Without overnight stay</p></td><td><p>36 (0.5%)</p></td><td><p>21 (0.3%)</p></td><td><p>1.70 (0.99;2.92)</p><p>p = 0.04983</p></td></tr><tr><td><p>Major gastrointestinal bleeding</p></td><td><p>140 (2.0%)</p></td><td><p>65 (1.1%)</p></td><td><p>2.15 (1.60;2.89)</p><p>p &lt; 0.00001</p></td></tr><tr><td><p>Major intracranial bleeding</p></td><td><p>28 (0.4%)</p></td><td><p>24 (0.3%)</p></td><td><p>1.16 (0.67;2.00)</p><p>p = 0.59858</p></td></tr><tr><td colspan="4"><p>a) intention-to-treat analysis set, primary analyses</p><p>b) vs. ASA 100 mg; Log-Rank p-value</p><p>bid: twice daily; CI: confidence interval; Cum. Risk: Cumulative incidence risk (Kaplan-Meier estimates) at 30 months; ISTH: International Society on Thrombosis and Haemostasis; od: once daily</p></td></tr></tbody></table><p><strong>Figure 2: Time to first occurrence of primary efficacy outcome (stroke, myocardial infarction, cardiovascular death) in COMPASS</strong></p><p><img alt="" width="779" height="436" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAwsAAAG0CAYAAAB9pbszAAAYOWlDQ1BJQ0MgUHJvZmlsZQAAWIWVWQdUFEuz7pnZCLvknJEMkjNIzjlHUVlyBpeMigiIJEUkiIKiwEUwgJkgAoKIIpJEUUwoSFBUDGSQN4B673//c947r8/pmW+rq6urqqtDzQLArUSJiAiBGQAIDYui2pvoC7i6uQvgxwAECIAFKAEMxTsyQs/W1hKg5ff7P8vcU5QbLY+l12X9d/v/Whh9fCO9AYBsUezlE+kdiuLrAGBUvCOoUQBgp1G6UGxUBIpxqJaAhYoqiGLhdey/idXWsdcmttzgcbQ3QLEnAAQShUL1B4BuXS+BGG9/VA5dNtrGFOYTGIaynkGxtncAxQcArhGUZ2toaDiKuUkoFvf6hxz//5Dp9UcmheL/B2/aslEIhoGRESGU+P+nO/7vEhoS/XsMIbSSAqim9us2r/stONxiHaO6Q/fDvKxtUMyE4sFAnw3+dTweEG3q9It/wTvSAPUZYAMAJvlQDC1QzIPiLWEh1pa/6Np+gcZmKEZ9DzsGRpk5bvaFfajh9r/kw3G+kUYOvzGFujHWOk9mdLCT3i+ZpwN8zX7LbEwIcHTZ1BPuiwl0tkYxHYpfRgY7WPzi+ZAQYGD9m4cabb+uMzrnCPCjGttv8iDCoZG/7UI0AgLNrH9hy6gAR9PNvshOb8qGbhwoDvKNdLX8raePr6HRpl1Ism+Y0y/9kWMRUfr2v/grIkJsf/EjTb4hJuv0LSjuiYxx+N13JgoNtk17MSAiytZxUzcMSxDF3HZTB4wksAQGwBAIgGi0eoFwEAQCe6brptFfmy3GgAKowB/4AulflN89XDZawtCnA0gAn1DkCyL/9NPfaPUFMSh99Q918ykN/DZaYzZ6BINxFIcCCxCC/o7e6BX2ZzRnMIZSAv9rdG9U1xC0rrf9F02A/jcNZ4QzxJnijHESGC6MNkYTY4k+ddGqgFHDqP/W629+7Di2H/sO+wQ7gn2+KzCZ+i/NBYAVGEF1NP5lndc/rcOIolKVMfoYLVQ+KhvDhuEC0hgldCQ9jA46tjJK/aeu0X8s/tuXv2QR5YgwkZ2oSxT/twZ0knTKf6Sse+qfvtjUy+uPtwz+tPzbDoN/+M8HfVv8mxNJR64hncgd5AHShNQBAaQFqUe6kdvr+E9sjG3Exu/R7Df0CUblBP7XeJRfY657LVLugtyU3MqvNhDlGxe1vlgMwiPiqYH+AVECeuhu7StgFuYts1VAQU5BDoD1vX9za/luv7GnQ2y9f9Mo6B6npgAAjf7ftHB0bdcUoCF/4m+aKLoOOdUBuGrvHU2N2aRh1h9YQAPo0ZXCCfjQvUsctUgBqABNoAuMgDmwAY7ADexE/RyAxikVxIK94ABIA1ngKCgAJ0EpKAdV4BK4CupAE7gD7oGHoA88AS/QWHkPPoIZMAeWIQjCQ2SIGeKE+CERSApSgNQgbcgIsoTsITfIE/KHwqBoaC+UAmVBx6CT0FmoGroCNUB3oAdQP/QcegtNQd+gJRiBSTALzAuLwrKwGqwHW8CO8A7YH94NJ8Cp8BG4CC6DL8I34TvwQ/gJPAJ/hGcRgNAibIggIo2oIQaIDeKO+CFUJBHJRAqRMqQGaURn+jEygkwjixgchhkjgJFG49UU44TxxuzGJGKyMScxVZibmLuYx5i3mBnMTywZy4OVwmpgzbCuWH9sLDYNW4itxN7AdqBr5z12DofDseHEcKro2nPDBeH24LJxp3C1uFZcP24UN4vH4znxUngtvA2ego/Cp+FP4C/iW/AD+Pf4BQItgZ+gQDAmuBPCCMmEQsJ5QjNhgDBBWCYyEEWIGkQbog8xnphDrCA2EnuJ74nLNIw0YjRaNI40QTQHaIpoamg6aF7SfKelpd1Cq05rRxtIm0RbRHuZ9j7tW9pFEhNJkmRA8iBFk46QzpFaSc9J38lksihZl+xOjiIfIVeT28mvyQt0zHQydGZ0PnT76YrpbtIN0H2mJ9KL0OvR76RPoC+kv0bfSz/NQGQQZTBgoDAkMhQzNDAMMcwyMjPKM9owhjJmM55nfMA4yYRnEmUyYvJhSmUqZ2pnGmVGmIWYDZi9mVOYK5g7mN+z4FjEWMxYgliyWC6x9LDMsDKxKrE6s8axFrPeZh1hQ9hE2czYQthy2K6yPWVbYudl12P3Zc9gr2EfYJ/n4ObQ5fDlyOSo5XjCscQpwGnEGcyZy1nH+YoLwyXJZccVy3Waq4NrmpuFW5PbmzuT+yr3MA/MI8ljz7OHp5ynm2eWl4/XhDeC9wRvO+80HxufLl8QXz5fM98UPzO/Nn8gfz5/C/8HAVYBPYEQgSKBuwIzgjyCpoLRgmcFewSXt4htcdqSvKV2yyshGiE1IT+hfKE2oRlhfmEr4b3CF4SHRYgiaiIBIsdFOkXmRcVEXUQPidaJTopxiJmJJYhdEHspThbXEd8tXiY+KIGTUJMIljgl0ScJSypLBkgWS/ZKwVIqUoFSp6T6t2K3qm8N21q2dUiaJK0nHSN9QfqtDJuMpUyyTJ3MZ1lhWXfZXNlO2Z9yynIhchVyL+SZ5M3lk+Ub5b8pSCp4KxQrDCqSFY0V9yvWK35VklLyVTqt9EyZWdlK+ZBym/KqiqoKVaVGZUpVWNVTtUR1SI1FzVYtW+2+OlZdX32/epP6ooaKRpTGVY0vmtKawZrnNSe3iW3z3VaxbVRrixZF66zWiLaAtqf2Ge0RHUEdik6ZzjtdIV0f3UrdCT0JvSC9i3qf9eX0qfo39OcNNAz2GbQaIoYmhpmGPUZMRk5GJ41eG28x9je+YDxjomyyx6TVFGtqYZprOmTGa+ZtVm02Y65qvs/8rgXJwsHipMU7S0lLqmWjFWxlbpVn9dJaxDrMus4G2JjZ5Nm8shWz3W17yw5nZ2tXbDduL2+/177Tgdlhl8N5hzlHfcccxxdO4k7RTm3O9M4eztXO8y6GLsdcRlxlXfe5PnTjcgt0q3fHuzu7V7rPbjfaXrD9vYeyR5rH0x1iO+J2PNjJtTNk5+1d9Lsou655Yj1dPM97rlBsKGWUWS8zrxKvGW8D7+PeH310ffJ9pny1fI/5Tvhp+R3zm/TX8s/znwrQCSgMmA40CDwZ+DXINKg0aD7YJvhc8FqIS0htKCHUM7QhjCksOOxuOF94XHh/hFREWsTIbo3dBbtnqBbUykgockdkfRQLesnujhaPPhj9NkY7pjhmIdY59locY1xYXHe8ZHxG/ESCccJfezB7vPe07RXce2Dv2316+84mQoleiW37hfan7n+fZJJUdYDmQPCBR8lyyceSf6S4pDSm8qYmpY4eNDl4IY0ujZo2dEjzUGk6Jj0wvSdDMeNExs9Mn8yuLLmswqyVbO/srsPyh4sOrx3xO9KTo5Jz+ijuaNjRp7k6uVXHGI8lHBvNs8q7mS+Qn5n/o2BXwYNCpcLS4zTHo4+PFFkW1Z8QPnH0xMrJgJNPivWLa0t4SjJK5k/5nBo4rXu6ppS3NKt06UzgmWdnTc7eLBMtKyzHlceUj1c4V3T+pfZXdSVXZVbl6rmwcyNV9lV3q1Wrq8/znM+5AF+IvjB10eNi3yXDS/U10jVna9lqsy6Dy9GXP1zxvPL0qsXVtmtq12qui1wvucF8I/MmdDP+5kxdQN1IvVt9f4N5Q1ujZuONWzK3zjUJNhXfZr2d00zTnNq81pLQMtsa0Tp9x//OaNuuthftru2Dd+3u9nRYdNy/Z3yvvVOvs+W+1v2mBxoPGrrUuuoeqjy82a3cfeOR8qMbPSo9N3tVe+v71Psa+7f1Nw/oDNx5bPj43qDZ4MMn1k/6nzo9fTbkMTTyzOfZ5POQ51+HY4aXXyS9xL7MfMXwqvA1z+uyNxJvakdURm6/NXzb/c7h3YtR79GPY5FjK+9Tx8njhRP8E9WTCpNNU8ZTfR+2f3j/MeLj8nTaJ8ZPJZ/FP1//ovule8Z15v1X6te1b9nfOb+f+6H0o23Wdvb1XOjc8nzmAudC1aLaYueSy9LEcuwKfqVoVWK18afFz5droWtrERQqZeMqgKAV9vMD4Ns5AMhuADD3oXeK7Zu52a+CoJcPGH07QzLQR/gukoJxwOrixPBcBA4iP40WrTUpmHyUroF+mlGayZe5nGWUTZI9nqOFi57bhaeC9zv/NoFUwUdCjML2IodFH4oDCUVJP6njW7uk52XF5ezkkxQuKD5RhlXkVXeoZarf1Hi7jaylpu2pk6F7Re+lAcFQxcjb+KhJvelrc8hC2NLEKsg6x+a67TO7BQc2R0UnG+dQl8OuNW4P3d9un/GY37G8C3jSUDi9pL31fOx9d/n5+lMCHAK3BQkEQ8EjIS2hZ8JSwgMibHerUQUiCZFfop5GN8dUxebFJcaHJLjtMdurtU81UWW/epLeAYtklxTf1KiDB9PyD1WkX8tozezOepr95vDEkU85347O5s4dm82bzV8qxBxnLdp6wuSkd/H+kqJTNadbSh+eGTw7XDZSPlXxoxI5x1olWa1/3uNC7MX8S1dr+mu/XmG8qnjN4XrkjaM3q+sa6+80tDe23rrVdON2bXN1S3nrqTsFbZnte+8GdTjcU+nk6Fy8P/Kgt+vew/buO4+aemp7i/oi+w0GyAOPHxcP+j1Rfop9OjRU9Szmue4wbrgTjS/llxOvcl9rvh59c3hEc+Tj29J39qPIaO2Y09ji+/zxreMtE/YTY5MHp2Snxj5UfQybVpye/VT72fsL45cbM7Yz41/3fmP/du97zo+wWcqcHxpHY0sdqzJraxvzLwRdhoMQBWQScwWbhHPFaxGkiWI0YrRbSHJkDTo7em+GRMZSpmbmKVYGNjV2Ckc653Wu1zy0vIp82/mTBM4Ktmx5ITQrQivKL6YsbibhKRkvlbf1inS3zKQcRl5QYZuiu1KUcpZKhWqD2iP1dxo/tuG0uLXldax0Q/Ry9C8b9Bl+MiaY8JoqmBmZO1l4W4ZZxVkn2qTYHrRLs093yHTMdsp0TnWJdw1wc3Q33K7jYbzDfWfsrgLPy5Q2ry7vDp8bviV+e/xdAuQCSYHTQX3BjSHVocVhOeHJEdTdHlTdSP7I5agn0Zdi0mK94ozi5RKE9/Du5dzHmsiwH7d/Lundga7kKykFqbEHd6SZHzJMt8ygZB7I+iv73uHXRz7nzB6dz5099j1vJv9TwXTh5+MLJxhOqheHlVSe6jk9Wjp15v3ZN2XPy/sr7v/VXNl0rqvq03nBCzsullx6Xsty2fpKOrp7Ld6QuelTV1w/0Ii9pdS06/bB5sqWptbmO+fbjrbvuxvbkXQvp/PU/fIHp7uOPIzudngk3YPpGe692pfVHzRg99ho0OiJ3VOvoehnqc8PDe974ffS4BXXq+nXDW8Ojbi+lX5HeDc+2j526v3ucd0J0sTgZPnU/g+BH32mAz6Ffo74EjET8ZX6LeZ7/I/Y2cA5k3n6+WsLRgsPF90XPy31rZBWhzfmXwrchSygZ7AvgkNyMFKYXmwCThY3hf+LEECUJS7SdNGWkmLJ9nQK9HT0cwzPGVuZqpnzWPax+rPZs2txSHCycq5wTXIP8DTz1vCV8xcLFArmb8kRShOOEaGIGokJiC2Id0uUSkZKmW4VlIalp2SGZO/LNcqfVyhSTFLyVFZXwan0qhaouapzqj/XOKXps01BC6f1WvumTo5ugJ6hvqgBgyEw/G40YfzU5JZpoZmvuYj5iEWRpY0V3qrdOsXGzJbD9oNds32eQ4CjphPZ6bXzJZe9ruZurG5v3Ku2h6Pn/+KO2zuTdhl4Ejz7KSVewd7bfEg+w77n/Hb7q/mvBLQEJgXpBoPg1pADoQZhmLCO8IMRehELuy9Q3dAzuzrKJupHdFHMtpjXsUlxvHG34z0T2BKG91zYm7LPNVE8cW5/e1LeAf9kwxTJVI6DtGkg7ceh0fRHGbWZ2VmUbKXD+MPDRy7nZB4NzjU5xnTsXt72vOn8hAK9Qv3j6ScIJzOLx05xnlYoVT+jfla5TLZcvELwL85KxnM0VcRqejSStC56XjpUc6n28eWVq+LX3K8fu9Ffx1Lv1lDSONSEvS3RbNLi1br/zum25vY3d9fuCXYa3Pd/kN115eHT7tUeid7tfcf7Xz9WGDz85POQw7OGYcEXBa9k39C9jR3Lmoz/ZP1tbtFuff43v9GtF5wKAHlonul8GK1TAOTWoXnmLQDYaQCwJQPgqA7gQzUANqkBUPDBP+cHhCaeBDTnZAP8QAIooZmmJXBH8+Y4kIFmlBdBMxgA42AFYoIkIF00P4yEDqP5YAc0CkOwIKwP+8CH0CxvAF5ChBArJAGpQoYwBIwGJhRTjnmOZcJaoBlZOw7C6eKScG14LN4cfxT/jCBICCE0EPFEF2IVcYnGiuYszTytNW0VCUPyIrWTRcgZ5M90jnRNaKaTywAYdjOMMbox9jIZM91mVmO+yaLB0s5qzzrKFs2OYy/kEOWo57TmnORK55bnHuUp5fXik+Jb4L8nUCDos0VJCCf0QviaSI5oiJiFuJQEWWJG8onUra2npRNlPGTV5VjkZuQfKZxXzFAKUDZXkVFlVV1T+6T+WmNAs2tbh9Zd7U6dHt1hvUn9OUNghEP3OYIpwYxoTrJgsRS0UrK2tgmzzbdrsn/vSHZScnZz2ed6xu2u+4QH7Q65nc679npWUHq8FnyEfR38Dvo3BSwFGQSfCFkM8w4f2G1MbYpSiq6NlY67krBtT9++8P08SU+T81MtD84dys/YmtmR7XuENedN7qO8VwVrRQIn1UssT+86E192pmL4nHT1mYtyNSNXzl7fWUfbUNO0o0Wqjb/D+H5ZN6lXvH9uMHdI/Hn/y9Nvjr8bGPecWvzE9OXiN/BDbk59fm0xc6l+eXDl1mr5z4g11Y39A9r45sAEuIEoUAA6wAp4gFCQCHJBBWgAveA9WIXYIFnIHPKDUqAy6A70DsbAYrAlTIVPwu3wF4QHsUD2IrXIGIYLY4/JwnRgIawWdg/2FnYFp4NLwT3AM+Dd8H/hvxH0CHmEcaImMY84TWOMzvkKrSvtdTQTppIGyerkM3S0dHF0E/Ru9D0MxgytjNqMLUwGTF3MDsyv0Mx0iTWHTZLtIftuDjaOm5x2nONc8dxk7goeXZ4x3lw+c346/lcC1wSPbAkU0hfmEP4oclv0qJifuL6EiCSTFGErVpogQyfLJMcoT5BfVJhUHFLqUr6jcke1S+2F+jdNum1yWnbagTpRulS9AH1XAxNDdSMlYzUTE9NdZonmZy06LWesuW2MbIPRMy3f4bhjgVO+8xmXFtev7srbkzwe7eTbFeXZ6yXk7edT4HvDr8d/LGA5iC1YMcQxNCbsZHhrxAcqe6RxVEz0uZjhOIZ4q4ScPc/2iSbu2z96wD+FIbUrLSodl3EoC5OdfoQ7pz03Oc+1wOC45gnNYs1T6qUSZzFl9ypiKrnP3a72usB68VVNx+Xeq7M35Ov2Njxsom82bKW2Vd6d6tR/cLVbvqek79XAj8GvTyeejQ5PvvzxBnpLM8ryXnjCdKpwWvVL5vfK+ZDFnuXUlfbVHz8XN+YfRlc/I+AD0kAb2AE/sA8UgsugG3yAiJAUZAVRoSKoFfoAs8GGcBRcCQ8jjIgZkoq0IqsYTUwCphGzgtXDZmKHcBK4A7hXeG18GYFACCcMEtWJp2hgmiCaJ7SGtLdI6qQ7ZFvyOF0yvSB9K4MHwxzjUSZppkfMYSxklipWfdaXbPHsfOw9HEc4vbj0uSV5WHiWeV/x1fMfEwgVtNwiJ8QhjBNeFPkq+kXsu/iqJJ2U8FZdaU+ZJNlTcvXyjxW+K3Epm6kkq7arkzQ8NC9r4dG7arPeFv08QzajGhN3M0bzfsuT1uG2TvYKDsNO7s7drqZuj7f7eSzsTPGEKBFeT3xUfUv8iQEHgmiCy0OtwkFEHTU8ii+6PTY63mfP58SKpPgDT5NXUuGDhDSGQ4rpkRmDWU7ZU0fSj8rkPs9LL9As/FpUfXJnCc2pc6WqZ26X6ZS3/mVY2VVlWz14wfFiX41xbcMV8avHrxNu7Lu5Up/RKHqr73Zyi0rrVFvJXZt7mM5bDyIfSnWP9Zzucx1geTzwJGfI/Nna8MWXNq8m30SPrL5LHkPeJ0/AkykfMB/3T3/+bPwlfubU18Pfor8bfp//cX7WevbFXMDc3HzM/NSCx0LvosHihSXyUsTSwLLyctHy1xWzlbKV5VXH1Us/kZ+uPy+uQWtOa+fX5z/ST1Fh4/iASPoAYF+vrX0XBQB/DIDV3LW15bK1tdVyNNl4CUBryOb/PhtnDQMAJW/WUZfkEM+//3/5HzgJz+4sIVWHAAABnWlUWHRYTUw6Y29tLmFkb2JlLnhtcAAAAAAAPHg6eG1wbWV0YSB4bWxuczp4PSJhZG9iZTpuczptZXRhLyIgeDp4bXB0az0iWE1QIENvcmUgNS40LjAiPgogICA8cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPgogICAgICA8cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0iIgogICAgICAgICAgICB4bWxuczpleGlmPSJodHRwOi8vbnMuYWRvYmUuY29tL2V4aWYvMS4wLyI+CiAgICAgICAgIDxleGlmOlBpeGVsWERpbWVuc2lvbj43Nzk8L2V4aWY6UGl4ZWxYRGltZW5zaW9uPgogICAgICAgICA8ZXhpZjpQaXhlbFlEaW1lbnNpb24+NDM2PC9leGlmOlBpeGVsWURpbWVuc2lvbj4KICAgICAgPC9yZGY6RGVzY3JpcHRpb24+CiAgIDwvcmRmOlJERj4KPC94OnhtcG1ldGE+ClZGGzEAAEAASURBVHgB7J0HYJXl1cf/Nzc3e++9N0nIYK+wERDQOoo46179WrXVDq2r9fu0VVutdbWK4kCUKXsmkIQRCAkhe++997r3O+cNNwYMCmI1wnn05t77jud9nt/7kpzznKXSUYM0ISAEhIAQEAJCQAgIASEgBITAOQQMzvkuX4WAEBACQkAICAEhIASEgBAQAgoBURbkQRACQkAICAEhIASEgBAQAkJgVAKiLIyKRTYKASEgBISAEBACQkAICAEhIMqCPANCQAgIASEgBISAEBACQkAIjEpAlIVRschGISAEhIAQEAJCQAgIASEgBERZkGdACAgBISAEhIAQEAJCQAgIgVEJiLIwKhbZKASEgBAQAkJACAgBISAEhIAoC/IMCAEhIASEgBAQAkJACAgBITAqAVEWRsUiG4WAEBACQkAICAEhIASEgBAQZUGeASEgBISAEBACQkAICAEhIARGJSDKwqhYZKMQEAJCQAgIASEgBISAEBACoizIMyAEhIAQEAJCQAgIASEgBITAqAREWRgVi2wUAkJACAgBISAEhIAQEAJCQJQFeQaEgBAQAkJACAgBISAEhIAQGJWAKAujYpGNQuDyI1BQUID4+PjLb2IyIyEgBISAEBACQuC/RkCUhf8aWulYCIwdAllZWUhLS0NRUdHYGZSMRAgIASEgBISAEBjzBERZGPO3SAZ4JRIoLy/HgQP7h6e+d+9e7NyxEyUlJcPb+AN/37dvH3Zs3479+/ejp6fnrP36L7W1tVCpVEhMTNRvknchIASEgBAQAkJACHwrAcNvPUIOEAJC4AcjkJubi9zcHFRUVMDIyATTpvXi4MGDyM/PQ3/fIGrrajE4OAh/f39lTKxU9Pb2opBcjNzcPZCUlIjY2AmwsbH52pi7urrQ1tb2te2yQQgIASEgBISAEBAC5yMgysL5yMh2IfAjEMjIOIVT6ek4dCgRTs6uuPbaFaisrMSmLV+il6wGsTExsLa2UpQF3s5uRRs2bYKBSofmlja8+vLfUF9fP6qyYGxsDEND+Sf/I9xWuaQQEAJCQAgIgZ8sAXFD+sneOhn45UjA1NRUcRdycHRCf38fdDrgyy+/xPyFC/HQgw+gsbEBHR2dytQzMzMxQFYGnVaHX9xxJzQGhjhx4gS0Wi1KS0vBcQqZmadx+vRptLS0KBaIy5GZzEkICAEhIASEgBD47xGQZcb/HlvpWQhcNIGlS6+m1X8NLK1syP3okHI+uw+FhYQgKCCAshklkAJBGgQ1rXYQA/39sCNLg5+fHzy9PEkpaKU9OtTV1aGpqRmnTp0iJaEHndRHBbksSRMCQkAICAEhIASEwMUQEGXhYmjJsULgByDAygDHIegbuw7VVNbA2MgYPd1fBTCrVAZQGRigu68PVtbW5H5UB0vzCXSaSjm1u7tbsSh0d3ehm1yYWOnQaDT6buVdCAgBISAEhIAQEALfSkCUhW9FJAcIgR+agI5ckPoVNyRKYIRly67GW2+9hc6eTsybPQe2FLz8yquvYJDcj8LDwtDQ0IhbbrkZzc3NmDh5MgwMVAggK4SXlxemTp2iDD41NVUJbt64ceMPPRm5nhAQAkJACAgBIfATJiDKwk/45snQL08CRmRBmLtgHgU4O1Ggsi2mT5+BbrIosALh7e0NIwpUnkAZj7jIGqdDfeKJJ5CedhKBgQEERAdPTy+YmJicBYe/Syaks5Bc8V+4QB8ro3Fxs7+RxYEDB6BWqzFr1qxvPO5K3jnEUkUs465kDDJ3ISAELlMCoixcpjdWpvXTJRAaGqoEKE8hKwELaePGjUNnZyf6yN0oODhYcS1qaGjAjBnTYWtrh8KiQrIgTFVcjCIiIs/rasSBz1dC44DwqqoquLu7wdHJiZSqQrRTytj7779fmf7rr79OaWmNKC3tNDQ1NqK2ugZ5pHix2xZnjPLw8sDNq27Grl27kUVB5O0d7RRErgUHn3uRsmZlZYWuzi7cTNYcfXv7rbfpmpUkfBtQTAlxJiGc72NY2DhkZGQgJztHsfhEjI/ElMlT4OHhoZy6f/8+FBeXopTqZZiZm8GPFL4br7te3y3Wr/+C9pVR/EkTHB0dEED7Oa7lUtt2qsuRl5cHc3NzslBpMXfOXHAaXk7TW1xSjPvvux8ODg7KZbJzsik2ZkB57pYvX35Bl+YCgHwPTtPcff18sWLFNQrzNR+tQVlpmeJO50Dz8aN9y5YtV5735KRkYlGM6fRc+/r6KpYxvpi+NkhNTS3q6eXp44WFFPC/9rPPUErHO7k4U5awWLS2tqKExl5TU0N8PXH77bdf0Fgv9SBmmZubpzwfrNDPnz//UruU84WAEBACY4qAKAtj6nbIYIQA4OrqqrxGspg0adLwV0dHR7IiBJ71ffiLfFDSw7JwzdmgHCmrVEtbK+ztbBVh8tChQ9i0cRNUagOYmZmR4D4ZOVTbggPBfXx9FKUsOyeLYj8sYEr7U1JSSEHwUlLRmpqaKQI0K25pZMkZqSwYagwp4FyHxKQEUjhMEEIB6ewelpSUhKNHj9K1zGn/AIpIkWGBcuKEiYqrGGep6u/rQW1tDcWfqFFFgq4dxZ/waj/Hl5SVlePw0SOwtLBEcEiwojDyLea0uXl5uRTb0qdYl1gR5NobZWVlGBgYgKWlJSmStqgkBYZT7mo0RqSsGGA8KStOTs5KTExhYZGioISRK9uuXbvg4+NDz50bykhp4OJ+u/fsUVzhSkpKldoe1jSukY2v+d5775G1y4uEfv/h2h98DLvEsUK7fv0GzIybhauvXoaPP/kIu3fvhpWlNcXYWKKFhPvKiiqly/b2NiQfTkYCBfDHxsZQxq+O4Us1NjXSvWtXihL2USzP//zql1Sw8IDSlxExyqYaJGpix7E+mZlZVKOknBTEYhibGGPlz1cq/XDhQuai5eQA9L+NjbWiGFZVV8PczBTR0TE4fvw4xfZ0w1BtSM+QGs7OLoiMjFTOz8rKJOWnWhmXtY0Vpk+boSg/O3bsUPZzZjJ3d3dScnyU7/JDCAgBIXA5ERBl4XK6mzIXIXAJBDiugYvBsVDF7k1juXHQN9ebmDXr624fLNRyUbq8vHxa1T+tCPszp09XLAf1lCXKgBSF9vZ29HZ1o6CwUFnN5v4mTphARe/qSeBPhMbMRDm+jYRYFxcXcu3yJMXDUfnMQmVTc9NZeJzIgsGuXoePHFGO4xVzFvaryWrBK97swsPZq95/fzWaJjShgWphcFwJr4D39vQilAT2trZ2pRr3Y488otwDPp+zWxXSGFn5YMWH5H2lsUsZn/vBBx+QpcNGsX6cSD2BttY2EnKdFAsIC7cs+Dc21LN8jPlz59K8OxRlge9uV1enklaX7zVbGFqpT2OyuFSTRYCVJFYm2ojTqfRT8PAcsoTwxatJwE6nWiAcMM9C+H333Ucr67mKYhESEsqHKPuOHT0GJwdH5R6wksBKVBH1yZm7/AL94eHmrqT9ZWvCsWMpylhYMdtOAvjdd9+t9MM/WAlgSxC739XV1SiKi6WllXL8zTevwv59+1FXW6fUF2HGEyZOJItQlmIp0XfCihMriu2UdpiVusHBfnrXKpnH2HLHdU24GGJLSzP6SJlj649KVaeczookW2HKyyvoVUbWnUD09/YrSiizYeY5OTlwJgvHmdwC+svKuxAQAkLgsiAgysJlcRtlEkLg0gmwoqCmVdX6+gZ6H9slWNzc3JTV5NFmze5FXJjOjFaMi8hFKzommly2ZtAK/xF8svZTEvjdYKRpQCKtZMcZz1b6YeE7g+pRdJIw6eLshnYqcKchBYIFVRb22QrhStdkoZNdlZjTyLZs2TIkJycrykSAL6WxJeWCK22zkBkUFIQ777xTsSgc2J9ArjMlGB81XjmdLUZsBUg5noI6GjOv8vM5PD9uLKRHRUWhlSwQ2WQp8aSgdW48rtraWqxe/T6uu/7niqXDwcFecZFiBaiB3KvcXN2xmywG48LDsH//friQQuNN1gNuKgqCH/qgUpSUivJK5VxzmmdBcSFiYmOH58PzYDcsDpznxhYDFriPkGLEbkusJM0mSwgrXKwssMtVdnY2jSkNE0gBO0TKVz2Nx4L6njdvnqKkdNB8mkh54JictPQ0VJNFhYXuKVOmYOu2rYih4oPMmt21XGiFny1FMdFR6KM0wKwQsBLEysOK5StIacgkC0qVouQEhwQpq/vtdM+aKXWwvrGlYsuWLXQP3ZX7OUh9ODs5Kve7ip77+fMXYN3nn2PenDng9MQaSl/Mzww3/ndRT3PevWc3AgP8sXHDRvz5uWdxnJQz3scxRgacmezMf/pryrsQEAJC4HIhcPZfvMtlVjIPISAELpoAC605ObnK6qpeMLzoTn6gEzh+g4O9R2scI8DCXV9fv7L63tnZoawqO5FlIJMESytLG+W09NMZmEqKBbsQNdOKspIxioRMb09veJGwX0xxBGxlYWGZ3zmmgVPQ8ndObXvo0MEzl1cpQjG7LWmoL65roR3UkhJiQEqJRln1j0+IP9NHF8ytLYaFdV6RZ6E7/VS6snJ92623wcLCQnFfYlcYf1qFZ8Vh44YvcPBQAmbN/MqSwuPgOIopkydSDEW74jbFAbbJyYfJrYoK8TW3KNaXW2+5FfmkgHABP31jYZ9X1sPCQhWBe+/efUpBv2kU+6KlmAu2kKgNVeQ+tJRW7vcpVgc+nhsrKqxQlhAfvg8cm1BDK/5OLk7K/mxaZa+priWmLWhsbVasFRs3bMDtt92GyeT21UcMuVDg9m3bFPelhYsW4jApWqzcNVC/rDSwQsL9s7LACgQ3FvbZAsB+ROwmpqX5nDx5Urkv9hT/YEoxH93dvWRJaVQsIrbkeqZvfP+4/wnk4sQuXFzckON8OsjSwmOzJkuUCga4jeIcyiurFFckmqhyeg+5JhWTAsaWLN7/m988jiyyQpw4nooZM2coFqJOUkYG6RqKCUd/UXkXAkJACFwmBERZuExupExDCFwqgTm0qsqvn3orpQDavPx8xd3oqqsW0ap1reIKM6AbRBT5oI8fH664xBw7doxWwbOVYOUFFJQ6e85sHKVtx8jNSGOkUQR/dmniWABe0TekYHMWwHvIbai1tYWEzirFXYtdeHjlm5uB2lCJh2B3FA4QtqRgaHbZYaWgi5SI6voaLHReQAqLlXI8KzZpJ9Owc9dOLJg7HyzghlBg9OZNmxARGUFCebki1Nva2nPvyriUE8/88PL2Ue5ZMsVGuJNS4UKuMFZWQ/EKDqQcsWDM82xsbCLLgHr4VK7PwdaFqsoKxVe/pa0FgWQB4YB69v/38fMh1x7ilnZKiYPgeXDMAzdWZkJCAkmJuUdRnK677jrF1YvrgHCQNAd6V9dWY8GCBeQ65YBAimfYuXMHjqecgCO7SJG1xMvXFyWlpYpiygocKx1XLb6KeldRMPQKsrQcV2IA2ELE7l/clJV7GjMrgYb0zopSNim3LPCz1cSa4jrY7SstLZ3iIVoo3iBcOY9/sGLFMQjszsXxETx3F4rPqFPXwtzSgpQSd6iJ7zFyv6qpqYYvuUPRzVXO53gPB3t7ZGVn4cjhw4qVxcnJhaw+nqigmJI2UjDZkuNLc6JBShMCQkAIXHYERFm47G6pTEgIXNkE2KfeWGNMQajT4OPjqwjMvHJuRAGvt//iThJi58HOzh7vvvsuua9UKwK+J1kpWAhdfNVidHR2Y9fevZg7cxatRlviiy+oNoVKB0cS/mfPnn0mLa2agntXKwK0i7uL4irUTT787HLEK9imJqaYSXEKanLN4WDhDST8c2zA9ddeh4ULFil++3yXeEWaG7sHVVM8xfr1G2GqMcFJEqzZ4lGQX6gIqRzYO3PGzOEgYo5nYAE7KipakWk9SJlh4XWA5uBo7wB3EoQDggJRRPEAH364hhiUKW5VysXoBys+QYFBiiJxmARgDlJeQC5CrFSMCx2HeXFzUFtZjSMpRxWLRDgpJRzgzU2JOSCLBwvg7KLFAcm+5HrFbQ8FRbu5uSKUgrFjYiZgyRLiSXPkeIh6ip0oLimi4OROOtIA48iqER4+TrEGsPXgj398UukjnlK6btryJQnzrhSwnKkw5x0aYw3CI8KVxfvZ8+Yi8UgyTlKcTRDNkwPGOah6YGBQURYi6Ljg4BClP/4xSNsD/AOUOBLOIOZEigPHUJjSa9qUqWRBuRpHSVFYs2YNuYHlYjK5h+njdjgYOoziGnIo49HOHbuVIHEf4jV/3nxs3PiFcn8sKGDbk7bpzxm+sHwQAkJACFwGBFRkUh6ytV4Gk5EpCAEhMDoBzh7DKSU3b96MtWvXjn7QZbKV58pCGwv23Dgg2dPLW3FxGTduKABX2UE/9pEvfwRZG05TEOvcuXOVzbw6zoK6Ma0ok4xJ3ijsvsO/JlWK+4wJKR2BgcHkrjPk1sMr7uyCwlmsOM0n/0qdOXOm0hf/yKYVaV7VZlcYFvLZF1/fDhzYT/ELUbRPqwT7VtOqtr+frxIg3N/fp7hRxSckKAvW5+bw51V3FVkBdOR/X04WBF9SODLJvYeVCE4lmkNC73v/+TelJa1QAotffPEF5Vos7HNjTrEUG8AxAxwoznU77EnRYHejvr5eZT6czYm/89i5fZvlifvkGAu2mJyvLgMrAxER48lVKk3hwf3q4wP4Mzd2CfP1pfmQsjCDlCRu7K4VFBxEQc71CAkOVradOpVBvLUkwA/FgHDf3PT3Xvly5gc/B3xsB2WzYiUrnWIqOBaFA83bKbj8L3/5C2rImpJXlI+HH3gIYWTh0T8T3AVbiPgZ4IxS+paScoz46JT7xdu+jY/+PHkXAkJACPyUCIiy8FO6WzJWIfAdCVxJygLHFnCwLQvm3HgFnDP3sALBLjQjG6/6cypTzrbDgcvcWNjn1fDRGh/Hrjp8jZGN++X+z702H8PCNqdb5cZxISMbxz6wcK9vrHiwWxNfn9+5Tx4jX1M/H/2x+nHytfm6PE8ONubtLOT7+voq8QYc8Dx12nTFX9/Z2XnYnUh/be6Xzxs5znPnw33yS89IP4Zz38/t89z9/F3PnPvi+bEiwi5FIxvfL/189PPm43ieekZ8PHPlsTMfbsyS58Hbzm3cJ98/7peP099Ljp/g+Jft27bjJKXEnTpjmpLFaSpZHPg50jc+j8fO90XfRvbJc+E+pQkBISAELjcCoixcbndU5iMERiFwJSkLo0z/itvE7kEcR6EX8lnAZoGY36WdTYAVHHZdYyWDebHQz+ly2eogTQgIASEgBMh1VSAIASEgBC43AvHkjtLd3UWvHsWawBV/2aedg31LKbCWC3Z5Up0CXkHn9KXsPsRBy51UmfnGG28cFQdX6mVhm1e6WZgso5z71RTzwEGzHKvA+fg5CxPHA7Cr0UgXllE7/J42cg0DzvPPY7CnQNyJVGeAA7PPLaL2PV3usuuGLRw+5MIlTQgIASEgBEYnIMrC6FxkqxAQAj9hApyhhv3duTozp8jkysZ7KWj5ENUFMCdXIF5NDvD3w7hxQxlzOGsQFxjjQGJeUeaAV33bRMHJnM3oJGUtmjhxglIrgHP77923R8nlX1FRSSlVe1FSXERViI+gh9xdJkyaqKxSc12B/3ZjFx4uOMbFxVhBkiYEhIAQEAJC4PskIMrC90lT+hICQmBMEKig9J2ZVMSMawA4OTlTwO0psiw0YRcVKXv4lw9TMTA7Jc0o10XgbEBFRUVKcS/Ot88pUUc2vU89WyY4/7+xsRFZIDqUys/XUFGwtZ98qigkB8ia4eXphYpyqvRL6VsdqXoxNy7clZycpNRR6B/oI8uDRvHR57gEtmxwLYHBwQGlmnQfKR0aWukOJisBBwjb2dkpikApKTsVFeWKAhIUFAyuh5BICkJ2TjbFN3QqysxQvMTZMREj5yGfhYAQEAJCQAh8FwKiLHwXanKOELgMCXC2F86Iw/7u7G7DwbicQ58bu/Ww4M0Bnhz0ybUHpk+frvh6c2Gs2toaEmShBHjOpixELABz9hl2+eHqyOwHziv2HGDLQjCv4vM5vb19iltPKGWe4Wq/xZTqkwNOGyjNJvfHLiKLFi1SahZwNhwWvHkM3D9fZ7TGwb35efnoISsBV13m7EYqqrDLRdNiqJozuxoZkMDu7u6mbC+misqcMtSaagm4uroocw0MCsCM6TOU+TAHJ8rjzyk62bWnnfL619XXUf5/JyWIuLO7EydSj5P1opyE+Gl0jjEVJaumGgItyvCGYgeAtZ99pqQZ5euxUsEuUqYUiGtsZKTkWuKCY85ODkqKzkmUmae9vV1RFhpJSSkgq0UWWUqYfRkpI10U2Mv9ZFGdCAP6jxUavmfMWZoQEAJCQAgIge+TgES7fZ80pS8h8BMmwMWo2OedlQVe9ebKtfrGri4sqPI+FtZ5JZ5bHdUGCKY0lq1UdZf3cRpJDhbl1kiFqob6a1Oy1rAwywoAB5Hyaj8fy+f0U20AVhK48bmc2lPfHx/L/XDr6upUhHUWjFlxOV8rJsG6hhQRdsnh+AFWSjhWgbMD3X///Uo2nKysTCWFLLsXFVK2oCyyQpiZmVAK1D4l1akZ1RTgeXJjZWXlypVKnMLQHCgIVvmPqgWoubgZpU6lTDmclpM2K++6EUI7z4EVJlYaQkNCMUiBtJZWFoiK5pSpA0g4mEDpS9MVxSg8PIJYtSupPPXzq6WUt0UFhXAmS4UH1U8oJvZ1ZOHgtK/z5y/AXHJ1MqG6DhygO5TiVX+mvAsBISAEhIAQuHQCYlm4dIbSgxC4LAhYUAVcTiPKwr8BVbhVJN8zM+MUkewSw6vsLDDrU1VyGkmu38DnsFDMwb/6wFquR0CbaF8QrXizEM357+OUHltamhThm5UJFuhNzqTO5OrDLS3NZ/XHrjrc2DpgaGhARb/clO+j/WCrRFZWNu3SwcPdXRkvC/KpZP0ICxunFFbjYm183F6ybtTV1ZIg367M19fXD12kYLiSQL5h/UZFAYiOjh7OisPzYz6sONnRuJvIGtHc0AxDIxOlX65OzK5KXDGaLQbMSt90JMiHhYXhlltuwXGqIRAbOwHeXlQlmZStqqoK6pMKhNE5bK0wp0JwIxvzsSTORlT3gXkzI42hms4xhtqIKkbrSAnj/xiwNCEgBISAEBAC3zMBURa+Z6DSnRD4qRJgt6LztfMVm+KCVvwarcXFzR5ts7KNi4CN1nhl/XztfGMYeTyv3neQm1BkeCQJ5LFYSFYBDmx+7fXX8fFHHymWgM6OdqhJqeFibKam5oo70Oy4OPzmt79VioFl5eZg9erVeOy3j5FVolaxSPA1WBEypBdbEpxJMTAlwf2Nf76BuLiZVKl4KSkKLUiIT1AsEkuXLoULFWLTN3aBsiEXJm5mpGywwqWlYmqsUIWQtYELuiUnJeOtt95CCWdrIvcrfXMh1y0newccTExSxj9lyiSqfjwO9VSc7M1/vqkoDwakjQ0pXOKGpOcm70JACAgBIfD9EBBl4fvhKL0IASEwBgjwyv+yFcsVQXzhwkXKiKwoFuHRRx6h2ABjGJoYKRWL3Ryd4czpTylw2MHRkRSMduVYTqk6bcpkpahXR3sbKQhGw7NiC4mzi6tiSfHy9MTTTz+N/Px8TJ08WXHReuKJJ+Du4a6kZOWiXwsWLFDO5UJdYZSpiK/DSsJC2u5PCpYJKQQL5s+HEVkV2BUrJiYWVWSl4fgJVij0bSllZuKK0tNmTCcXpkFFkZgzZ65StTiGKjBbW5qTRaRfsaSwZUOaEBACQkAICIHvk4AUZfs+aUpfQmCMErhSirLpXXHODfTVbx95e/iYkdv154y2jc87d/u530ceo+9Lfz39sedek/dzsDdbLdZRADTHSURHx+DOu+5UMi95eXkpXejP1/en7/982/XHybsQEAJCQAgIgUslIJaFSyUo5wsBITBmCOiF6HMHdDHbL/TY0Y4bbRuPZeT2kZ95H9eBaCcrxpNPPcVflcYB0e4Uc6Fv557zbdv1++VdCAgBISAEhMClEhBl4VIJyvlCQAgIgUsgwEHL/JImBISAEBACQmAsEpDUqWPxrsiYhIAQEAJCQAgIASEgBITAGCAgysIYuAkyBCEgBISAEBACQkAICAEhMBYJiLIwFu+KjEkICAEhIASEgBAQAkJACIwBAqIsjIGbIEMQAkJACAgBISAEhIAQEAJjkYAEOI/FuyJjEgJnCHC+/uPHU9Da2gatTgsLcwv4+fnBk/L8c+PqyZmZmVRYrIsKjJlh1qxZShrOM6fLmxAQAkJACAgBISAELomAKAuXhE9OFgL/XQLtVCxsYFCL1Ws+RCd9XnXTKrACwcpCXV0dkpOTkXoyDUePJCMyIoIUBhMlT7/piKJe+hGeL/2mfr+8CwEhIASEgBAQAkLgXALihnQuEfkuBMYQAS669c47b1NFXzPY2Tpgz5490FfpzcjIQH//ABX12o+IiPHYvnM3mqiCb3l5uaJIlJaWQv/q7u4eQ7OSoQgBISAEhIAQEAI/FQJiWfip3CkZ5xVLoJ4sCPPnLYKbuws2bNioVPllGAMD/eSe1EJuST545JFfo66pHvn5+QgMCFSUBBMTU1RUVCjHcZGv06dPX7EMZeJCQAgIASEgBITAdyMgysJ34yZnCYEfhAC7Dj340EP4x8t/R1t7C9Rqw7OqAY8chCHIUKgd2qLVanEyLRXxCQfR2dmpuC61trTAydFx5CnyWQgIASEgBISAEBAC30hAlIVvxCM7hcCPTyA4OBjLr12B+Ph4WFhYgC0G27ZuIxekfpiamSnWg/fffw+pJ1JxzTXXKsqEl5cnHBwcMG3qNLArE1sV2H1p9+7dP/6EZARCQAgIASEgBITAT4aAKAs/mVslA71SCdTXN+BYSgp0UGHxkiUYHxmBwxTY3DcwiNjJExE7aSISkxIxedpU2NvbwcPDA2akRIxs7I7EgdHShIAQEAJCQAgIASFwMQREWbgYWnKsEPiBCVhaWmKALAg33niDYjHg77UUw+Dq7q6MpKO1FQvnzcOMqVMVBWHy5MkwMjIadZTsmiRNCAgBISAEhIAQEAIXQ0CUhYuhJccKgR+YAAv+c+bM+YGvKpcTAkJACAgBISAEhMAQAUmdKk+CEBACQkAICAEhIASEgBAQAqMSEGVhVCyyUQgIASEgBISAEBACQkAICAFRFuQZEAJCQAgIASEgBISAEBACQmBUAqIsjIpFNgoBISAEhIAQEAJCQAgIASEgyoI8A0JACAgBISAEhIAQEAJCQAiMSkCUhVGxyEYhIASEgBAQAkJACAgBISAERFmQZ0AICIFRCdTX16Oi5ghWX++NCYEe8HGdhVte+AIbPn8df741Gt5ukzFn/l/xDlWHvtiWkfMxXpv8e7y59iB2Jydd7OnDx5eVlaGkZD/evdoGkX4eWP7SLuxPShnezx/SjiXi8Ks3wtMnGB7z/o7NOcUoKCw465hDSbuQ+NFLeHraL/Hn/Rc2n+LiIhQX7MHbi40xztcDnp6ewy9vtwlYdPtf8fq2xLOuc+6XAwkbsPOlp/HMtc/glZ1Hz939g34vLsxH2bpfYeZfjyE76TU8OisK0TY34KF/7sSGgweVsRxPOojEd57Hnw9kYXBwEMdeXobffnICR1JPXdJYC/KykfD8dIWfr/NCPLz2KA6fOKn0mbBrLdY9vQqzXcIwefavLvj+XNKARpyceGAztr73Nzz80MfYkZ4+Yo98FAJCQAhcGQTUz1C7MqYqsxQCVy6BkpISdHR0IDc3F9dff/0FgeAaDzVVHfCbEgHzk6VwuukBTAi2hm1bNRx9wmEZtxyP3TERgWYmcLC3v6A+9Qdlv70Kb31uDKtVC+Fm3IUgb2/9rot6NzExQUVFG8YvnAFtTQ5qsu1gE+yFruZyeJPwzq047zSK41/Fxs478cq7d8KrowaB/v7QaDTD1zI3s8GghTNCropBhIPpBc3H1NQU5eVtmLB0LlQHMuHywHNYuXwhHnn4QYQ6GiAq1BUttm6YHjBUQG/4YvRh9zvvIq2lBb0GxvCNmIjguFBEutvBztZ25GEX9XnPu/9GenMDSqqqEOh1cTwzT6Wi9uiH+HlGDN5a4YGmbY8iK/JpXB3RgGZzO6odbgxVZyUpCA3IKfLEolhHODk6osM6HLoDv0VCVzBUPW3w8/r6XM+dxJ7V7+NUTS3yq6sRTPc9I/0E2soTsKNxMZ79w31Y7noKr1X5Ic7dGBWlR9GdVIzqmkBMfvVWLPMBKv9cgNypFggxNz9vAcJzr/ldvu9ZswanK3NQ13wKKZ/vw1Gz6ViwwAd+Nt/9Hn2Xccg5QkAICIEfm4AUZfux74BcXwiMUQIsTIeGjkNNQxc87ezQE+gDm95jKGntR4N5EG6dEYLIsNDvNHqnWfdhydRCkLx3Sc3YmIRt3wCo6d096g7YpX6Ahu4o1LQOVbFOTUlGb8MJlFmuxHgLT0SEOMG1XgUW9Ec2BwcH8OtiGisq3j5+sLC1gLe1NbRB4fCzaEVbaS5sPd1RbeGKhR5fn2D8wW0wyK2DKjgGWnQgPDLyYi476rHxB7cD+fWAXyQ6BrtHPeZ8G0+ePIbW/GMo+JgKAD43FdHh3tjz70Kajz98bVJQ0NmDvj4d2qsbYd7bif4J/ggNDlK6Cx4Xic7Z10C1rwy5lqRQHDmCuVOmnO9SOJBAcy+oh84xCF3aAeW4vp4+RPhNRbGTE2JjvHB00yGEuj0AjVoFk8ZyHDc0Qr6TNW7vN0ebsRl8vd7A4db7sXKw97zXudQdBxJ2wKCoDjrzcLjOmQuzBkMMpF5qr3K+EBACQuCnSUCUhZ/mfZNRC4EfnED7ic9wxMUfFkYeWEoCo15RaGioR/aud/FpYikGBnUwGPRAUFwkgtwG0FzUhIqqBhgZFCG32hxqp/G4al4gZk2YizCXOrQa6aAZKMcbLzyB9JJmqHRmsLILRtTVIfBqy8WBw2o4WqajoKoPTVbjsHL+JCyKmzrq3HWmvoiLdcBzFbWw1zgqx3Q0NMCDBEzDmADYDXm1KNu3/Ps5HD5djgaVH4LHhyI8wBh9JVWoyuiH9ZJQXDd1Kra+8SgOFvShwzQE0VMcYNY4iK6aUrQZdqPVZDxmTnDDlPCIobEY5ODgm0/iGCkQRnVtcF64EkHh5jBR67Dto5eRnJSP0oBAXOUcg6v8yvFixn6cPF2K0GXRqE7Lg1GbGjaz3GBTX4qkE0CIbwkOn2pGm1M0Ztg3o7GqEgXtdvDycoSHWR0Op9XQddVQD/ghZmUsVthX4tXT+3AstRDjli1ER/m76Mo7ivQGKxi7RmLhbF/YdOTi8O5TyLN1wjj3SEwL98LkyTHoaqmFqaodn1v64FFdDdRqP3hOWwWD7f/Cfwq7YXfzbIyz7UBHTTVOIgATvc8W0vssouBougbNRmGoaB7al33qJHKTNmH7yWoap4rG6Y+oG2Kw1LEa/8k8gISkLIQuvwrm2iSyVvkiJe0YJpsfwb33nkLNIR+EveECI00zepsa0GFmD3NbS0yfNAXpBjrYxuiwlfQibgk7P0TqyR6Ym9ShtqkOJb3O8HCzR8BAPg4V9tPzFkXPWwDiSCE7tP4NHDldgvpOFQbs6FmZOhFTgl2Rn56I4+n9cLdNw8kiA3S5T8Gd0V04mhuPPfvSENE+G2GuwbCqzkbB1o34LMMCPb6zsDKULHXJWcgxsYKfRzjC3czRX1eMirw+WMXF4Lar4oYGKT+FgBD4XgkcP34cheRK2tPTCwNaVLC3c8CcOXOURaCtW7eilay2AwODMDUnKzEtAvl4+6C0rBS9tDAxf/48GBqK6HuxN0RiFi6WmBwvBK5EAqpy1Jzchz3bslHdokZvX98wBUO1IQZN7OHh4Ql7R0N0n8hEo2E/uurykLbuc+xMykHxgC1sLAzRm78NRwzCoDUyHj6/b1ADa3tnWFqawHKwA00n8tBMMQAmJ9fg8zXrcbLDEmauQMeJBiQkkzBNfyjO1+wmX4fIlhKUl9Vh49496OrsQm27NSJdtcOn5Bz6AhVdg9CZ2MCooxD1PQNoHOhCb/peHNrejoHwICRvfgclKieY2zjAuOU0Tqfsxvr1m5BwsgyVWju42JBSYDDi16fOBBYObnB2cYWTvQWsTNTK9Vrqq+ClzUZejwt8jApQYT4F7SpjmBqYwM7RHjaqMpQlHsLx1B6oAyzQl/IJPv14C5LayJ3KrQ818QeRVkCr+VbWMGyuJ3edZrSYO8Le3hbODmrUrUtCo28sujRGMFLRH0Yne/g562BjqULlgA2sTVUwaslCijoU43AUxT32sFTXo8PcE6W1HcoYdb29aGmsRE2EBxZNmw6VSoUmx2swPpaUtsXTEe7eC387E6htSJkxb0HWlzvw3POvYfWOBHR3d2PKlBkwtOlBVVMTOruGrAUaUprUlo70h9oeri5GqN9yGE3uEeg1NofGwAgONHcLMzUsTTRwdXND2ISpKKo1JGXICwE+dsg7nons+layLnTBmBQEU8MhlzEem4W1M1QGhjhyIhEmOVuwd8N67MptRZelIfqrs5B58DTKVHawtwSaDmagPWQ6Uvetxf6cUrRqTWFppYG6rRCHkpOxN/kQuo58inVf7EaekRccvHpRu6UGeQ296KT7ZG9vB1sHS1j0VaC9Kg2F/T5wcu1Cxb+roO0gq0uvOY2vBX2mjqjXWsHQzBLWztawNBq6/8MPnXwQAkLgeyNQV1dHLojG6O7qIddILXx8fNFLv8e4dXR0Qku/7rvod5OFhSV66L2FlIfJkybD3dNDibX63gZyBXUk6tUVdLNlqkLguxMYgLHPDEzv6EVvcTmtGFvTyu8JTI2NhQ352c9YcRcJjFtRnzuAQybF6OnqRHtvN3roF7eRfwj8pyzG1b5G6N70Myw/0oSHo1XDQ1EZuyBmOq3cmsejMiUbaSoSiFt06DFk5aET9pPvwx3zOpGTvwXVZnao7GvC1s8/QDm5R6nUJPjZe+GmZR5Kf8frrTDdug57DLzRauaIYDtT5DYNIlI7pGCweD9JdxBvVkTDw8QY1toMpGacRFOvL+bDAIaklJiREDuhZyueKrwaC927YVO6H18kNqO13Arzly9GaFQEHlo2XbleY2Pj0Dx0Poi54UFMIjcko/Y6WmHvgDUJryTVwpDiFoK8rOGdcxonxmnR5hWFSa7FCPn5Uni6FSLrZAXSdToMkFDMQrAVuedox92Mh+aXI3D/M0hxvA4Tb52I5RTom5Tdh16/OMy2Po5Wij8pMa9Fe5MOHX7jMdmtGMEUMxHuW4SsXWnIaHXGFAe6D/n78PyOG3BPnCt8/O1gWkGKnw/dxzO//bXaQQz0dsHF2mpoLvRz1oIb6DX0ddfn76K5wQ0GtlaIbU3E3+NzYelqiJ0By7Gsq3vYpauNFDMXy6E+AoJCYWFlA2Or3WgrzEUpWUPa6J62hYQjxnUCfOJmwsBJhdlTJykXcXRyxrwb78c8+law7Q/433fI52fWrfCwc0fvMRW6BvqV4wgTOlsNYBVJdhWdiuZgCLPBHmjcpmHezcGw2PARtuztgnb+XfitVRY2HnkBuc0qzGzegHiTu/HsVe5wMB1ER9oXFI9QjtMqshCp1LAz0MBh/p/w4LgjWPfJF2ixm0oxL/0IC4uB39IgGG0uRpaVE7yW/RG3uCbjjWc/R4mxPex8HWBfWo/m/h70DJri6p/fNgRNfgoBIfC9ETh8+DBZEXoUhUDHvysHBpQYPAO1AbSkLHCyCV9fH+V65uZm5IraQBZSNVqam+Hq6gJb+ht1hFwke0ihCA0OVo6THxdHQJSFi+MlRwuBK5OAzhde829DiHEuinck4zgJcLvtNGTOTUdYQABOJO5CbUMR0pPzkN/aDU+tFyKW+MK8n1aym8YhyEUHku1g7+AFx0ELWr3uGubY1V6LU3nH0FRdR+4gpWjUeCLAygeTnvg15m0pxcIwK3Jz0aDa1QStdoCVmRb1RSew91gl1GbWcJhGygL90eDm7OwF7YA7VMcbkb3+MLxXBMAkNBDI+coa0dRYhdrMDtQMAnYcJOuihrurO6ZErERffRZ0lOWnvqYIden7cbiYTNnG7nCcMR5Tav0xLzACNjSGb2ozFi1DEWcWKi9HUXUrZnmNg3f7GuwhN6iO2XWwIqGcg8e52UQuwsw5gGVmF6xcwxH10MNYsLcWN8xzgrWmF/bukzBlKrF3MwWLy/2tNSQsl6K2phInDmajzNAApN/QH0M71Jzps7uzHbVFGSjKKIWRoxF0RiFYoimEkfNcBA98gF059ah1ayDGQ/EUKlJoDGiVrrXx67EOmWnH0VjWiR63QfiSEtY7aILeW36JvzmugTNZmbBwMk9DaaYUN8J/vLlVVVYg9dB2tLTXI2V/JkppG4fA21rbkguXCR9y3mYZPh0T7bMxWJaPVl9ape9qR3VjOxKOJaOzogitJR6IXDWAiXbTUevdijlpbfCcPA7j3W1Rax2GcZF9cBhvQ5HtX12iiWIfnGuaUFxnjuiZ43E63w0W9nUwdg/B1KkPIje9FYvHgcK4yRoSqIGRmw1UI8apNfeGrX8AZgWoYdDtBJcoHXo94xBQuQWp+WWosGqCneXFxbx8NTr5JASEwDcRMCTLorW1MTIo856lpSXUZNW99dZbRz1l2bJlo2739fUddbtsvDACoixcGCc5SghccQT6+/uRk5MFk25awW5sQGlOPiyDnRAwwQPdW3fh0382ov/RqairqIJ31lNYuno+nvzLHVhh9QbyWypQU2uNrt4WNJVnojjfFT0GWpSlNWLKtHrKXFSF0naKEahowhyz0/gyIROpFnNw550+aDywGxWp+SgYyEZVZw0KyF3G17wSVc0VFPfgDFcHJ9z/xGvgPxW82pSVeQrNp06gpLgRagsvOHn7YWZ/Pg6UtuDEYBiu0ZYjL7MYja02OHG6BjPtIzBv1WK4aNtI0fFRrBM1daVorqukcddDU9QKR00slt91P6bbUvyBowMKihNQdbgdeXXV8CUXIW7sglNUlA83oyIUtTajLCuNFAkt+f9rkX9qP5rILaWs2g+R3eXoX/FL/Mbt75icUor2OGfoDJpQk5cPM68BGFAcRG4D4FhaC9/yLFR2dSCvqge+pkUob6uibE9N8K3ToK+NMhGl7cWxkgxUYy5eePxBhLz6EDKyilAbaoledRNqC/JhSH9InaauwIoQZyyb4EfWDRUGVYZoP7AdjVNuw88dv8CLpY1obx9y7TEgJcPK2gUDR6pwKiuLYlHClPnl5WaT69k2NLjEwsXWBpqefsogpYZ5dQZOtLWQ5E8CObXc3BwMdqvh5mZHsQNDfRaePoqe1E/wyLE4vPzsrxDyysMkoBejNtyRMkA1o464GWjcUVxaSgqENUoKctHdP+Qq1l6ViayICVjhYopGslyE99bCiLInZegc4KXqRb7BQkxoyYahUxC6q0tR09yE/vooBNT2or6xhFyINOiqbEBUSxXFebSjuKIZOu/rYft5PE6PWwrV/v1QV5KlQ20Cj/5qtJRlo7JjAHk1PfBRFaKEnsua8ka4d9BzWlqAvrR+GBfnobzdBsX0LLp25qGwqxZt/9kKJ7I0LbWJx/sUb1PaYIq01BMYHNDBhBTCcWeCwBVI8kMICIHvTKC2tkZZfMnOzlbSK4ed+R31nTuUEy+agCgLF41MThACVwaB1tZWWFJg64G/PIvPSgbQkP0ftN3/APxjfWDhoUFb6jp8/MdD2Bp6NX4/xRXuA1vx9qNfKnA0PUZkMg6HXc9ppH5+EDviKbjZktbAF/wOhSvH4fDrf8HG+lM4usEbphFtMO4tQkViKp7bSbKtllaTD/wDPddsRyL1k7llGiwc92N7USK9+vGQ/dzhG1BfXwcbq1bsfOw32JhrgubEG/HgY9diztQC+AY4UECbAYq3forX/7YdFcYWeOYxB/z9lV8hZtMv8MaWcvylXg2rySuxbKIbqgo+wepyMzh8nIbfPvs+Wv4QjBf2GCgBsfoLdvlV4kbnJcBioIYCfm3p2lsfexifNVij7bU/YJf+QHp3nbgci66PQGH5Eez60yt4meIKbn7SCb0t5Bpkmon4fx/Fvl12ZHGpx6lmN7i/rIZpx0tIHHRH4dolcDB6B5tqM3B4kzvsW4zRn5OKnfW9QH0ZrYCvxrP3rFauZpL8Dlx9V8DFLBcJqw/DcOGdWBBpALOER3Hzq+YwpNgB99texXNejThKY/1HUy88bpoCN3bqp6a2sIFhhzNuIqvQDs1cWJWWwJPiT1qL92BPrR8mhZviZ1fNQHLyQegGKuGZ8AweafHG3b9zV0z9/Z1Z6KgOgUWQBvY2Q776GopN6CHXIcuyNXjmF2uGxpn0Huw9lsPLNBdJaw9gkNyMzIzMEWuvRsnG3+GxdVXKcVrfu/HM8w6wJQtSTNTPkNj6AQzb1uLllR/AxW8Orv79nVgSRX5I1PIpmPFwaTnFJrgQl3aKd/kS/y7xxvh3HBBhvx9rSfEq+Xw/Xn36IVyXezc+/OxJ7KtVw2LCdVh59UzMsh5E0tuvIL7bF/lrroKL+g1sbM5Bwmf2uA9ZaN2/D/mbKXuWRQ0aBiiA+6MAWPe+hs+0Zejdm46gnVuxjgIsHZY/ggUL3VB/dAeSt3TA9JHrSVlQhig/hIAQuEgCvFBVTamV2eWIX+PHj6cFDWtEjafEDBRXJe2HJ6CiG0FeoNKEgBC4nAkcOHCAhNsabN68GWvXrv2vT5V/2Sfvfg8V2W1IbQ5H3LVOWD4h9r9+XbnAdyOQdiwJRqfXYPan0di07W54N9TCnQKPv61xUOGOP4zDofA3yd3KAivmTf22U2S/EBACQuAbCbAF4UBCArlzFiIxMREvvfgijI2NKHvb+dMyf2OHsvOSCQw5mF5yN9KBEBACQuArAoeP7oZhQRK2vfU4Vu/7ABuOktuKtDFLIDxmMrTRdyHzvlN44O1Syiby7WtIXME5+59LcWjyeizyt8SSWRPG7PxkYEJACPy0CJhRzBDHJ1x7zTWK6xFnQpP24xEQy8KPx16uLAR+MAI/tGWBrRgd7W1KWjsd/ZI3N7cg1xb3H2y+cqGLJ9BH6XDLy0owoFPD39f7gnKRFxcVYECrIiuEK2WRMrv4i8oZQkAICIFzCLDFsry8jFyQhnYYUByWi4sL/R0ZSspwzuHy9QcgIDELPwBkuYQQuNII8C92+u1+pU37Jz1fztDkHxB0UXPw9Qu4qOPlYCEgBITA+QgcPpyMkyfT0NnZid/+9rfnO0y2/wgERFn4EaDLJYWAEBACQkAICAEhIAS+ItBMdRH4VVFR8dVG+TQmCIiyMCZugwxCCIxdApvf/hNOlHSik4o2q7QOcAsNQKCXATpLcpGS3widoTFUXrF44e6rKQjtq8rMFzOj48eTUZmZgdpKLawnjMPPF866mNOHjz14aA/qM1OQV9aAxh5r2HsGIHKiF5bOmDl8jP7DwcQdqEpJQ0F5PVpgCVtXf4RP9sGKWd/t2vp+R74X5OciNy0JWUUahE7xxNyJk4bddRKT91Jq0hw0UxVg15hgXD17mnIqm+CTj+xF7dHT6PQZhynjgy45DScHnB/Z/Db2nxiEy4RAzAj3pz6/StfDdSGSNv4L6XVGMA+ZhVA0wMzdBaH+/gikOhr6VpCXjWyqqXEk3wShV4XiZxMnDs9Hf4z+vaSoEMk7/oNiy5l4/Kb5lHZ1KK1q0oEvUZCWTlmiuqFx9UV4bAiunTuDUrm2U22GdVQ/Igd1feZwjorC7OhAREdQAYQfqaWkHEFtfjaamvpgGhyGGxZ8/TnSDy019SjK6dkrTC1CJVWp1mi8Eb44DCtiYhTfaz7u8OGDqMtPQ1FeCaXINYOFDc0/LgDXx8XpuznrPY36zM/PQxeljb19JaXgOtP2fPIq0ns9sXjaeLqPgfrNKCykOienE1EQfxrFBkM+3iqdFTyiiWVMIKLGDaXFHT7hGz5cyHz49BPJB5BJ1bTTS1pgZGELn+iZuOvq6dj6zitocIvEvOhQ+Hp7f8OVZJcQGCLAcQkcp2BNmY+kjS0CEuA8tu6HjEYIjDkCKrUhNJUJ2LxmA7YfaUGt1lQZo6a7Dp2lKdhXTvsv8TdJQ3k6mlO24sCOMuRrHBTBcc9nq/Hpjv1obGq6YCbmrSXQqAdR19GN+vyTyEih4m3lWuynjBrnNnOqf2Cq1qKmpVvxz1dTCszvM4gul+oUFJzchfo9u7E+fgBu06crdSH04zCgYmhUxYxeKvr/q+A9VhY8Ovch4aMdyNX4oLJ+9PmzqT4+YSc+X7cF9fX1+m5HfeeKp+6lJ3E88QukGbmirParPgvzc5C6Zy0SjuehhRgYtFONiuMtJBxHoa7pTIXqM73WV1bAhgLX9x/bgRzXmeimOhejtUJSko5segO7Nq3BJ7WeSsVVPi4pKQG6wuNor65HY38vOjv6SBgewM74Azh2dB8ccxNRTJWe+1QdaKgwxIkcqv1AhZh+rNZUlobWE7uQfJRqNqi+WYBpp1odPhYDKGvsUZ4nQypQd+4/i24q9mdLxfaqO7rQWlOCfFIYv6zQYCdlfuGYkZGNFYXijKNobjVBFaUA5sZ1ReIPbkHXl29hT6kpSqiexMjWWFeLCc4maNNph8ZAFa6rE06i1ZGeo4bmkYd+6+cLmc+JE4fRkLIfDScKkNtDVcGpLkjBzi5sSjyEQOcatKdUYHvyaeQXFn3r9eQAIeDp6QUHBwfExEQLjDFGQCwLY+yGyHCEwFgjsPzuP1GFYAf09e7Eaa8g2Nkaw5qCWdtdQzFroT+CrSPxyM9HXxm90LloewZIEOpE35nqyK0tLfDM2ozDN36EmMZq2Nt9S9nkMxdqatOhyXY8brhtKVrzEpAdH4/9O6nw1h+izhpKSsph6KiYWF6PI6wnzcH108IRHXnhq65ndXaeL11UedhQ24G6kgZ0jfKbdtrUuQC/RmndVbmobh+A0VCdslGOAPn1dmBmnB9Wv1WKurp6ODo6jnpcR0cHUlMTUZrri+vnH8bHpTXoCrQYPramJBuOqiZsNbkF7y52hkn2NrzZ7oyeQRVGhiyXlFBV6+pKtDW5YtXCw3hjdyUeuWn0gMPujjZoO2qpMN3ZY7LWliChWIcapwmYGWsP06JMVGYdw+Cy+zGtdSt+9VcjjLtvCSKcmlG1fh90ftcgt6oRkeHDw/1BPwz0dKCpkebRE4xvWhvPyjqNwVpSdKl4XEfMdFw9IRjzZ3w9O5SB2hwVMMKsa6bBZqARtXv+hv997QTUB+9RivzpK3ufOpWG5pxj6GkxRZ25LWL8hh6g7q4u+KtL8VlNGzp8v/5w2FjbIyurFl4/+xlunjkTR44koqbPCEbeZtBQFewLbTwfbV0ZCqpr0RlN85k4+ny6SLHsblChzXgO/uf/liMsez8+XXEQ7W89j4YjtfDen4yCCm8kGxdABR0CyFIlTQicSyCLikFWVlZSQoxBhISEkLIQc+4h8v1HJjDKn7AfeURyeSEgBIYJsPtIRkaGIkhwSRQWJjw9PeHq6qoc09DQgIICqjJLq5LsAhQbG3tBWWyGL3CBH2Ze9yB6OtvRdugwsuuMEeblQAW6THGiwx0v3xtHqTa1OEVVlLub2tBFaTd1MISRmSlMTAyg6u1Hf9cAtMZa9PRSgSsrCxhSZefOXh20KiOYmJlQJeNAzF5yA1R7StBsaIBCcuc4QW44BR77kOZuiZaGalIm+tA/qAMMjZTMGOEhXw/GXbDq3uEZxTfnItp/Asq3NaBhxMo9H2Bh3YOmwV5UJKxFkeMCDPbReDWG8HBzRn5uJjq6qAqvUT+6umncBsYwM1ZhoL8PfQMGMDQxhbmpIQy0/eglQZymdqZpYGJhCn/vofsTHT0JKd2duOY3Jkh+sQetOXubwuArAABAAElEQVSRWNwPU2sHxIaHkGsLuUrV1FE2IQPYuzjChStFZ5MrVnMbdO7XksD8GUiuvOTG15kc24Y9uxbisRlabFlXhhJzJ1TQH2cPd8pQRdYNjY0ZnLvLYKkJRNy9f0PL4JtQVWTB0t5h+PrlVOnYN9wBCaVXY2WsBf7+vweQGhWAadHjv5alJDx6Ivr7HsCfrF/AHSMWzHWFR7HHbBLmuTtg5ZzF2NtSS4roBuxIuhaxfduwOvA+VE8PhouzMzYfeB8pzYWwhxuOJCejf0ALtUEfunro+TI0hbXJIN2nPuUZMqVnyESjgra3Bz3dPehV5GiyFFH5OjNbU8SEh3/NRa66qhLFhblUZZwOpudDbWqFGROjFHepXKoKXlvfgPJOQ5i6RiGoXge1kRrHjyahs60fhjaW1GcYTE2HrGz1jaVwczDEkS3xqNQW4JOuX1A163RMnTB+mB9/mL38huHvR5L2IXLa1Yh4qRZlZFiaNLyHFMGGbLRXGaJ00BwhURpKSxunBH3mZp5Ew5f9cF8RQFaLoWuPOA1BVNmWX9zYmhTo3YNcuwiYU3Vwb6eRqt/Is77+ua7hzHw203wGaT7do89H1adFn7Ux+qCBcXcv3RcTDE6zwuDxk5gYuRwpq7Ro/GQ/DAOuQ2ZJpSgLX0ctW4hAJVksW5pbSDFvhKXF6AsQAurHJSDKwo/LX64uBL6RQFtbG2xpVf3zd94h4bIJ16xYobjosLLAgWDHjh1DJQk9BxMOYdLkyYoyEUbCwneNHfimwSy47QkSlB7Cl7lv4Ol9cVgVPhtxi4eqALN7hKd9Kl6/813s7WxDfWkw5rzwIFbe6YCBt7dhw6u50JIcf3KbGW55/y9w2HAP3tnfg2JdLG589EHcfU0stNuLlcvbOpgjqHwTbjlYib7C30Pz1Ie4Jv8jbNidiKNFjVD7zMTkuKV4cpUpfLw8zz9kQw0snJ3gYEWCILEa2ZqbyF9+8v24OzYOpzavxe4k4EMLJyzxLYRz0x78+kkNbr+7EGs2ZqCwcQZ+8XM7NFacwp4UM8QuvwN/+OMs2OdsxhtP/Q7bWqzQUlINjeEtuOGtm7FAVTKszPE1VaSU9JHwdWz1K1h3wADpvrfhP6va4W5VgrrPjuJkdzRVWJ6I6KIMGB9fiwc+y4J1fyNqcr2wvJOkSNuvRt7S0kxWhFoM9g+giawvVXUtdP+rUFTUR2kGWehVw9nJkawMXwn5pLnBILcKrgt/hiLXWizJ3o6e6bfgaF6hoixoLO0w0GmKqzI/xbWvmCP+SWOEz5uvsNULw8oISOkzI2XPcnY0KlUVuH3/l8he/T686PrBgV/5zX812q9/am1phDMpVCZGQ396DCnexczKBcUkLDSiHJ6+HsMnWdk4o5vmaaBqRO7efdiR0oPxkbn4YEsVOrXL8MrvevGv9w6gqHU67vvzA7hllhFK1n2C99/5HEcaDNBRo4Otx8N4YMu18Kd/R04jLC/stpV6YBPKEj7G35ObSVEk96u5L+Mt40zYW5qgMf5DfLL/OPZnl6G/1gjOE1biDnoutVkb8P5zufB55Y/wIeHG/YyyoNOq0UVuWYt+HYGp2Rvx0eqX8Ybjathb58PP13d0BZ6UNCNHJ7i7azFYXAK1+1dzR2U29sIJhhYm+B3FM7DLWUb6CfhrcpCx+FHMy9qFz/rpxn5LUxUeQanvtZht1Y1JF7NaS+lzO11mYiHNZ8o3zKff2BkeNqlIzz6NDz8ywnUBzciOGI8PJkxURhY3fRWad8UhpTYC/gZu3zJa2X2lEmDXy6LiInKnbEDgiFiqK5XHWJy3KAtj8a7ImITAGQJsTVi/fj12bt8BLQmDvbR6t2z51cretLQ0Wu3ux3vv/AeOLs547bV/ICoqAqWlpQgKCgK7n/AvYW5sobhUf3xFcYmciusra2AxQD7lARa4h1ZsuXHf5evWIv3uv+NvC83Q9MabOKUuRPraZOR98AI+t5mLKQ7PY/vuINgnPoQZ1q/i2b9pULn1KezJ2Ivt3o64SukJ6Da2RnPQEjwTkofy9/biYdOP8cJL/ph8z+14MrIGJ999HZ/u2oBXPALx2i3nVxZ05EPd5+WI/iVWuOucyp/Tpiw5c7UINHX04rriJiTkVkA9TYMdf6Tg0QJr/BVJ2LGzBnsXPYx/JN2I2578P2yM24uDqak4etINAYmf4/+iP0LPa17YtPiXKH7kV5hk0Yq5pLSNbKquagxW7ET2wnxsfDwNJx9dgN0VnyKmNwVJaQkoDY/BZF9r2CbvwAtvReL5U6/j9rbPcVfsZtipzhYIM2nF27r3NL74/f/gn4W2xJ2sNT2DpCQaQq1Woz7mDvz15ln4za1DzwivLndQ4HDlrk6of1EPXbUHjGJTkNE2HWZtQ8LppEkzkJ5ugjv+Y4nuKU9g0frxWLHlI9zamoVJ9DyxNauL3F96m3vRWt+LZv8iaMwmYPyqu7Dm0D8x779YmFunakZuYjJ6d32AeNPlMLzrNRy6Jxkv+N6FGxO+RMa6u1H+5J9xur4SOfEkYJeqUXPvOuyLqMa2v3yOsmfuxd2+5sPB1fr7kpmyHYN03zMtf49P9wbC9tQHeHjRErwUWYfXozbiyw8M4Hrvc/jijQGUvr4eG4/r0FzVhknXP0UvfS9fvc+O0z+9wHHi9eQLQXjiuT1ov+deNNbWwpksJV9rgwPop7/A3Y/Pw73BIWft7uhogY2RM9TmJsr23NwsBHuY4IvXzDDuiXpoCkgx7D/rlLO+sKWvmRYX6pIr4bDIHur+qrP2f9uX0ebz+CjzmRO3GAld9ZjuuxlPvfQSjs97GM8/HXpW93b2nmgl603vOTEZZx0kX65oAiqK37K2tqG/UwOYO3d018wrGtAYmLwoC2PgJsgQhMD5CLAQ7uPjq7h58Oqii6sTCT5D/2zZ9aiuntwL/L3xf//7Ih5//AmcSk/H/PlDgkkyuW4EBAQqK8729vYUSJp/vstc0Pbs3CSoDzRQsCTFLcS0oWDNbvzLwwq/nx+puGOE/2oPXiw/goK/3obn12ai57p/4JHHfoE7DZ3h/mYf7JY4gVe5ywvTUfTXq3DVUwPQkVAzOCUCTlO/Wvk31pjAg1yt9K0+iTIDhd+KSZoWeHvNR3ZIBqYOHMDx8wT+6s9ra1LRCrsFYida6zeN+q41tUeArSHailrRGnIjbv7wY1QFJiHoHn/YkkncMzQWd86cgclRHtCVV6GVhCODFgu4e/rRZEbt8qyNOgtvmMc+jl/OJhekVne4kItOq7YLdksfxwMaDxxpIkGqphJVLcVo+J/7sZxcszqcaVV36jbKJHRWV5g2bRb59U7Hk0n34T5aHbcl3/4PKWZhykwPhIUNCWlcwEjfsrMz4W5Ti3WfPYnfPPsMegfpFjDzmVn46102+sMQGRlL/Ubhqdqb8OsPZmHujXdgcPVb5PaVhjlTJ+FYykG4GmbirT8+j38Vq5WAbF5NH9QdwtPREcP9fN8fOPtW2K33kc9+FIJ3GCH0Gh8YVdZjXOw0/PHhOXCwrUeZQRqqKWA7yskZtvZDyvG3jaOvqR51vU3oomxTkQ4BqA6+D4/c8X94jOIOyhJ2oGLl7VjiqkVTXg/8woMwsa2BMmZdYFMbwZJclxZrNyOdTjlfKULW42sqTbD0mlEUiXMupSJl3zg3F+WrrsEtZG3Ip3gW8kM6b6slBcXGvgk7yiMR66iBqua8h377DpqPFc1nyXnmo+6kOc5djKtsi5D/uxexwt4Kutd8v71fOUIInCGwePFi7Nu3T9zUxvATIcrCGL45MjQhwJaFCqpk6UjuCo7OOoob6CZrAkl81Hiflj5qyN2GV5WtLSwUv37ed/BgAuWqLsf6L75AFykZbGFoJrcVe8o08V1b9e5taAldAK1JKCa058GmJQkff1mMaNIBZpMlo3HTY7jvxSoE/fqP+NngW6hwZP8Xilmgsalp5ehMJkfl8vNeOopbfFswLogEbvIsP517EuT4rDRWkPg13MiikkHWjIV+Zoo7h7GpBZxd+bzzt91rXkJzvwUy6z1xX+w3H8vX19nZwtTDDL702YDHS5KYIQ1Y+Y/GwgK4esSYBqy9YOc3E8+8uoDSyLqgfNKz2GHUiGkxX19m5wrWKnI54eRHfJ94FY0bb+N+R8j20FE2Ij6GD+YMSSMuOXQObTCkDDfc1JRtR0OZqtTKSz28Xdmp/6GlIOnuCnT9ugDHp/TDgp6RnLwkNO1IRmFDK9bsTECQSRfQkIHP+hbgbyvHo3/VXryQHYCkfnrWBoYsG6oeSpHrMRm+v9mJ0qXjyF2gDjZ2rdhy96vYVPAMxaKcwsSoSP1Vz/tu5+CCyqIuhDoNaUED/T3oaC5DaJQvnHv9UL6nmB7sIWtVU2MFzF1UpBDYEouhe0JPk/JsqOjeqPnZGgGoL2AG5tb/A/kvL8R4xMJu5l2Id+kh5forpWjkwGpb2ijYuFXhxvfcP9SD7j2xpedNN6Lvoedx5Jnf/llH7kmqUErFS4eOeJKHT0zYthat5adw0OpGPG4yZD0Y3nnOh6MUJ2HVfRpvP30//lH8J6wml6mBjjq06FYh98bnKfanHzcunnXOWRxjQQHXOi8ElBUjNubse3M4fjuKNj+L36+vpl8gxnC9632su9UH3p4jXKFG9MjzoTy6YLVw5HwO7ngfRQXNqK6IxE33LIUmdBwm/n09nk2OxaMRtsMpY0d0JR+FwFkEPvnkEzg6OSnBzVOmTDlrn3wZOwREWRg790JGIgRGJRAfn4DQ0DDybXbFoUMH0dBYjwMHDpCSQEG5xkZkXWjEjt27kJGTg7gzJlxOQWdjY4vo6KGsEtmUbaKmpoZWiFNGvca3bfzihZuQbbMILgYmWDY5CjmnBzB7TjMy//06/vDlb5H4SAAqjv8LbjftxvWzfTCQo0EjybxfayRpuHuFYcuJevwy1gn5RUkoytWRMuT4tUP1G+xiZ2LmR0k4ZmcPK7djcGpvRnetNQKnjy4E7iK3p9RmQ/RbuGKSawcyMuORl2GGex9arO/yrHfDZgp07TNAPFzIReo4nM63FDziLHV7Lfrbc3Bk/qdYt8wHamMzhAX5U0D3+QU/A0M1Khv349RawPMeCmgeEXBqYm4Oi25yI1p/FOuX22BVoBEpDsex/ZE30fzUDTDUHCb3pqkjRnBhH3WkTLae+H/23gMuzutK/3/ovfcqehEgQBQVQL3LcpPck9hxie04m00cx1n75yTeePefbLakZ+PEGydx4hZJjmwVq1dASEKA6Ijeexl6/59zMVioICwJGOBcfzDMvO/ce9/vHc28557yDMF0sxtcTfpgaWlJrv4YDLmdQD+VJ61spJ1zpx7otNbjSGoljiw2gAvqYdDai4FuMkY/uzUcIO/HoKERzIOpZr+7Oxzpy72ASsOuWFqPf6/uR4I9hcVMog0GrMBj2SlUZccQuyiMCJRvc6l1B+5b7QDj1gfw/379G7x14VWstdiDnNpoOIaFYbG3Lj4v9HrjQQyrMlGl7wmj7f+NA1ujYGxmAZcbqIgbWNsicLgYF1Py8Jszl7DcoBiFR5yw4jU3+Lb5oPM/E5H42Fp8abs3hW4lIf/UfmTXecHRouuakLarZ6RDBlBP7lns8oxHDP27s70qn+PYP/6EopICZOlH4W4PDUor8/HBXxzw5PNLxhLFzc2toKmjG34KlfL3D0ZNtQXW/vo8Ej7DXPze8/j18ON4INodq2NGEprHzYM2EgwTD6Jp+SuU86S5JocpaNFSmFn/Frsf+8wYJG+eM+W6XK/x9XTT9eym64m96nr00AvdSkpMJb9Lm5kl/BytYdPfgTZrZyp60K26a2muIE+LLowoPEuaEBgl8NHuj5CZlYncnFz6LllF329u9J11/c/00dfI75kjIMbCzLGXkYXApAhsWL+BYucPID09DWGLwujmIQBl5WWqAlJISCjFQzvi7x98oBJbo6Oj1W61t7f3uL5byatw5S7suIM3eMDJtHkFVP3o/T9iD3kVLg/aUgLnNvhQCc2BtjqkHnobx1IaUFr033i4sgA/WLwaBTt/iZ/QTZdNfxEqO87gcgXV2x86iRPVHnB/Pwguqy1ovl/Hv3T9G378A0P09Xhh0QOPwM+uFik7P8SvT+vB9a9nsfYZRzh6p+DXLz2I3ue+j1VxGdiT8ib+64wuvL1i4Be6DPd6XXvz8dGvX8ZR2rU9WGENIwtHJFOVHwf/FVhy/704/dH/YPcfCuH89MMUxnQOe46mobC2A51WHghYFI2nNyyAXp8GGX95DrvIs1D424fhav5f+AsJc6VXeKFdkwoDErz6c5IF/B1SsHYZVX76x+/x/2WaK7aWMQ/gm3eF0w7752E5w7oGMLO3g3/bT/Gte3bDHA1wjP8u4q2p9CXxO392L/5W6IuljqF4ftlqbDv2Gn710jEavxM151phtmkpPPTphtHN75pV4hjf1HNF8As2pgpZ43eEuTRsS2kq0nfvxKGCITSmu8LhHjss9/ZEed5plGRk49C502hwW4mmGB/cv9ga4Z6Z+OSlN1Gq1418o1fwkkUdhvt1sevn30PSp6SDQPvKnlsehvPwCcRRrkpX5XF8cqCAKj69iFdCNmJ7aQOW+tggnvJD0s8nIXvf/+DN3amoNPwentV/gXIpojFs7AuPsDw0JR/A+590wChoOfziF0InL4sSvQ3x/Ase+Nf//Tf8Z5cebDc/AxfdVuS/tw+5p/+Gt2ui4P5bJ5g2vo5fFdZC8z+fIGZzCv6a0YiU3ItwcvCBTXU6cveU4o3UfRTvbwO3+Ifx82fXj3hrPiN47ORxOPoEw12vA8W5H+DNN87hIFUy8tzw79g0kINSm22ID/4JTh5IxMufmkO3vBDthl4IWUFihP2X8OI978H5mUfwRKwvGU0jN9iJBz7ABQqXO5ZZj14DS5gtWo1vrTFACBUbSDrwWxz94DJ0lq6A+9BFXD7xIT7JGYbGhATXDpAwm00gwp96dUyLQk3TNQgr6zTI6ezCSdKZuO8qoUDDU+aw1Q2EjzN5ijJOYW8iCb110PtsTQS+smkleR2B/H0aBDxHHpxezTXvHS6awD83auOvx4KuZ811ryfMZwEsvCtgduEP+O49f4S9kTUsFj+Cr2kyYBYQiZNn3kNDYwwWUtUsS7Pra3LcaA7y/NwjwOFxxUVF6sIWLVqkPE8LaSNsYKCfNsTG57rMvauf3VekQ6EMI1sLs/s6ZPZCYE4S4PChEydOUEhRJSU4D8OEdq7ZOOC6+hw64UBhRRUVFapSkjvdMDpR3HYEKd9evUPDngj2LOzZswfvv09b25No3d3dYGVlTUUJGqiU6MCQGaxc7GgH3QsGwwPISU2k58lVwGE1Rg7wtutBJd3g9PcbwMCQSo4OGVKIB0Ui6dPOZLcBVXZxgJebFd34x+H4J++ivLGLviRMqU97KoNJJTGbGtHQqQtDCwe4OhpTnfdCVGio1r+jD+wo0bWFwkbaOZmXVGJ9fH2REBt5zVWcObwHZVX16BpL/qSKM1QS05bmbTlItftLu2Dk5QHboSZUN7Shk/QdhoytEBrkj7iYSNTTl9n543tQ3a6DQSs3uOvUoKV9CN26lrDmin4DJKZFHoC+vn6qnNSG/0g0QITrSBhYae0QgiJ9EOrhiMjwcDU3XrfLeRlUBrMKdVRJiJuZkw9W0W5wHd2EFhZeRmuvIUyt7eFAm2r9VNuexx5tpo4LEEcKuBNWfRo9+Yrf3G9ZUQ7a6Hqa+sjFY+KABe5WlHcRgfycNFSXlKOlk7wHeqYwszCHvTnQQcnQ3TUUx0/DD1q6YvuaJSgvL0ZjRRGaWzrQMWxCZV/t4OVui0gyFi4mH0YVaUh00PtyyNCGQgmssdDXE4EUklZWUoSs1NOobqGFoFAhQ3sv3L92ibo5uEiGRFVxEZra+qFrSYq/3h5YsSRalQdOTTqIqjLqc8AQ5i7OiArxQ7emGflZF9FM7xUD8hY4DtYpRsP0nnOhnf6Wti70kAK31UAtLMx0sf+SBuE+jmht60A/3+RH2GMlGdmj/yY+OULhdN7kcmkpRYjGHO9dLMR/VR0E4h/AJzYRMNbRx7GS3+NvBRmINl2KOPtIlFKZ1nIPQ7xoZo3KbCpaSnNetyRyLMwmK+08CkncrqGtRyma27oswA66aeeWSDkQNSWUk0N5QybDbehobYOmd3SxOOzMHHZe7tiSsGQsETst7QJas5PQUDCIPMp5CVtqP85gOPXpTlT1mlPYWyjammpQUViCzn5DuPh60L+LKFU9KXHfPvRT4YPli8Jh8wV3bCd7PREh/lQ+uBWXczLQwHkUFNJk4+KFe9cuxxlaS900Kq+rtx7WLjpYusgLQbTRIW1+EiguLsbHH+/hKD/YkqG6ceMGpGek03veEJ6enrQJNrmKavOT3sxftRgLM78GMgMhcFMCx44dwyAlKPj5+oG9BmlpaarCUWxsLGpqapCdnU2Jzetu2M+tGAs37GyeH8gnMbeKrLMwyyvC/i0v4odhFnRjtB/1WX3QcTHDwmC6QQ2SXbLpfJuw+Fhv+hm0WPih1NYV94e4ITuHDN1c2uWPNMUKyiXhECxuSSnJONdyCdWOXTDXMyEjeBBtA53qmI2hBfmUdNRjft6UNDZMqLxrL2lqGLQMYYlOEDav3qjOner/pZ5PROU5EtNrcUADGbhvfGn9VA95x/rnUsrFe/8LKVWO6HZ2w9rFgVRe91rv2B0bUDrSegLnKQQ2JSWFcui6aYNgAf17tKDCCuFwdZWSulq/eDRB2veTJgSEgLYTuLqcXGTk57vqrLkwKtKm7dcxF+bHLnM93QG01OZQmM87eDOJIrd7u2Hhfzf8rZvEUJiBRR4Y6IPuYCfKM07ggo4TutL0YOPkCV2/INwf5zm2Y89TW865HylU4rQxC2fNyuDUZ4aVAwupUNcwDhilo0tvAGs7AmFD3qSC4QpcMquEX7cdYthQWDM9hgLPMyomjswWHfQUFsBkYMwVwYe0vnESfn7VMJUu9sSmiCDSmvDS+jnLBO8cAaX/Q9opHR2dqoAAew44J4Gr8rm7kaglVZnj7zD72yi4cedmKz1NhoAYC5OhJOcIASEgBD4jEBISpiolldblw+DQCRzNpspEdLO51KeUSneOzx0QaNNDID5+DZI6W6BXfwRdmWlIHTaHlbUxVnytlnJ4vK6ZBBsMehf04NHuBB2KlLp3w91KhVznKN2e6+sgeEEAgoKCcPT0MQT2ecJQxwBb114/Qf6azu/gE4tjloN/ZltjY+G+f/7+bJu2zPcWCHA+XA4lvo9GtHOFNzMq2KDRtFMY6wVVvIJ1WuIo/NTLy+sWRpCXaAMBCUPShlWQOQiBKSYgYUhTDFi6FwJCQAjMQwIcAssCoGw0cGMju4PKdVeUl1Mp7x6lwcMigaylIG32EhDPwuxdO5m5EBACQkAICAEhIASmlUBbWxvaSRmevQn89wdUja/osypHDz30EEJCQrBp06ZpnZMMNrUExFiYWr7SuxCYUwQGqGLO4OCgKkU5Kg7GXxisJn114+NKYOyzA1eeZ2RkdPXp6jHvQPWTWu1ou/K80bFHj7G728DAQD3kqlFXtqvHvvLYVP3N8+b585x4btdrzGnUXX/lceY0ynP0+avPvd41jV63IdWw59K4EzHifq/uk5+73tj8/JWN15z7vl4bHZuPXX0ez4mPXz3P6/UjzwkBITA7CFy8mEqJyW4oLyuDpZUVfvGLX8yOicssb5nA9b/Rbrk7eaEQEAJzmcDHv/pn/ODfXsOP/3po7DKrqqh0a+suvGFDZVXj/h2/fOMVvHkqBf84njR2Dv9RWJCHAy8ZY9kvc1BdUzvu2OgDrlW//9UYuAeGI+6XuWOubT5+9tBb+PM3t2GZfTjWPPwT/OxYunoZ73Bpsn6O58P8sNB2NZ763Ul8fDJ5tMtp+/3J62vw+p8/wUdHrj8232xXNuzGr2JJ5ZbEwrgKCP/Effk1/GQnZdxe1fa/EopVYU7wcIjHo//2Ef526My4M1hFGfuew9b/TUd2/mV1jMtVnvu/f8azkQuxavu/47+PXxr3moKi09j/0kpsDHaES8TjeP53Z7A/+frzvfKFpxM/RvL/vYivWNiOzdvVzR2PvVeLgsLisVOPvvcz/MeXw9Q5Iavvxbd3kUYBrU/hr9fhpX+U42Jmzti58ocQEAKzk8DQ0DAupl7Ezp27MdB77UbR7LwqmfVEBMSzMBEdOSYEhMAYARZYMjM2RWeWAXQsDPHxqVO4m8SiBukmePjon5D4zffx1qpSHPpRNvpdh+Dk9/leRGZmOob7UlDT8RBs9lxEyrrlCOloR8BVtbUXRi5Hb88b2Oe/G4+0m9JO/YgMzMnEd9H8jwYMuj6O719wgxFlFWf8Kg1/DTDF4u40HIquQtSxnXjKrRLZr6ShQjcC/zA4hXsTVozNfyr/yHnvZbx9MB/ddxsh3OMzmd2rBmSPgkuGPvz/tguvk85BsJ8fzrz3PgzdvdFDCrejrZPifes/eQXnY/+Cl0klu+vih9hXlobkclfYnTyBrStXoegyjZXyv/A4vxVHHjOAP5UiPLP/TeR88jEONwbA+6uv4+1tpAhsbjrarfptdzkHmQ/8HF9NqEJsWIjS6rCiEoY3a3qk4OwR9RDi/74Br5OOQmN9Pcp+/iu0bbYDNDXq5ScP/ImEwczQu+hFvPmwOWz6GnHyRwfxfuQmJGz+LeLf+RLe7XwDHV09WLk06mZDynEhIAS0lADnIlRUVaGzrwdGpiZaOkuZ1p0k8Pk31J3sVfoSAkJgzhGwamwGQuPg4W8K564SVPV9pqBM9/ODzXWoJ/G0Pn1/LF3hBO8FxuOuv5+qYXiROFjzji9jbdfHqNBzRE/v5+FGoyebm5MyrZMHAl3H38DaNhbiqI0NKm0M4NFlgQHTfjh57kdhvQt8Gi/hNxui4TlEyXSdVL/bKwU9JKZW1zx9epODwQ/isXVhCHEfP+/R6+LfHEZU6OwDl/5BrE5IQG19HizcfalqiAFWu48oAfN5xiS8p/F7BHd5G2Ltijh4Lo/BmmFjeFZ2oMVAnzQ1LqHu8gkk/UQHT319LfwXuCPl/FH0p3+K9KFA+C2Nwde3x1OiYQA83EeqM3H4Ucr5A8g9/Bf8+Yffwf6CXhTXtZGAmj+cyctxs+YdFYMmfVOsWxhM8zOEnmEFSq22IaQoE+6f1UkfqL+MZtI603N0w8qEjaTW7ICVWy8ivcYDC7z9EHrXU4jKzENudQuOU711aUJACMwOAseOHcVJ2qg4SQKhSYmJcKfPlajFi3Hf3XeTAOdn3wOz41JklrdIQDwLtwhOXiYE5huB2tp+mJFCbNzyElwqqEVxle8IAl0dWK3fgbinXsFv67fh8ag18Dfpho/XgjFEg4PDKKvUQ+TqCDjFl+AnGfWIC7/+DvzYi674o72mEj0OnvB1sEB0ZBRO1hbD2N8QabU9aK6/iMIlDyLUz5GMFE/UHbeAgYUB+nSG8N5bv0UxqTY7WJfiZGYXugM24gnrCzic0YAmgwDExIVjkXM3ai+l0810CZopxh4kxAWnpbhvWxASggLh6OiI/e/+Cilnk1HUrEvKzu4IiV6GpzbF4HL+WRTu/TsS6/XQVFAIPQfKnXAxxdmUE6i+lIHy/H5Yro3Bk5tXqpyCMPqCHW3GbWXQdwnCoJEOAkhsb7RxDkE49T/a9CytYBNmjdb2FoRaeaKnvQn2w/V42y0UP2rOhdWCxXAyqsXBRAt06FOIV3chXivLQWzsUrz4pbtUN5xLEBDkgtLV38PTy7OQdegIPm5uQjfleuzYeHPvi7uHJ/iHW05WOsL0q/BW9GN4PpAUoKlMIjcj6KGzrgnl1l64mJcDB2d3tJhcRAvZmNw6DULhYvUHNOgtRl3L+ByTkTPk/0JACGgjgeaWVrS0tKjco4ULF0JTWwNjyjuztbFG/3Xy1bTxGmROt0dAjIXb4yevFgLzgsCJUx+jXc8DrTk1cDfTg5WpPjRlXTh08iSWREQgtSQMqx82w+ncgzh0OBRhqyJga9eu2OTmZqGhqQzNtU6wy8xG0JYo9O3KRrq5FazMjJUq9c0g9pG729SAEpr19dSpnEBsamaDYUoo7upsQ4CVBclXjTQDIzMYGA2gv7EAZUfew+5ydyQ8FImggDwc+uuHOPsV8o4EmaDnJJX2wwraJdNDe04/qowXYJFNHbIPZKL52a9Df6BNJeee2fcukiknoB728FxggIF+DfLPJeLvJoa43zYVPyixwOpwDxhWH4FGl+N3TWFuZg1jGwc4BQwTq+vvvLWXd8DATwcmTuO9MJ9dxtiv/vJumIYHw76lHREhoTh/5ijaqopQEr0C65ctV+cZ1BUhxckKxpbeiPbuQWFmCVL26eAda0t8+a4VKun6/IUG9FrYwdY2Bkvj+nAhewB5Oe04aZGElctH+hkbdII/hsnwq06qh9sWV0BnpFwin67nRMrVVekoPvMnvFNgDdPuTnRVO8F27UhnsbHLSen6F5S30QIL+xEDY4Jh5JAQEALTTCAtLQ0lJcWooZwyLk7Ant7HHnsMRkaGKpGZVdCbmhopfDQA4eHh0zw7GW4mCYixMJP0ZWwhMEsIuOsW4MzldtS0d8LKpBHVJX1ot3RE9cYR78FgfRsQHIk15hqk7U9HbvdyWFc3I5q+T5prS+FuUI63j11AZLsNcjQNqDh8GJqvvIrqhjoyFm4OwdTYDB1tg+jrH6nIM0zhLn0dOrAN1INFqz0KClpJf3ckdra3i25c7Snsx5Ye05edo4UbPFd+CU+7pUP3tRdRGPpTPLNOB4WlP0ZWdxsadRxh5WAHN5tmDOpbwcxnDbbcvxCrLckrQF+OKPoEOXorkLDMC6soMbj+0gFUZlzAkc6HEJv1ByQvPol3HrdE7tAhnLYfufEPDY0A/9yoJaccR73GHN3lzVgYcWMAZ49+jJJqoGdYgzCfkVClYbr43u52uNt8HvKkS/kfrSHeCDH2Q5C3HgJ0j6HoUjXOaWzxZZoEh0CtSFg/Np1E2hX00eTDwtkabUSOG98EZJz8GBeLR1wBhk5+uCs+ktR3P/cQlZWVorQ4C9WXPRFcfRombjFjfcLKD2ZuHVjSa4T86lp0kwfkctNyPOc10v/oiZrOLgzaTGwgjZ4rv4WAEJg+As3NzRSW6IK0NPqs1NWjnLGRCmfb7tqGEydOqEpuHkHB9NkWOn2TkpG0goAYC1qxDDIJIaDdBDQFFLLSX4eqBg00JiboJLVcY+vLyKxYhNWOTQio+hgf2P4e/7LWC05d/w/vdzSQMM/Ize1A7wDaLleg06QJuXkNdKE28HbIwoWSJroBHn8jeSMKxm6esM9rR72OCY4nnURrfS266l2xKMAIVsbRWPxWBlLiNZR0V4i2ZgqNWeCCoI2+GNSjMqafmmFLhB30m1zgGhAP9wRHWJq0jA01bGQBS9r8H64uRLGxI4wjw2BTmgrD6Gh1Tg/tkFtUNaDO3hn6ZLQY2vrAxjFDhfD09zXA23nkpt3c2hFt+bko6PFCbn4BggMDxsa4+g+jnmz0ei2CwXAvEmJjrz6sHp87dZASmdOQreOPCL1e9GnakJaRRR4UKkdK3pP65s6x1w3a2iM2wwnmZHeYWlmix8wR7gGGqLzBPbmlkSV6jfXRpafBgsGRXf4+CknSbS/HpUtFdFNAdlaYC1bQjf2Vra66FCG+wziYvhi/XJlw5SEsW0bhTPRTXFiAzDN7UVbdAZPQZbAvT4e+69Kxc01NjKFHNyLShIAQ0A4CGRkZaGhoUCJqXL2M85iU99bUbKz89apVq7RjsjKLGSEgxsKMYJdBhYD2E+Ck2KysDNrBb0diRgd87/0nxKEdIT4LkHPiPZRlJuHdRF9c0HVCIBqQl3ICyY2D6Cym3f8gU/RSzsD5s2dQmncZ7X3+uP+bL+DxaH/VZ+/up/H/zh/BBUpINqHwIg9XZ3h6eKCpsRFVlzNwOacCfZVnceKCFzbGRaHJwhfxfZkobNJFdq8eLAeNUWsYg0V1BcgY9sc3Kk8jp9MJuqZNqNWLgk0/3SUXpqO+7BKKW9xQUNkGm8YsZHdVoS+vEet9qlDe2qiSbQPyU9HaQeJCgVvx1XiKyyf3u4GByZiGg7H3GjgknUeFhQk+MmiAXXsdOnvtqOpRD5zDd6DlnXeQ6OgPTXED0s+dguc2Z2SUlaOjuQF9FJpv7mCD8JCF4xa8P78Cut60K09J39y4DGppSRGxHqBKU6YwHCBF1NP/i+9lLsST0a3oKS9GvVECLlPscJSLISxcvWD5aTHOXjTDYtrlqzT1x6LKDBSa+SHfdxCW5HWpaHOGl2kzUi+cRW9rD1kRenQzwDoPQHnmCRTr+yGAPAzrP6sY5UJ1010efx2rHh831fEPqExif3kZdOI2jD2fnZ0BDRmRQ3rDGKCtyMK0JHTW1uFYozvWbDfBtoR4dW5mZgYGOozgscCWVF0nZySODSJ/CAEhMGUEaigHoYs2Btiz8PTTT0/ZONLx7CUgxsLsXTuZuRCYUgK8w2Ru1YXEX7yEvVl0k6kbiu9sC0NpWT6M0Y2i9ALSV/gA/127Gd+OicDStvfwq/8pwkBLJNZHmCA0wgGa4zuR9slunNJfhMUmwXhgoStMzDuQXkkfPVl/wV/yNqLb0gHxvd3KWCgrzEFr6rt445NaWOO/8Zzed5Ds74nVKx7E6fo6aA7tw+5vdMAzeiM2PByITRFL0dERCvv/SMXffvUG9jQ5YdnXvoZ7PAzQktuI1NO7cUazGO0fusGg610ctK5Ew59O4N4ll3FK04zTmbkItrCHU0MyTn1UgNQPh6FraQ+bHb/G3uBOFYYU/+C30FD3HXx64I/48KA+TH2WUJWfHXghzhttLZvwbNF/4n9+ZIBuSpqwXfMwdsS6wca4FfV0k556og8Wz2whY2H8UlU128LIvQk2lGvBraz8MnqrKLTpp7kw/PE/YW3GG/jx3lLYdBTho2wKq+oPQsyDPli3lq7DzIK+2D3w9OkMHLS5G3rZOVgSfR8uVpbj9N4P8JcPauEUtQWbNt+Fdd526GhMwqfPHIDV8+7YvSeZqi91o2Phdrz+iBu+fM+a8RO7ySNdQ3NkF+ohbGs1nTlSRamtMwuXfnMGbfYDSGurRWaZOcI33I+nnnDBtvgRQ4G7NRzIRUPNIlgsGoK91YiY3k2Gk8NCQAjcAoHy8vIxIUR+OYdTOjk5obu7G5WVlWM9cj0HFxdXJabYUN+IXsoNkyYErkdAh2p/yxbP9cjIc0JgDhE4fvw4amtrsWfPHrz//vtz6Mpu/1JOf/g+nBZ44GBnD6KMjeDsboS9HzXhia8uH8lZuP0h7ngPhVRtyPD8LxD1uyD8385n4N9WieCgoDs+zp3okL9iWqmSysl/W4wTYX/CXVR6d1389UOv7sR40ocQmO8Ekklo0c7eXmngWFtbIzc3F2vWrKEQwwxK47JQ4UacwOxGJVCLCgspobmGvh/qyZjoxAsvvDDf8cn1X4eAeBauA0WeEgJCYP4QaG7KxEe/fAS/TNGn4p8WcLTfgCcO/5EAjCRTayMJ38Bg1Fr+AA1WL5NQ2jr8Zq32fpR3dHSg8e11OBh3Gl9Z0ISlUZT1Lk0ICIEpI5Cdk4PCoiK0tbYifkUCbMlg4NZPBSLe+etfUV1draodPfvssxSWOARTU1OsXbNaGRNTNinpeFYTEM/CrF4+mbwQmBwB8SzcmFNbWxvaNZrPagLxeTpK2djVxVl9od74lTN7ZIjyA2prqjFE83UiLQgDA+0M7WHPQk11lZqno4ODKkc7s+RkdCEwtwnUk8I655xxYw8Ca6Gwh4Gf42OjjY/ZkweCVeN7eqhEMyU083nShMDVBLR3O+rqmcpjISAEhMAUELCyIr0H+pltjauVuLq5a/20+YZkNsxT60HKBIXADQiUlJQgLzcPZxJPY4GnF9asXQM/P79rzjY0NFTqy1cfMKJCB9KEwEQEdCc6KMeEgBAQAkJACAgBISAEtJcAewU0VJAij8Qjbe3sKLlZEpW1d7Vm58zEszA7101mLQSEgBAQAkJACMxjApmZmWikctMuFDLp5eWFRx95lAQYdZWw2jzGIpc+BQTEWJgCqNKlEBACQkAICAEhIASmisDFixeRlp6Ogf5+SlzuZ3kYCqe0xNKlS6jikflUDSv9zlMCYizM04WXyxYCQkAICAEhIARmJ4HLly+juLgYnR2d8PHxwfr162fnhcisZwUBMRZmxTLJJIWAEBACQkAICIH5SuDChQtoaWmGnp4+JS/7YmBgAHY2tvAgrQQxFObru2L6rluMheljLSMJgS9MgL8Qcqhm9tDQIL1WR7ma3agCDpe749bW1ory8gqlwKmnr4eFwQvpy0RPHZP/CQEhIASEwNwg0Nragr/97V3ExMSoMqcuLi6qZPIglVCWJgSmmoAYC1NNWPoXArdBgI0BTmJjl/Pg4CDsqNIFu5zvvvtusNjVedptApXQPJuUiOjoWFVr39fHV2tr7t8GCnmpEBACQmDeEOjt7VXJy1x6mA2DyyUFqKqtxkoSUDMzM8fKlSvnDQu50JknIKVTZ34NZAZCYAICOqioqFDGwq6dO/Gb3/6WXNEt6nx2S5PeFV577TV8+MHf8e1/fpFK5vWjtLR0gv7kkBAQAkJACGgzARZczM7OhrGxMaqqqsmD3AYXZw98/bnn4e3tJYaCNi/eHJ2beBbm6MLKZc0NAra2tnj22WfJKBjGN7/5TdiTUq8lVbzg1k9qnJVVVVjg7onXf/hDfOc738H5c+eQkBB/3YuX8KTrYpEnhYAQEAJaReAcfY5z++7LL6Onuwf/+Z8/RaCfP5ycnKTSkVat1PyZjBgL82et5UpnIQF2QdvY2ODDv3+I+oYG3H3PPWNqwxyryiXzDI30SZBHAwcXJ2g0bXSVwzhx4sSYR6KPjArOfeB63NKEgBAQAkJAuwkM0ue1Iakqm5BnYft99yvPAisyswKzNCEwEwQkDGkmqMuYQuALEjhGN/9+vr5kB1DcESU6J1GOAtfSZm9Bu6aDXNVVqK6shKUlex10SJTHWf29atUqrFmzhmpvL4WHh8cXHFVOFwJCQAgIgekmEBAYqIZ89NFH4UyCa0FBQWIoTPciyHjjCIhnYRwOeSAEtIsAJzHv3bsPGRczKAzpG3Bzc6VdJg0aamvRT7tP7lQ2j0skvff+++jr7UNkZCTlO+vA3z8QfX29aG5uoS8ZA2VU+JKxwYnS0oSAEBACQkA7CaSkpKjNn2HyEG+/f7t2TlJmNe8IiLEwiSXnajTnz59HXV2dCvvgl5ibm9GNmzuioqKo5rHfJHqRU4TAFyfAFTG8fbxx97ZtMCK3tIeHJ1VByoW1lTUqqipVeNGqVStRVVmFLZs2oampkRLgvNVAixaFjw14/PhxMh76xh7LH0JACAgBIaBdBE6dOoWUlHPopY0eCwsL7ZqczGZeExBjYYLlT0tLQ3lZGXLz8ij+uxLVNdVkLPTRzq0erCjco4l2bZtJJIXjxoODgyfoSQ4JgVsjYGJigibKNQgNC1GGqaurq9p10mg0CCTXdEJCAiop/IgT4iwtLRAXFw9+zfUaV9iQJgSEgBAQAjNLgD3Ghw4dpg2cHhVZyiGlHGpUSx5j/hxvbwdtCFnN7CRldCFwBQExFq6AcfWfzc3NVHnGmspR9tFvK7i5u0FfTxe2tnbKy8CGwmD/AEmuF4mxcDU8eXxHCJhSTe0tW7aM62vZsmXjHnMokgpHGvesPBACQkAICAFtJNBO1oChoRHdR9Qq/Rxvbx+qbFepcs14s0eXtHOMjCSZWRvXbr7OSYyFCVZelwyDPgoDYcVEExNjxMbGIjk5GV1dXVTz2Bm2drbQtLWrnYAJupFDQkAICAEhIASEwDwn0NzchMLCQhWNMDw0CGtra1UWW0M6Cnw/ER0dPc8J3bnLLysrJWOsfiz8lisLcigvh47z39K+GAExFibgFRoSqkqWcY17U1MTlJLY1c6du0gsJQuDA4P43ivfg4O9A5YtXz5BL3JICAgBISAEhIAQmO8EsrKyUUMqzI4OTth297b5jmNKr7+4uASdXd34ZO9eWNlYwoxCvRYGBCIsLEwZDVM6+BzsXIyFCRaVE5vZAK2uroaFuSUcnRxRXlqsKs4kJZ9FaVk5bG1sJ+hBDgkBISAEhIAQEAJCABTS3ItTJ09h1arVgmOKCQyR56a5qQmWZCQ89vAjVBGQlAKo8rh4FW4NvOgsTMBt5cqVVF2mGSVkof5959+RdC4FDz3yKOprqxCzNFbVr+eylNKEgBAQAkJACAgBITARAb5RtbS0VuFHE50nx26fABeisbAwh5Ozk1LBDqBy4gHkWRBhu1tjK56FCbix4NWGDRtUrkJ6RjpSUy8iLzOXVHTvx8KQENhQ0rOfj88EPcghISAEhIAQEAJCYL4SOHz4MBVFsVXJzKtXr6Eb1gAYGMgm41S8H1ijYnBoGB3tGlW1Mic3n7w53eBKgGIk3B5xMRZuwo/1FcrKy1FZUQUfMgxY9Crp1Bkkn03B6tWr1HMRERE36UUOCwEhIASEgBAQAvONwGhpa65ytGXLVnh6es43BNN2vayFdfLUaVXi3szUXIV9hYYuVKKk0zaJOTqQGAsTLOzp06dQXl6GlHPn0U/lUysryvDgww9h7fq1uJSZBTt7e6qM1DlBD3JICAgBISAEhIAQmK8E2qjSEYcze3p6zFcE03bdTZSjYKivjwXEmnUrOOyLPQpczVLa7REQY2ECflzWrK1Ng8aGBlUuVZeSnQcHB7GeQpM487mbSqj6hoZM0IMcEgJCQAgIASEgBOYrAQ5B8vHxpRKevfMVwbRdN1euZFE7X19fFUI+bQPPg4HEWJhgkVmMzYn0FOLi4tDZ0QkLehP29/Ura3Xjxo04TdLs2VQKjQVWgoMXTtCTHBICQkAICAEhIATmAoHTp08rYdaBgQHo0062nb0dVlOFo56eHhw8eFD97uhop5LrZrCysqQcBX04OjrMhUvXmmtgvYr09HRoNJqRCke0mVtUWPTZ/KjskbQ7SkCMhQlwsvvQz8+fkmU6YE+qzVw6tb+/H3upbu/g4AC6NB2wsLYi/YUyMRYm4CiHhIAQEAJCQAjMFQIVFRXo6OhAfX09XFxcxhKWWbCVb1NLSZOppKQES5csocpHVti8efNcuXStuQ5eg9aWVlRUVijla5CxYEDVKT09PGBoIOrXd3qhxFiYgChXQyopKUJVZSVYedHI2Jjej7r0YTCMgYFeaFo08KA35rqNFJYkTQgIASEgBISAEJhzBLiazrlz59RmoQ7HI1NrbW1VHoSWlpYxvSWOj29oqEd3dxfsKaeRw5VtRItpSt4P7NWprauFm7Mr7Bzt1X2Zk5MTaWJZjLCfklHnb6diLEyw9qtWrQK7G83IlXgmMRHpGRkqZ4FfYkO7BRyeFLc8TsmHT9CNHBICQkAICAEhIARmKYG+vj6UkwjrIAl92drZqZ3sRx999JqrMScBsGeefuaa5+WJO0egpqZGeXRYLJeNMQdnR9x33313bgDp6boExFi4LpbPn0xISFAPtm7diuLiYlDxXvXYwswMDg4Sg/g5KflLCAgBISAEhMDcJHDg0/1KL8Hbxw9hUthkxhb53PkUyhepx5HDx9R6LImJnbG5zKeBxVj4AqvNOgvShIAQEAJCQAgIgblPgKvrcAVEDnl59ZVXoUfJzHIfMLPr3t3VgzbKF41dGou777qbnAuSzDwdKyLGwnRQljGEgBAQAkJACAiBWUUgOzubchAaKKBAVxkJrq6us2r+c3GynDNiY2uF7s5Oyk2wFcG1aVpkMRYmATo5OVnFyF3KuITIxZHgkCQW+5AmBISAEBACQkAIzE0CXAp1H1U/DAwMRHh4uNyYzuAyf/LJJ7hM5VLz83NhbWUNb28fFYY0g1OaV0OLsTCJ5ebkJpZqP3b8OI4fO0p1lD+lD44I9QFiY2OD0NDQSfQipwgBISAEhIAQEAKzgcClS5dQWlZGN6f5WLNmzWyY8pyeY3d3NxobG+Hm6o7Vq1dT6dr2OX292nZxYixMYkW8vb2RX5CPhx56EEX5BdhPxkJ6WgaCFwYjIiJClU+Ljo6eRE9yihAQAkJACAgBIaCNBA4cOEDGQQGVRHeHm5sbli1dii7SUzAxNYUZFTWRNj0EuNIRi66xZ4dzRrhx3sgg/ZjRBi2XsnVxkZCw6VmNkVHEWJgE7c7ODvT29Ko3bmdvD5qprjKX7Coi0ZV2UnbWNzBQYUlRUVGT6E1OEQJCQAgIASEgBLSJwKlTp5Cbm4fy8nLKUdBRJdELaJPQw9NT7WRr01zn+lza29tha2WDD4/uhBFpV3DYd21tLfQod8SO9CtWrlw51xFo3fWJsTCJJeEEJxZWOXs2BUPDQ3jgwYfgTGrOphbmOLj/AIbJym1obJhET3KKEBACQkAICAEhoI0ErKws4O7uhpCQEHh5eakfbZznXJ8T31NdLriMDAoFi1u2DMYkiGtlZQVHRwcE+PvP9cvXyusTY+Emy8KusK6ubnT3tKC7qxNr163D/fdvJzXHFLAAS2tTM+08eJCysyQ83wSlHBYCQkAICAEhoHUEzpw5rcJc3N09sHBhCJbRDaq06SXAuSEFBQVKJZtVsavLq7CE1iEmJgYGFL3BulacaC5tZgiIsXAT7nl5eeSS1ENmZiaMTYzh6+tLrsocfLT7IzIc1qoPFXPyMHAMnTQhIASEgBAQAkJg9hBIvXgR+/btQ3x8AoyMjMRQmKGlS0k5i+Tks2htbYUdqWT39fZhw+ZNCAoKovwElxmalQw7SkCMhVESN/hdW1uD9957XxkLnGhz7tx5dSbH0PHuA7+pJbn5BvDk6TtGoLS0VO188fuO33PW1taq7w5KvqurqwOLB3EtcC9ynfNvaUJACAgBIfA5gebmZvCONX9WctMngTX+vLyYkY7MrCw4OTkjMjLy8xfIX9NGoKGhntamVW26btmyhcqielMuqD4sLSyVV2HaJiID3ZCAGAs3RANwqS7+AHn55ZcxKs4SHx+vXuHsRpbu4LCqvTxBF3JICNwWAf5ia2trQ3VNFVrpw9TDYwHKytOwhkrHcUnftLQ0qtrhTt6ubOWirayspJhbdzEYbou6vFgICIG5RuD8+fMk5mWL4qIiVdmIlZj589XV0VGpM7PxEBsbO9cue1ZcD0ducKhRL3kTeB1G77NmxeTnySTFWJhgoU+fPq1uxPiUHTuCkZKSoioi8eOigkJ1c5aamoolS5bwU9KEwB0nwDthbKj+6I03KHemCxs3bqTdrwg1ztmzZ0kkSAff/OdvIiM9kxRGF+D3v/89SkqKKVzO747PRToUAkJACMxWAr19vbhIIUeHDx2iTUAnPPDAA5SfsBDr1q1Xl8Q3q9JmhkBvby866PvNjgrH8GaXNO0jIMbCBGvCYUfZOTloamoit5gXfvGLX6gbNn4J1/x96aWXlAQ8P5YmBKaCAOfC7P7oIwz0DSAqMgqrqGQcv/e49dGXXw2Vk+Myf2+++SZ++tMfI42+DBdHLb5mKhy+xPG40oSAEBAC84FAUnIy9PX00E+flwa0W21gYIgtmzdj86ZN6vJ5B1s+F6f/ncCbXvl5+WjXtKCru0eVoWePQm1NDYYwLEnM078kkxpRjIUJMPFOQ8SiRaijeDo9+tB55plnxhKZ+SaO4xs5ZlyaEJhKAsWFRSRMM0DCgDnYvVuHakyvUMMNDAxSha5uWFhYwNzMBF4UolRXV0+udeA4qY3XUL5NRXkFGReDqsJEfX39VE5T+hYCQkAIaA2B5sYmnElKVDld9lSbP5gSAvrAWwAAQABJREFUZUcNBa2Z5DycCN87sbf8xInjcPfwoO8uc7DXx5K+xzhMzJHCwqRpHwExFiZYE7aADx0+hL1796rYRt6FGG0c68ilU8VlNkpEfk8VgSF6ry1fvhw+vj44dfI0Oju71FD8fuSf/v5+dFJZX01HOwwMR1zp/N7kmNyhwSHyQNDxznY0ihbIVC2R9CsEhICWEbB3sMfqVauUAvBo8Qctm+Kcnc7HH38MjaZNfTeR62DcdQ4NDZKhcIJyEwzgRQnmfA/F91PsIXd0dBp3rjzQHgJiLEywFuxZ8PXxpRu1OHoz801X37izOe7xSgNi3EF5IATuEAE2FDjWtqm5icRpjMDqlm/94Q/qg5hLynVoOnDg009RQ25cLjPH70nevdG0aUhM0EZ9EGs0RggNNVQf0ndoWtKNEBACQkBrCHDFON6x5nr9BlRJ55FHHgV7FKRNPwFOWO7gzSu6hxrNBWGDgNvQ0LAKpV22bDl9J4VKNcnpX55bGlGMhQmw8W6EhaUlFoWFwdrWBvvIwzAaL85vfP7b0NBwgh7kkBC4PQKmpqbw9/dDdXW1MhIWLgxS+TOd5PWqqqwiRfFhrFmzBqnp6dhEsbhd3V2wJVduQEDAuIF5J2f0Q3vcAXkgBISAEJjFBNhAaG/X0OebIUW8A4cOHcbDDz+oQoTFWJieheUNrBMnT6CZ8jsHyZudnnEJHqSE7em54IrKfCPGAnsaeJOLS4A7OztPzwRllNsmIMbCBAhHdmfb0EV5CbZ2tqirr0NvT696BRvJ7fS8iYnJBD3IISFwewTYWNixY4fyDnBYHJf2a2xsRA9VjwgODqYPY0+VuMzGrDN5utasXgN+zdVt1Li9+nl5LASEgBCYrQR4B5uFU03I42poZEwbKJUICwslHRobFSY8W69rts2bjQX+fko5lwJ7WweqIumGhIQE3HfffbPtUmS+NyAgxsINwPDTJqYmKvzI1sFO7cp+7Zmvoay0DIMUc+fm5k7P6cPKymqCHuSQELgzBLjM341aYGDgjQ7J80JACAiBOUsgIyMD5eXlMDYyROTiKDz77LNz9lq1/cIupl5EW2sb/P0CEBDorwwGbZ+zzG/yBMRYmIDVqpWr1FFWfmSNhfoGqq5w5gz6BvqxfOky+FF4iAdl80sTAkJACAgBISAEppdAHVV4q6qqRgjpJawmoUppM0eA05gDAgKVFhDrV0ibWwR059blTM3VsKuzm+oB/+j116Gh2Ehdirn71x/9CKXkZeBj0oSAEBACQkAICIHpIcDaR1zQwc3VBVu3bqWd7PE5WtMzCxnlSgIaCkXqo/DY0UTmK4/J37OfgHgWJlhDzlngNz6Ls3GFmZCQYHzwwQfqFY8+9iV09/aM6S5M0I0cEgJCQAgIASEgBO4AAf5eTiL9BN7F5mIOGzZsvAO9She3Q4CLvaScPYsnn3zyioTm2+lRXqttBMRYmGBF9u3bR6XYsnD8yDE0tbSi4HI+1W1eCVMTUyTSP4wllGwqpVMnACiHhIAQEAJCQAjcQQKJiWfwzjt/haurK+Li4u5gz9LVrRDgBPOc7BwMkxG3fsMG8SzcCsRZ8BoxFiZYJDYEnJyc4eLmClcSDomIDFeJzhyb502CV4tI3ZmVnaUJASEgBISAEBACU0+Aw39ZdHIp5Q1KgZGp532zEXopwmLf/v1Yu26d0rUQ8c+bEZudx8VYmGDdOEmnrq4Wvr6+5EEAWsi7MFq3md1uXLaytrZ2gh7kkBAQAkJACAgBIXArBLja0aVLl5TYmqOjA55++hnSmfFWJctZ+ZdLdEqbGQLnz59Hc3MLLly4QGXk2/HVrz6B4uJiJQw6MzOSUaeSgBgLE9D1Ie8B//AH1uXCyzh9+oyq48wv4TyGr371q0pYZIIu5JAQEAJCQAgIASFwCwRaW1tJV6aJKh5VISpqsVKtZyFUruHvRLoy0maGQErKWcpN0KNN1GFk5+ZgOYWDxcfHz8xkZNRpISDGwiQwt7S0kNvTgmTkCzBIZVP76UeH/mul5znBSpoQEAJCQAgIASFw+wSSk5OVACrLMbPoqSeVJ7e0tKC/TZXgJAtTSpsZAqdOnURBwWVlvFmSxlRJSTH6+3oR4O8/MxOSUaeNgBgLk0DN1RdYudmdhNhiY6Jx9PgR6OmMoJMyYZMAKKcIASEgBISAELgJgaSkJOTm5qK6ugY+vj5UgTAElaTKvH3H9pu8Ug5PNYFTp06hs7MLRRRq1NjYCC/y8Li4usHPzw9bNm+e6uGl/xkmIMbCJBZAV1cX9nZ28PH2goWFOXpIc6GL/tEY0D8WqYY0CYByihAQAkJACAiBmxDo7OzEwMAgGkhszd7eThkKIrZ2E2jTdLigoACsb9FLWgoR4eFKlFZXh1SnOKFT2pwnIMbCJJbY3NyMXG398A/wg42NDWKiY9HX36dCkKQawyQAyilCQAgIASEgBCYgkJOTA1MzU0REhCM4KAhDw0NYtWrVBK+QQ9NFIC0tDUeOHFFlUYODg+Hl5YWNom8xXfi1YhwxFiaxDCz+wgk90NPFBx9+CD19Q8THxcPIyEglQE+iCzlFCAgBISAEhIAQuIIAh/iWlZWpgiFJiUkIDQ2FRqPB+vXrrzhL/pxpArt276T7HUM88sij2LRp00xPR8afAQK6MzDmrBuSreqOrm5858WXkJeXj4ryMnzzn76hYvfS09Nm3fXIhIWAEBACQkAIzDSBtrY2pZmwf/9B/OxnP6OKg6dmekoy/nUIXExNQ2zsEkoyN77OUXlqPhAQz8KkVnkYbFWFUbLVzp071Su+9NiX0d6moR2RoUn1ICcJASEgBISAEBAC4wno6evD0soC3/nuS1hA2kUSejSejzY8MqVKVA4ODqpcqjbMR+Yw/QTEWJiA+X5SJSwsLCbRkVQ0NNQjg7wIX/3yEyqu8tTp01ixYgV0JblnAoJySAgIASEgBITA9Qlwzl91dRVWr1qpTuAbUj09veufLM9OOYFPPvkEaWkZJEZbR+vw+e1hbn4+BkhbSm53pnwJtHaAz98NWjvFmZvY0NAgjAz10NXRBhNjAyxZEgN9Q10MDPVj2fKlWLDAEzq6Esk1cyskIwsBISAEhMBsJMC5CgcPHqSp6+Dee++Bo6PjbLyMWTnn/v5+JCUlUsIyVNLyyEUMo7S0BK2tLSR6F680LUYvLmHFcirsEoOamprRp+T3PCMgxsIEC+5PQiMsBOPpuYA/z+gfURv/yyILe4BqQPuijR5zjWFpQkAICAEhIASEwOQI5OXl4TBV19m9azde+MbX0dfXN7kXylm3TYA1Ei6cP49Dnx6EuZU19A0M+PZGJZlzaVSu/uji4jyuJKqOjjUZCtVU0MX3tseXDmYnATEWJli3wMAg8E9WVhaKioqUWAyrF+qRN8GPDInIyAiq3NAmsvMTMJRDQkAICAEhIASYwIUL50nQq4li33Xh7e2tyqQaGRrB2tpaAN0hArt370J5WTnYe3C9MOl+2uzkY5lUqnbbtruoBLzdZyMPw9/fFx6kmM0h1tKEwJUExFi4ksYN/mZr25g8DEkkQx8aEgpzMzN8SlZ58MJg1Nc30D+wgBu8Up4WAkJACAgBISAELly4ANZS0KeEZldXVyXuxTelW7ZskTyF23x7NDQ04MSJE+jp6UF2Tjb6u3thR6J2JiYm1/RsoGOg2N99993YuHEDAgLk/uUaSPLENQTEWLgGybVPcC1o/sfYS8rNzzz9NFniNkgkWXqWoXd1cbn2BfKMEBACQkAICIF5SKCjowPnKcyF9RKGKWx36dKlqK2tUd+XZbTjzWEwcXFxePDBB+chnTtzyZmZmSp/gD0EzLi5uUVFQBiSFsLly4XYsnkL5RyYkGF2/WRxHVJe5uPW1lZ3ZkLSy5wnIMbCJJbY0tKC/gFehqmxCcX5fUpxfpYqxtLezl65UyfRhZwiBISAEBACQmDOE2hubqYYeB1cOHcO9pS07EIbal1dXSpkt7e3F25ubupGdc6D+IIXyHkczG4yrbq6WoUSNVBIl4mxMTj6oeByAaIWL0ZsTAwxdqVcSw8sXBgyme7kHCFwUwJiLNwUESi20geVVVUIDQ/FW2//n9JWWBQeDkcnB1hYWEyiBzlFCAgBISAEhMDcJMDeAi63ybvcLLR2NjkJnZoOBJM2ESfMLlmyZG5e+C1cFRtOZWWl415J2JCRcYnuJywVQ50JapTyMc6drKgopwpSDnAgg8zSwhwPbd+BR7702Lh+5YEQuFMExFiYBMnMzEtY4OOD6K5OPPHE46iqrkVkRIQkNk+CnZwiBISAEBACc5dAe3s7JS5fUKU2a2trsXnzZpiRgeBLlXNkM238urNnJSMjA+7u7uOqDbFH4QhVh2KDy8PDc8KIBTYWBgb6yGuwkKoTeeOuu7aNH0QeCYEpICDGwiShVpSW4cMP/o6A1wKwbu1a9Y+Zcxm4qoM0ITCVBPh9dmW7+j135fGrj135OvlbCAgBIXCnCSRT4Y+S0lL84fe/RwIlLEdGRiIiPOJODzMn+mNWx46fwJHDh8YZUt3d3cp4ePjhh/D881+fE9cqFzG3CIixMJn1/MwlyLsnbMVHUlzgIKkZPvLwIwgODhIX62QYyjm3RKClpQWZmVn4w1v/h8amBvVFnEDJgbx7xy0x8QxSUlLodyIWR0Xhha+/IGUIb4m0vEgICIFbJbAwOBgvv/wyvLwWwN7e/la7mdOv279/H46SoVBOYnSvvvrquCpE7C0wNDREPiklSxMC2khAjIVJrAona7mR23D7jh0YHBhAH1UgGBwYpCQiF2U0TKILOUUI3BIB9hq0tbWS6zoN999/PylrJmCIDFVuZ86cIf2PQnxKKqgBQUH4xz/2wM/XTxmvXl5e6pzR//GXkZGR0ehD+S0EhIAQuC0Cb775Oyp5qg8HBwdKpvVUCsympqawsbG5rX7n4os/pcIo5y+kor62Dg898KASc+X8jtHGf3PZ08W0ESlNCGgjATEWbrIqp06dIgn0UqRQKbih/gHcTSImpubmymXIOwGi4HwTgHL4tgno6emppMHMS1mIjoqGsfHITX9XZyf6yWg1Id2PDWvXobqkglTGW1UN7ePHj6u/ueTv0OCQUh2vq6u/7blIB0JACAiB999/H0ePHcOyZcvh7OyMINqskDaeAOsesPFUWlqCs2dTKNexGkGBAQgMChRe41HJo1lAQIyFmywSx2LyP/oyylmwIZXJ/Qc+xb333Yfo6MWwIql0aUJgKgmYk2FqaGiAp596WtUpP3DgAFavXqWGHKLdKPZ0WZiYqfCkj2x2oZMMCG78Ot64Yi0QTqrr6upGVVWlOib/EwJCQAjcDgEbG2ts2LARBlTH39/f/3a6mlOv5c/f48ePqcpG/BnM9wj5+XmUkDxIAmgbYWdri7CwsDl1zXIx84OAGAsTrPM5qhNdU12lakSz0iHnKeze/RG+9e1vqZsvMRYmgCeH7ggBfs81NDQiPHwR+vt6kZaWTjf9Vdi9axd6yAgwNjJGC9XY3v3RbkoyLMG6DRvUuCzW096uUfHDHMrEFUvYI3Hx4sU7Mi/pRAgIgflJ4MiRw8qz7kYqzN7e3ggMDJyfIK64ao4+OHs2mTZnqsjbO4CS4mIsW75clY1lr0v/QD+cnZwkROsKZvLn7CIgxsIE69VFpVI5WcvFxVnFilfSzizv8rIASjF9GLBsPcdrShMCU0WAq2T09vWhsLBQldULjwhHBJXtbab3INc259KETq4uqhyfpbUNxRDrqQTnq7/A2TvG71sxFqZqpaRfITC3CbA+wAGKvefynm6ubhRfH0llPj3m9kVf5+rOnDlNOgnlahORc8G48WdxTX0dWhqb4evnhxUr4mFrZwcDA0P1Gc15HLGxsdfpTZ4SArODgBgLE6wTGwP8IcDVC9LS0pRqc2tLKzhZiRNIebd2Oe0ecMymNCEwFQQ4L4a9C5z8xl8+vEvFX9qNdOPPyqj8mI2JMtrZioiIxLZt22BGOQxXN06g66PzpAkBISAEvigBLrLA1QAvXkxTN8r33XvPWMjjF+1rNp7P3tmUlLN0zV0oKSmm6nNJ6vPUibwF3NiTO0AehWXLlin1ZAsLM/K6+Kr7hNl4vTJnIXA1ATEWriZyxeP4+ARcupSJmppa/OY3v1GaCoNDg3j33XeVV+G73/2u2vEVY+EKaPLnHSXAnoOnnnxywj4lBnZCPHJQCAiBL0igjDbI2BPJN8m8e85edkNDI2hIPGxFQjzlSEWQIJjPF+x19p7OGy1Dw0MqFyErOwt6lKsRHxs/xoAZGRgYwMTEGDExser+YPZercxcCFxLQIyFa5mMe4Y9CM8++zV0dHSqD00O8xgig2FoaFipMHK1A2lCQAgIASEgBGY7Ac6HsrKyQl5eHmwpGbe0pETdBA+S0bB9+3YVjjvbr/FW579z9y7k5uRj1cqViKOIAi5jLU0IzBcCYizcZKW3bNlykzPksBAQAkJACAiB2U2go6ND5TRxGCPvpF+gcuHnSPDRxMQEXpTIPN/bcP8QXiLhOWuqchQdHT3fccj1zzMCYizMswWXyxUCQkAICAEhcDWBjEuX8N4HH2Db1q2qcMfjTzwB/uGmq6urfs/n/3FSMyWQzWcEcu3zmIAYC19g8YuLi1BJblozUzOqYT8MS0vLcZLtX6ArOVUICAEhIASEgNYQ4MIdVRUVVGLZWBkHEmI7sjQ1NTUoLy9HK+VrGFHBidEKSFqzcDIRITANBMRYmATk8+SOradycXv2fIzsnGw8//zzKMjNQ2DIQlWZhktZShMCQkAICAEhMFsIZGdnY//+/Sop95lnvoZNJBoWtXgxPD09qaKP22y5jCmZZ1JSkqr2VE2qyxpNGw4eOgxjc1PYUSn1HipnLU0IzDcC4lucxIpzLKeunj5aWlsQGhpCnsgBVNXWoq1NQx8kmkn0IKcIASEgBISAENAOAlwKfD+pwX+ydy9srG1VeWYjIyPSB1hB+gmLMVoSVDtmO/2zaG1tpRKppWRMHUBBwWXoURjWc88+h6rKSmVMTf+MZEQhMLMExLMwSf59/X3Ki2BL4irHjh9HdnYOYmJjxCU5SX5ymhAQAkJACMwsgbNnWSugUyUw25KRsChsEcIWLVKTmq9Ju0eOHFEl0Pv6eun7fGT/tLmlGc3NLUrLJjo6ivSUlin9mpiYaKoWZT2ziyijC4EZICDGwiSgs44Cxy36+/tR6bRc1Dc2kHKlJ4yNDOFKkvfShIAQEAJCQAhoM4HTp08jMzNTfXdZWVnCwtIc8fFxpKfQiODgIG2e+pTMjY2mlLMpSkzt3LlzCAwMIuPAWW0AGpNeApdNtybD4J577pmS8aVTITCbCIixMInV4tJx+iTC4ujohGE6P94uAY5Ojli7dt28lLufBDI5RQgIASEgBLSIQFZWFomMXkIHqRAvWhSKBx98UItmN71TaaZk5X379sHB1h5Hjx9Tg9vb28GGIge4eImNrrUSVmMhOmlCQAgAYixM4l1QVlYKaxtbpKfvRkhYKJbFLkVPfy8qK0cqRzg4OEyiFzlFCAgBISAEhMDMEODcO18/XwQtDKaqPvPzJpgjBEpLS1FUVIS/vP0XLItbBmNTEywLXIrY2FiEhYXNzOLIqEJAywmIsTCJBTI2NkFHewdsbayxd99e/PXtP2ERVUD6+gsv4PLly6om9SS6kVOEgBAQAkJACEw7Ab5B9vP1JVVmOwwODWL16tXTPgdtGJC/rw0MDLBr1y70D/Vj5eqVcLB3gDkJrfn4+GjDFGUOQkArCYixMIllWUQJYG1tbaps2urSCrz40rdw+MhhxJPcOyc/SRMCQkAICAEhoI0EGhsbySueTjkKlli5aqU2TnHa5jRIomoVpCXBugmvvvoq1q5ZO21jy0BCYDYTEGNhEqvHOgvD0MH3X/s+cjOz4OHtia985XGsW78OXZQkJU0ICAEhIASEgDYSSE5Oxvvvf4h7771bG6c3rXPq7u5CTk6OigbYvn37tI4tgwmB2UxAjIVJrN7Q8BBY5D08MhzPf/05rF61SlVMYCVHa2spozYJhHKKEBACQkAIzAAB1lPQp9AbQ1Ifnu+tp6cXtaSRFBQUON9RyPULgS9EQIyFCXAdPHgQdaTc3E31l/0oMczY0AA5pHqZeuGCErFZunQplVP1VyI2E3Qjh4SAEBACQkAIzAiBu++6ixKb/VBdXTUj42vToH29vUovicXnpAkBITB5AmIsTMBqaGgIZpT41NPUi76ePop1rFSCNhz3yMcSKGehW6TfJyAoh4SAEBACQmA6CZSUFCOLRENTSIAtPDycSn47QqPR0G568HROQ+vGOkAelqNHj4KVqoOD5zcLrVscmZDWExBjYYIl8vDwoPKoleDdCFMTU5J590BU1EhCc2JiEoaoHjPXZJYmBISAEBACQmCmCeTn56OwqBAnT51Gfm4ONm3apIyFgICAmZ7ajI5//PhxJCUlob6+ntSYl8v39oyuhgw+GwmIsTDBqoWGhqoqSKdOnQKHJHGs46hICydJLV68GHBymqAHOSQEhIAQEAJCYGoJXLx4kcKMqpXHOyo6Grm5+fBe4InW1pZ5vYv+8ccfg7UVWBOpuroGoaFhCF64EEuWLJnaBZHehcAcIyDGwk0WlMVbOG+BjQOWh9fXH0FmZWWF/v5+tWtzky7ksBAQAkJACAiBKSGQlpaGqqoq2jVvQHNzEywszBEaslB5FaZkQC3tlDfzLlA+YVNTk5ohe/1TL1ykYiSAkbEROFKAcwwtqYSsNCEgBL4YATEWbsLLy8uLkpkH1O5Me3s74uLj1CssLKygaWsBGw3ShIAQEAJCQAhMNYG+vj6kpqaqHAR9fT0sXBiClpYWdHZ14dDhQ/CkG+LVq9dM9TS0qv+SkhLwT3lFuYoESDxzBi4urirUiFWrfXy84ePrAzc3N6yiSobShIAQ+OIExFi4CTOumsDJUCzkUkEfRpzQPKQzjPqGRrV7U1xcTJFIEop0E4xyWAgIASEgBG6TAHu3LSws8O7f/orY2FhSIzZUisy8oeXj44XwRRG3OcLseHleXp4ymNh7wHkanMCdcSkDw7o6yoPA4Ua6urqwsbGBu7sbhQyLeOrsWFmZpbYSEGNhEiuTm5urzvrZz36OoqJiZSz09/bh9R/+AKzuLE0ICAEhIASEwFQT4Jvjv77zDi5lXEJ0VDRMjI1VGe8lsUvg6uIy570KrLzM4b+7du2ksOAuDAwMqBAs/jsuIR6hYaHYvGHjVC+D9C8E5h0BMRYmseT8gdTa1gZn+jBetXI1WjStMNTRo3wFF3o1BURKEwJCQAgIASEwRQS4XDd7tXt6euBHcfcbP6tyFBISMjaiH2kpzMXGZcq7KMyKGWjaWvG3v72Lffv3q406X19flaxsa2uLL33pS3Px8uWahIBWEBBjYZLLYGCgr3ZuYmOj8e0Xv42B/iG4erhTCJLDJHuQ04SAEBACQkAIfHECGRkZake9sbEJO3bsoPAjA5iYmHzxjmbhKzjMqK25Ff/6xo/g6uSI1o5OvPLKK2ADIT4+Xl3RaOGRWXh5MmUhMCsIiLEwiWWKiYlRNZojIsLhTglkTz/9DKpIDXPlqhWkwdA3iR7kFCFw+wR+9+bvoKenD29Kul+3bp3q8Ny5c7h8uRBpaamUQxOK++6/X5Lubx+19CAEtIZAcnKy0vv54x9/j61b7sGGDeuVsaA1E5zCiXBJWPYsHDj0KfT0dfG1559HH4UhcWUjOzs7mJmZTeHo0rUQEAKjBMRYGCVxnd+HqbpEeXkF5SkUqaNGRoYqmYqTysxMzZShIKJs1wEnT91xAjv//nfs2rkTzs4usKWkPW7JZ5NRWlKKDyh+l3fWLlCZQEuqzsXGLX+ZXtl0qH4g70ZKEwJCYHYQYCExbnyzzDfIDo5uqhrffNpF7+hop+pPaUhKTsILX3tWCaGyMKqpqensWESZpRCYIwTEWJhgIbu7e6hudTPOUCk2rqxgaGioPrj5w5pvvhZHLYazk/MEPcghIXB7BLhc79mzZ3E+9QLq6+qpuofdmPpoR3sHuJTiIN1IPLR9O/78lz+Dz+f4Xr7R6OnpRie57PlmY5B+qmuqb28y8mohIASmnMDbb79NG1SF6KB/u1yJb+vWrWrMp556EpGRkVM+vjYMkJiYSIJyreBqgxyGdNfWu2Dn6Ag2FPh7WJoQEALTS0CMhQl4u7u7q4SyL3/5y+qDy87WbuxsXUpsDvQPRDvtfEgTAlNFoLe3F/l5+WAVcTNzc6oA0oG62jpw+BEn/PVSwqONlSW4xO+hQ4fGBIn4XD5eUZEH7qOrqxtl5aVTNU3pVwgIgS9IgKvs8b9rVhjmSkZfefxxGFN1o6GhQdjbO5B4mJW6MebvIf6Z6+3EiRNqs4NFUOvr6zA8BPX9uoCUqOPi4hBNytTShIAQmBkCYixMwH3x4sVUn3kxCgoKkJ6ejvKSMnUDNjw0TEWQdJQhMcHL5ZAQuCMECikMzsjQhHYa21FSWooBMgJqyWDoJ68Ce7nYw3Ds2DE0kIKr1WfqpGxENDQ0wJiSIEd24nTg6uqmxIvuyKSkEyEgBG6LABsJXVThqL6+HuGkC8BGPRsLHh6e6t+6jo4uiYvNHc81516UlZUpT+c14KioIAuodVEJ1EbSMNLV0yODyQ52DnbqM62NqhFKEwJCYOYIiLEwCfb8oc7qj/v27kP/QD/lKvQj/VI6HF0cERAQMIke5BQhcGsE+OYhMCiQyvQ64vy582hr18CA3PAcfqRPX6isVGpgaKTqrvf19yGUFF11yZBNSEgYNyDv2vGXMCudShMCQmDmCGRlZaG6uloZB2zcc46RmYX5WHjNhg0bZm5yd3jkxKRENFEFJy75ytcN6FJelYX6feVQFOVLhRoKYGlhCWsrayok4q4+84yMjahc+aorT5W/hYAQmAECYixMAjrnJ7Ab+N7778UAxX739vSitLIMA+wnlSYEppCAOYUTPf/cc2qEt956izxaunBydEApeRiGyMPFxmokeb9Ky0qxnFz1faTkanqdCiGciM+GrjQhIASml0BaWhpYD6CyslLlwJ1NSQGHtNrZ2uDJJ5+c3slM82jsAU1OTEJDYwN5QQ1GDIAb5ByE0EYHF2ZwdnZW2gnTPFUZTggIgQkIiLEwAZzRQ3yjVVVVjUMHDyljYQBD6KREUh0yHKQJgeki8PTTT4M9BOxt2LZt29iwfn6+aGpuwtIlS8eekz+EgBCYOQIsoMYhN319vSp0taqqShkKHI+fRuVA2SMYH7d85iY4hSOz17OwsFDpQuz9+GOVL7U4KhILyRjgz67169dP4ejStRAQAlNBQIyFSVDluPB2igsfHiDjgOLF9SllYcf9O7CS3KMtLS2T6EFOEQJ3hsCqVauu6cifFF35P2lCQAhoBwE2FCwsLfDAA08q/ZN/+qdvqCpmCxYswDPPPKMExebKdwfnGnR2dirwvLFWW1uLnOxs/PwXv8DQwAB++Pq/wsqaizCs1I7FkVkIASHwhQmIsTAJZFyJ4fz5c/iX115BGSU565CxMKynAxOq9dzc0jyJHuQUISAEhIAQmE8EOFzVk5KVv/Wtb6lS21fnEc0VFlzRyYa0X1JTU0nr5YKqaLRnzx48++yzeO7Z5+Dn50eikRfnyuXKdQiBeUlAjIVJLDvXfK6m3ZInvvokesi9zNVluCwlS87zrq40ISAEhIAQEAKjBPgGuZlCA3/+858rQ4HVhudi++ijj6j862mlReTu7gZPT0+VsL2OQo020A/nXHF58cWkjyBNCAiB2UtAjIVJrB3HYA6RceBEiVcvfvvbcHN1BZdyY5frokWLJtGDnCIEhIAQEAJznQALeBYWFpG+STm+//3vz/rLZUFIIyNj5UE/evQIsjKzYELlmFmklJsqz0wVizZv3oQdO3bQ8zpkHOmq497e3mPnzXoQcgFCYJ4TEGNhEm8APSpR6eTkBAvaJeHktAzSXLC1taUkNReVxBYWFjaJXuQUISAEhIAQmMsEWDPhbMpZ5U2YjdfJyu/sNe8kvQMus1xWWq7yDVgZPi8/FzHRMQgMDISBgYG6vAHKSeCchYSEeHo+aDZessxZCAiBSRAQY2ESkNiDwAlcZVSusrmpiXZajNSXAcdkajSaSfQgpwgBISAEhMBcIsA77b29fWp33dTURGnx8MYSh6ba0WbSbGhs3KTSBhiXd2XveVdXl9JEGKRKf32Uc+Hk4KSESZubm0lBOQpWVlZj33+j1xcZGakMiNHH8lsICIG5R0CMhUmsKRsLPaSuaUqeha133UVquobqVUP0gepKIUnShIAQEAJCYH4R6OvrJyGxIpSXl2HJ0iVUGa9V6Z7w94K1tbVWwygoyEdubh6qSByO8/CSkpLAN/3c2IvOmiwO9g4qcZkNISurBar6n1ZflExOCAiBKSMgxsIk0eqQwdBLKpTD9EXAH56kjqVcsfr6epPsQU4TAkJACAiB2U6gv78fyclJ0KOS2qTXCTMz0/+fvfOAr+q60v1CXUiiSEgC1IUKHYFopncDBve4JU7sOLaTeCaOk0ySyUzmvSSTZDIzyZs4bVJMEttxbNxwwfReBaKoAEKAukRRR72/71vyxdiAEUjAlbS2fzLSvefss/d/73POWnuvgp3nagmDg++IESP0x5n7ePx4hhw+nCL5eflyrhjJ0rAbwizJgYGDdNegH7JKcxEsISHBmbthbTMCRuAmEjBloQOwmcHZB1lxPWGnuXbtWqSk95MW2Gp+6amnsKqUj6yT4R2oxQ4xAkbACBiB7kqgFCaoR48eUXv+vgib7erqIqPHjJKgwCAZPXp0t+hWZmampKWmybGjx2THjh1y++LFMiw6GsE7gmFKFAeFIahb9MMaaQSMwM0lYMpCB3hTWaBT1ze/9S1pYGQk7C7wM64iVVRUdKAGO8QIGAEjYAS6M4Ec+Ky5u7lLenq6Ov9+C+8DRvzpDoUZlWvgiJydkyuZmSdl89YtcFZOlG9/+5+6Q/OtjUbACNxiAqYsdHAAkIdNGPnBBUqCC7Zt6cjGH/xpxQgYASNgBHoYAYYFra2tQYhsgelpX3GD2VFqSoqUlJRoojFHRCBn7nZBQT7eWy2SnZUloUNC5XhGhuxJ2iPz58+XmTOmO3PTrW1GwAg4EQFTFjowGG3SJtuQpfLrX/uaKgx0eG6Aw/PPf/5zSbRkMx0gaIcYASNgBLoXgaNHj2pSsSNHjmqEoKeeelLGjRvXbTrBxa16RDTasWO7rPlgrXghP4IrfOyWLFmiu+Jz58zpNn2xhhoBI3BrCZiy0AH+06dNFw/4K2RhdYYmSFXYzv3mN74pgwIGdeBsO8QIGAEjYAS6G4GzZ8/KypUr5dy5Ypm/YH53a76299///ceSlJQkn3ngAXnooQelsKBAbrvtNt0l6ZYdskYbASNwSwiYstAB7Pv27UMGy3L53ve+J4yEwRjUuxENY/ac2RIeYc7NHUBohxgBI2AEnJYA8w1UVFbI6dNnNIzoNAjU06dPl8mTJyNy0GEVsJ228Rc1jIpB8oFkRDoqgELgotmkqTD4+fmIt5eXTJo0SXdLLjrFfjUCRsAIXJWAKQtXRURfhSY8bP3wIjmtZkh9kOr+0c89inBzs6UOMaqtGAEjYASMQPclwEWgM0Vn5O1Vq6SqslKWLl4ix48fl4AAf01KxtwDzli2wlG5BAtZ586clTqE9i7Iy5P8/Hy544471M9i5MjRyPnQT81lnT33gzPytTYZASPQTsCUhavMhG3btkphYZG49XGRJ5/8EpSDenFDUraS02fxeQEewhOvUoN9bQSMgBEwAs5G4ABW4Gli1IgId8ydExkRCSVhsZSUlkjl+UpNsBYaGupUza6pqVEfhBMnEN0Iv9PZmrsiwcFBEhEZgehMERIdHSkREREasc8FC1tMtsbcCVaMgBEwAtdLwJSFq5A7deqUnIKvQlRklDzw8EP6cK7FCs73/+VfZJb7LKnEKpSzrjpdpWv2tREwAkagVxJgxuJDMC+iDb+vr6+aG+Xjdzd3N1kMhcHf39/puNCHgnl+9uzZI4zU5FAIwsPDZfjweN1JcHV10+zRs7HrbcUIGAEj0FUETFn4FJIHDhyQM9jePXf2nIwZPUaP9EZEiYMHD0pxWak0NTcKH+BxcXGfUot9ZQSMgBEwAreawKZNG6WsrFz64hnuhoAVgwcPVpMd7iqcP39e7r333lvdxCten6ZFWzZvhq/cXmG+h0kTJyIZaBgUHR8khBvTraI0XbGT9oURMAJOS8CUhU8ZmnrsILi09RE3rNZQSWBhJudFixbJij//WTN5trW1fkoN9pURMAJGwAjcagKbNm2S5EOHBJlxZPas2ciV44L8CW0yf948Wbhw4a1u3hWvz4zLOTnZ6i+XcuiwVFVVyfJly+SRRx5xyt2PK3bEvjACRqBbEzBl4VOGj9EwDuMFU55aJplwduPWNW1A6dScfSpL5s6Zi79dP6UG+8oIGAEjYARuNYGSklIpyM2XgQMHSGFRoQwaNEjNjW51uz7t+sy6vG3bNk0KV1x8TjJPZMoDDz0kn33ks5oQ9NPOte+MgBEwAl1JwJSFq9D0DwiQfgMGyOo1H4g77FkH+AfI66+/Ic0tzYiUMdDC0F2Fn31tBIyAEbjZBKqRC6ewsFDz4jA3ztChg+Xzn39U8wvQ4bc7lPXr12uOBLZ11KiRsnjJUvn8o5/vDk23NhoBI9DDCJiycJUBHTJkiNx///3y57/8RX7+i/9BRsw6iYmNk29/59tqKzp8+PCr1GBfGwEjYASMwM0kwLCnobDpP3jwkByE79kXvvB5cbbIRlfiUY5QqAzlyp0FhDSSO5YulQeQVM2KETACRuBWETBl4Srk58yZo7atA/r3lx/94IeSX5Ans2bOUnOkPniQWzECRsAIGAHnIkBhe9Xbb8mbb74h8SNHOlfjrtKaDz5YLUVFp9X0lUnhTFG4CjD72ggYgRtOwJSFDiCmUjBu3DipqKiQUSNHmb1oB5jZIUbACBiBW0Fg7969GlY0LjZWZsDvrF//ATBDGnormtLhazKYxrFjx+Sd996T11eulNjoaJkzc6YMDgnpcB12oBEwAkbgRhEwZaGDZD09PS2fQgdZ2WFdR4AKakZGhqSkpGhCwPj4eOnfv59MmzZNL8IwvmfOnJETJ04gGdMwmT17liVg6jr8VlM3IbBu3ToVtg8jd8LAgQM1ERlX5d09PDXEqLN2g/d2amqqFBQUyebNG2HmWi+fgdlrfHycjBkzVgKcMN+Ds7K0dhkBI3DjCJiycOPYWs1GoNMEWlpakPivSvbs3itV1VVIEJiNKFyztN79+/drnPjVH6yRM2fPiE/fPTRxVkEp5DIrkozkZcUIdHcCzFjMkKJUkhsa6iUxcaJ2iQs6QUFBOv+9vb2QqMw5/cl27Nghubm5cgiK/jkkV2MW5uDgwTJkyFBZvnyZ9oWKDvNAWDECRsAIOAMBUxacYRSsDUbgUwiEhobIfffdJ9u2b9cIL42NjXp0ZWUFhKVGKULUFwoZr76+En83IP9HjX6/ZcsWaWxskLbWNo0KU40Y7VaMQHckwB20srIy9RWLhonOIey0JSGTMVffY2IqJTAwUJ2CQ0KGak6c/jA9crayYcMGOXb0mOTm5Uo17lHeq1QKuCDAQBpUdvz8/BD5aJQqPc7WfmuPETACvZeAKQu9d+yt592AQN++fZEl/IzED4+X9Rs3iAcyz9bV1skh5P9obm6RqvOVGjt++fLlsnPXTt1pGD16tHD1krsNleWVqjBQgcjKyuoGPbYmGoGPCOyBQsAQqNnZ2WpeFBUVpV/6wzxnzJgx0n9Af/VHYDbjCRMmfHSiE/529uxZOYEIR83NTTJ27Fjxxr09GDshXl6eMm/efCdssTXJCBgBI9BOwJQFmwlGwIkJ0Lm+ublZamprZAASSuVm54iXd18pQ3hF7jDQtIjf79+3TxqQLNAdygQLVytdkXmcmWp5DH/6mBmSE4+0Ne1yBGpra5FALVDoi8CVeCoL/fr1kyAkVeNPQkKC7ipc7lxn+mzr1q3ah0b0YVzCOImF87WXl5fMhBOzFSNgBIyAsxMwZcHZR8ja16sJcEegsalBHZgZ0eXA/gNqqz0oMEB8fHwkYKC/tDQ2SU5OjpQUl0jMsGHwW+gjcxDyl9lfQ9V3gWZIbRp3/j1EW7FiBJyRAJUBmhtx5b2trU0VXirEDQ1VcPiNVxMdKr3cVVi4cKEzduGybUpK2ivH4MjMaEezZswQ+hN1p/ZftlP2oREwAr2KgCkLvWq4rbPdjUCbtElBfoHs3LkLSkMTTC9GScCggZKelqohfKOjhklEdBS+3ynjJ06CAuELm20v7ebs2bMvdJf+CxS0rBgBZyVQWVmpoanpuM8dhZLSEt01uPvuu521yVdsF5V8KgfMHp2bmydr165VJSF+xAgoOwOveJ59YQSMgBFwRgKmLDjjqFibjMCHBNxgSrRgwQKZNGmyCh4U+BMTExFmcZOuvC5cuAgZxWPUqdnPz1ejqvRHAkErRqA7EKiC0z0zFnMngcpCUHCw7NqzW6qra2E210cdf7tDPy5uYx3MAffBLHDjxo3oR7UcQAbpgTAh5H1MR+zpyP1gxQgYASPQnQiYstCdRsva2usIDBgwQPjzyXKxQ6Szhoj8ZJvtbyPwSQI0OwqPiJD09HSNBjRi5Aj58tNPd6toQDSVot+QozAp3FrkfVjxwgvys5/9TB5++GG9h+0+dRCyf42AEehuBExZ6G4jZu01AkbACPQQAlyFf+nFl+WFFX+ShyBUz4RNf3crSUlJ6lNRUlIs2xHeeOXK16Xy/Hl57rnn5IEHHtDu0L/IihEwAkaguxIwZaG7jpy12wgYASPQTQnQhyY0LFTCQsNE2vogwpGvLFu2TJ33w8PDu1Wv6GOxYsUKDVtMH4U4OGMvWLBQJiZOUKfsbtUZa6wRMAJG4DIETFm4DBT7yAgYASNgBLqeAH1tyisq5fjxDIktjZVBAQESGDQIisMCJFeL6foLdlGNzGvCfCebN2+R+vr6j9WairCuI0eOlC9/+ctSV1eLsKhxGt41MjLyY8fZH0bACBiB7krAlIXuOnLWbiNgBIxANyPg4eGhGcdPF56W4fHDtfV02Hfmwp0DjUiGpIcMUTxt2rSPNZehUAOg9ATBeTkAuR+YgdmKETACRqAnETBloSeNpvXFCBgBI+BkBJg/gSvyVVXn1SyHEYGYK8ETioMzRO4qKiqU1NQ0jTZGdHRWZrblJoQqZvSxxoZGKUYOk6LCIlm0aJEMHjz4Y4RdXV1lGPKbjEBYVCtGwAgYgZ5IwJSFnjiq1icjYASMgBMQYFjU/fv3SdapLM1CPn/+PFmyZIkTtEw0D0JqaqqcPn0aSoErdgf8NYQrcyTkIFO6P3YLBkKpaWxuQfb0gbJw0UKhPwVDoFoxAkbACPQmAqYs9KbRtr4aASNgBG4iASoLXHV//vlfycSJE2/ila98qbS0NCkoKJDD8DU4d+6cNCEDuruHO5SZKpFW7Cy0tEj/Af2lPUu6L/wP/JDo0Fv8fH1lDjKjWzECRsAI9DYCpiz0thG3/hoBI2AEbgKBiooKKSoqkrKyUmGOgbFjx95ys6OjR48Kf1KhMDDreWREuPoghIWFy9KlS28CFbuEETACRqD7ETBlofuNmbXYCBgBI+C0BEpLS6WkpETy8vLE28cXtvwjZfnyO6VPnz43vc0t2CU4deqUZjtnlujtO3ZIEsyicrOzZe7cuTJl8mSnMYu66XDsgkbACBiBDhIwZaGDoOwwI2AEjIARuDqBlJQUCQ4Ohq9CsqTAJ+AH3/83DTdKU56bWagoMHqRm7ub7NyzS4ryCmTd+nUSGRUtz37t6+Lj09f8D27mgNi1jIAR6LYETFnotkNnDTcCRsAIOB+BtrZWyTyRKfv37ZMZCDPqPyjgljSSOwoHkR/hV88/DwflATJ92nT5yle+DB+EAWpydCt2Om4JCLuoETACRqCTBExZ6CRAO90IGAEj0NsJrHxtpezduxfZi+PUoXnqlKkw8Zmipkdt0qYOwjeS0d///ncpLy+T9PQj6ifh7eWF0KeNCIF6TubPny/333+/VFdXS1RUlPpNMCSqFSNgBIyAEegYAVMWOsbJjjICRsAIGIHLENi5c4ekpaRKCXwV5oaGCvMODBky5DJHdv1HK1asUCWFuwhMjMbQpsyFMDwuTlrho1BXV4fs0GHi5uYmCQkJ0rdv365vhNVoBIyAEejhBExZ6OEDbN0zAkbACNwIAq2trUi2tlk8PT1l4uRJEj9yuPjD3Cc4+ONJy7r62gx3ugOOyulp6ZJ84KDEITTrY49+XppaW3TnwB0+Cq6u7a+2/gMGqJJgJkddPQpWnxEwAr2JgCkLvWm0ra9GwAgYgU4SyM/Pl+TkA3LgwAHxcPeQxIkTxA+5CMYljJPIyMhO1n750w8dOihFSJ529sxZzZGQkZGBvAd+Mn36dBk6dLAMDQnRXYXY2NjLV2CfGgEjYASMwHUTMGXhutHZiUbACBiB3kegsrJSQoYOlbdXrZKJCeM16zGF9DCY+3RlWbNmjRSXFEtjY6OGYmVm5bzcPDUp8kWCtPETxkNRGCoTJkyQUJg/WTECRsAIGIEbQ8CUhRvD1Wo1AkbACPQYAunp6RqGlII7Q6DW19fDgXkSkppFysRJEzVUald1dj3Cm5aUlEpSUpL4IZOyj7eXnD9/Xmpr6iQwMFBCsItAJeGuu+4SLzgyWzECRsAIGIEbS8CUhRvL12o3AkbACHR7AsePH1fzHwrtkyZNknvuuafL+kQfBNbf1NQktbW17RmWkZ+BPhEBAf4SFBgkUTBv6tevP/wjvDS6UZdd3CoyAkbACBiBqxIwZeGqiOwAI2AEjEDvI5CZmanRhBjZiEoC/+7ff4CaHXWWRn5+npSWlWlm5axTWdLc0ipFhQWycdMmjWo0cOBAmTFjhkRERMjUqVM7ezk73wgYASNgBDpBwJSFTsCzU42AETACPZFAQUGB5OcXIKqQC4T4QhXa6RewcOHCTneXOwnJyQfFxd1V6Lh8MvOkZGVly8gRwyVxQoI8/MjnxNPDQ2JiYjp9LavACBgBI2AEOk/AlIXOM7QajIARMALdnkAb8hLQF4HlzbfekvffWw3THz954IHPyINLl3aqf6yX9bP8+te/kRSYGVVVVSLUqr+MGTNGFiBx2mOPPabf2/+MgBEwAkbAuQiYsuBc42GtMQJGwAjcEgJZWac047KfXz+Jj4+XoMHBMn5cgpxByNLOlKqqKvnNb34j2SeypLSiTLJzsmUplI+xY8cggdrtWjUTuVkxAkbACBgB5yRgyoJzjou1yggYASNwUwhs27ZN9u3bJ9u2b9OwpL96/lcyCNmQY2EGxGRm48ePv+525OXlyTvvvCsvv/yyfOmJL2kUo9CwUCkrK5XbbpsGH4j+1123nWgEjIARMAI3h4ApCzeHs13FCFwXATqWMmxlUVGRtCA6THxcnGakdVSWmpoi5eUVWP09I8FYCU5MTBQ/Pz/H1/avEbgsgddee00VAX9/f406RH+EWbNmybBhMTIAzsVc6Wd40s6UI0eOyMt/f0X27tqjvg4jRo5Q52X6QSQmTtTfO1O/nWsEjIARMAI3h4ApCzeHs13FCFwXAYaTzM7Olo0bN0pVdY3ExcYgvGSNTJs2XTPoUonYl7RPjhw7huy5EdLQ0KA24J0V9K6rsXZStyCwcuVKWbt2DXYMJkjfvn1hDjRWTpzIRA6DQeKOjMxpUEATkGytMyUVPgmHDh2S3Tt2yZIlSzAnR2t0Ix8fn85Ua+caASNgBIzALSBgysItgG6XNALXQoBhJBMSEuQUIsacOnkSybFyVVmorKiQluYWFcomTpksm6BQ3A4b8Orq6kuqpzmJh4f7JZ/bBz2fQHl5ueyHmVEjFE+GIa1BLoPgwYMFHsea+Tg8PFz40xVl584dcuxYhkZSqqgoFz9kWk4YN1YWLlqkuxVdcQ2rwwgYASNgBG4uAVMWbi5vu5oRuCYCzJZLk5BRo0ZprPuqygpxcXHROpqam5Hptlj6+mB1GCu3aSkpWCE+oTsMu3fvxnclGiefUWjoZEqTJiu9i8CZM2cQpnS/nEJ40mDkS6iAghkcFCTeyHwcGxv7MZO2zpLZhBwJ69atgz9Cubgj9GlwUKDuci3GzoIVI2AEjIAR6L4ETFnovmNnLe8FBKgoeEGwO326CEmxTiD2/DCJiorSjLeNjY3SKm0wHXETL2S29fLyhP15i1Jxd3fXjLcFBUVqmlRTU4MdiexeQMy6mJGRIcxlQN8VF5c+4u3dV/64YoV847nnFA4jEXVFoRJK52gqos1QXNesXStnoZxEYn6OGjlSmMzN19fMjrqCtdVhBIyAEbiVBExZuJX07dpG4CoEaFLU2Ngkv/zlLyUubriEhYWpQ2paWppEwHSEglpdXb3UVtXI6aIzEhISAsdVgSlSlZSWVmjtbm5uQlvxwMBA/fwql7SvuzEB7iwdTjmMVf1g9XWJjo6WevixzJg1U+LiY9VHobPdc2RzpoJwEmZxhw8fxhxthE9NlcybN09Gjx4t85E3wYoRMAJGwAj0DAKmLPSMcbRe9FACXL19//33YEJUhYRZdZKbm6MKwdmzZ3WnYOSIUUKfht/+7+80DOWgQYPEE7sMc+fO+xiRrVu3ImoSYtxnZ33sc/ujZxDIyckRjn0KFIWUwymSl5uLOTBXzdeisdL/zFe+IlQcOuNgXFZWJpx3DIcaMChQzdpefPFF7HRFywhkX+aOVwBCrpqi0DPmlPXCCBgBI+Ag0AfCSHtaTccn9q8RMAJOQ4DOqUePHkUEpFqhKZEHbMEZ5rIF5kYUCIcODVEBkBGT+HlERIQMGDDgkvZv2bJFaL/+zjvvyKuvvnrJ9/ZB9yPARzcFeP57/HiG/svoWJWV55EvwVUef/yLne4UdxEYkYtl544dQhOn91d/ICFh4dLX21Pn5Tee+4Y6z9MJ34oRMAJGwAj0PAK2s9DzxtR61IMIcNeAEWwuV8aNHaex8luZfwEZd1ksE+7lSPXMz4qLi+XEyUz50Q//XdpaWuTf/s//gZ/AULnvvvt1XnRFrw8fPiQDB/hLIZSQbdu242erPPTgg3I7nJbpdO8oNu8cJOxfI2AEjEDPI2DKQs8bU+tRDyNwNUHsat/3MBzWnQ8JcEehramPTJl6m8yHrwCjY02ePLnLFEbuRqWnpyE0bwp8HXyFmZcfe/xxKCP3aaZnm3c2FY2AETACvYOAKQu9Y5ytl0bACHRzAjt37lSToFOIitXS1grhPUzNzu69525VEJgrgUnWuqqsW7te0o+kyXQkAAyPCFfH5X79+nU6s3NXtc/qMQJGwAgYgZtDwJSFm8PZrmIEjIAR6BQB+q3QR2HHrl0ya/Ys8Q/wVwG+U5V+4mRG10pK2itZWdmSjERuixbfDsfoKJmQmKgO0p843P40AkbACBiBXkDAlIVeMMjWRSNgBLovgQ0bNmBHoRGO6wM1/G1lZaUEIbFaQ31Dl3QqPT1d6P9QW1uj/+7atVt8+vrIZPjKhIWHyfgJE0xR6BLSVokRMAJGoHsSMGWhe46btdoIGIFeQGDNmg9kb9I+CYfJkUgfDZ/LPAbTp0/vdO/37t0jBQWFUoaIW4yyVV5eKvn5BVJYWKjhT2nWlGg7Cp3mbBUYASNgBLo7AVMWuvsIWvuNgBHosQRy8/KlCMK7wEchJiZGZs+efV19bUG0pB07d0h9bZ06QjchiVrG8ePSgH9ZGB7VG5nCGXZ32bJl8vDDD2v+juu6mJ1kBIyAETACPYqAKYT8jBEAAEAASURBVAs9ajitM0bACHRnAszYnZKSovkLuHvQ19tbQ+fGx8fJjBkzr6tr9HU4ePAgMnqXyvlKJPdDRufic2cl49gx8UT9Y8aMkSGDB4u/v7/cfvvt13UNO8kIGAEjYAR6LgFTFnru2FrPjIAR6EYEmADt0KFDUo2kahu2bJbY2BiJRJK9fv37SULC+GvuCRP6FRYWaKbl4ODB8o1vfEPGjhun0YxcXVxk2vRpEhkZpTsJ11y5nWAEjIARMAK9hoApC71mqK2jRsAIOBsBCvSMQNSnj0hOTq74+PrJj//9JxI/fDgyMguiHl2f2RHrTE5OlhHD41C3i7z11pviAgXh2//0LYmLa0/g52wsrD1GwAgYASPgnARMWXDOcbFWGQEj0MMJ0E9g08ZNgtRqwvwFTKhWV1cv3/+378tYmAZVVZ+/ZgLNSMxG/4R169YhR0K6/HnFn8Sv3wA5evSomhi5utoj/5qh2glGwAgYgV5OwN4cvXwCWPeNgBG4NQRWr14tO5Ez4eSJk/LQww9KRkaGjBw5Aj4EoxH4qA3mQiHX3LCXX35JDh9OkX3IkTBwoL989atfRUSjCdilaJPW1lYZMmTINddpJxgBI2AEjEDvJmDKQu8ef+u9ETACN4HAOTgU5+bmydmzZ6UEjsYRyIg8duxY+CXESXpamiROnCDe3n2lf/8B19Wa3//+fzUM6u7du8XXz08+++ijEgCHZTpGM38Cw65GRkaqKdJ1XcBOMgJGwAgYgV5LwJSFXjv01nEjYARuFoGmpmYpOl0k7737ntTW1cnnPvtZyczM1ORqU6ZOUUH+WtqSk5MjaUimths7E1RAysvL4ASdIA88+KDQeXnM2DHij50Fhlu1YgSMgBEwAkagMwRMWegMPTvXCBgBI3AZAnv27JGKigoV5GvramT06PZdhAULFmgCNHd3dxkOJ+YwTbZ2mQou+mjLli0IeXpezhWf0zrr6+uluaVZikvKpLystH2HAkoBfRUCAwO1ztjY2ItqsF+NgBEwAkbACFw/AVMWrp+dnWkEjIARuCyBM2fOSElJCfwHDsugQYNkxIgWOYcdgLvvvlu8kPyso2Xbtm2SnZ2NnxzNvUC/Ay8vTwmPihRfmCxNgj9CQECA+Pj4qMlRaCgzPVsxAkbACBgBI9B1BExZ6DqWVpMRMAK9mMDOnTtVQfD09BT+MMIRHYqHRQ+TuXPmXBeZs2fOyubNm8UTCgbrGTCgP3wbkGkZJkbeSKi22JKoXRdXO8kIGAEjYAQ6TsCUhY6zsiONgBEwApclsAu+A2Vl5ZKWli7MvBwUFKh+BEFBQTJ37tzLnnO1D3ft3iUbNm6UltYWmTxpEkyZRmvdVzvPvjcCRsAIGAEj0JUETFnoSppWlxEwAr2GQE1NjYY7ZVjSvn19ZM2aNZKVlQ2fgVBxd3eTmTNnXTOL2tpaSU1NFeZLOHHyhBw/mSl3LV+u4VSnTZt+zfXZCUbACBgBI2AEOkvAlIXOErTzjYAR6FUEKisr1XG5qKhQBg7wV3Oj02dOS+SwKJkxY4b4+fliB2DGNTOhonDgwAFJPnhQis+dkwOHDkjcsBiZNHGSmKJwzTjtBCNgBIyAEegiAqYsdBFIq8YIGIGeR4CKAaMMCfMstyFbQZ8+kpKSorkM/vyXv0p6apo8++yzMn/BPAj00zoM4Pz587p70H5Ce93MspyLkKg/+8lP5B//8R/km1//OnweQrCrMKbD9dqBRsAIGAEjYAS6moApC11N1OozAkagxxA4gx2D5uYmOXkyS6qrazTiUGJiopzKysKK/0R54DOfkTkzZ0tl9flr6vO+fXtloP8gqTpfreFPy8pLpbCwSN5//325CxGTvvbs19WB2dXV9ZrqtYONgBEwAkbACHQ1AVMWupqo1WcEjEC3JlBYWCiNDY3S2tYqoaEhsuq99yX5wCFx7eOiYVDpUxAVFaVhULnTQEUhODj4in3OyMiQurpaKB0tUlFZIfv2JsnepCTxDxgkQUOGSktTozQ11MPPwV3mz58vd955p7i5uenPFSu1L4yAETACRsAI3CQCpizcJNB2GSNgBJybwEH6ChQXw8E4RQ7sS5Z5ixbJiOFxMmbkSBkZP1wb7+bmivClAyUkJORTO7Nhw3o5C7+DI0eOSMaxDCRLC9IISWXl5TBoElmwYBEUD38ZibovLlQ+PDw8rikXw8Xn2+9GwAgYga4iUFVVJcePHxcmguSCyM1K9pibmyNnEDZ68uTJavrZVf25XD1btmwW7uDOmjX7cl/bZx8SMGXBpoIR6CYE1q1bh6g7fdU8ZSJMYBwlCyYxmScyxcfXT8aPGye+vr6Or+zfayBQV1cnQ4cOkeOZx2XE6FF4UU2Sfn5+Eh0d3aFa3nrrTaGPw6lTWZKfn69ZlrlDMGHCBIlHtmb/gQOktbVNXFxcVCGIQdbloUOHdqjuW3XQJuR4yMnJlvy8PN0Z8fHxxa5KpDz00EM3tElvvfWWZqtmlutr8QW5oY2yyo2AkxFgyGYmfuSzZOrUqfLb3/1ORmEBIiFhnISHR3S6tYzKxh3PDz74QJYtW3ahPv69b18SlIhGccP3YaGh8vTTT1343vHLjh079HnXR/pIFXZgi4pOy+OPP+74+rL/pqeny/79+yUmNk5effVVOXb0GJ6lTVBU4rG4MgKLMGfl4IGDKuD74fnM6HOZmSe0nXzW1mKXlj5hochx41AAjh07Jps34VmWl6OR6wYG+MtA5MHhbu8gZL1vamySd1atUhPQyzbKPhRTFmwSGAEnJsDwnFylzs3NVZv2+++/H7bz1RdazAfrW2+/je8KZQReEnWIqDNu7NhPNYu5cHIv/4UvvNPItFxZdV483NwlCJmWa/39JTIiUqKjoqUCuwBRkZEdovT888/LEYxF//4D4RDdLCNHjBTvvl7YTQhW5Y0J2mbNuvZQqh26+A08KA8vV76svb28Nc8DlYXAwADZiPwPubnZ4uvjJ7Nnz5YUmGZVV1dBeGjQsLEeHp7S0Ngo7tiJWbr0DnnnnXegKLXi5dwM5Wm8KgJcOeRLnRmoqfxSQOBKpru7hyrEXrhmOcaAAlFBAZQvvNiZv2LChEQkqtvULhCEhUkchAquflZhHFtwjf79+8uSxUtuIBWr2gg4BwE+90+dPCm33Xab3id7du+WObgfjxw5Klu2bFWBOhomk+6eHrrDWV9fh4UKTzWn5C5pAfykmEBy3NgxuCcr5Rx2Qxtx33LBaRJyu3CBiiUtLQ338dILnT556hTuuZOqpDQ2N8r27dvlqaeelDffeEMqeU8PCtA6CgsKkKiyVOLj4iUyKhKZ6HOloaFBqETk5+dp5nnmjxk5cpTWnZaWKunpR+R00RkZGhIqqz9YLTOmzUCbGrAgdkL6uPTR3V8+J6ZOvU0GDhyoSsiZs2elCc+WRGS0ZyjrKFyrsrziwzrTZDuut2vPbrkN53BXuD+SW7JtRUX5MnjwEKltqpVsLLrxXbtw4SI9z/73cQKmLHych/1lBJyKALd/PSE8HTuaIfuT9+vqER+QLEeOpAuzBh/AKsuQwcG6MsIwm1zd/qQNPaxbzAb+w5FlRuRWRDjiqlQTBNCmpiZ9sbXiJbNw4cIPj+rYPwx3+vrrr8vq1atlDJS0oOBACNOBMFUaoLsUkyZN7lhFTnpUelo6hPJqvHyjNUQszaTOnj2nQvxRrNa54L96rOR5IcM0ncArz1dCsfASD093cffwkmK8xCmcJO3dKwMgQFRC+Kep1wisEPr4+GB1ch8DTUkNOLLu9957T5Yvv1PnMCNDDYsZpooy/T6GDRuG1cU4+WD1B5IK4aUVyera4EdCBeUYzL2onFAZ6YOdG3cofwsWLHBSqtYsI9A1BLgwwXtj4/r1ej8dQ0Q13kdDIRBTuM6GUF9aWipDsGNaj/uDQj+TRz7zzDNQ0gcislsqdg5zVUnne4VBFirhVxUdHSXcKT0JRURwj/MZeXFpxt/lZWVYUCmTlrYWLBr4qJBOIZ6r+P3w/Fu6ZAl2AA7Iu+++J/PmzcPiiTfu5RzZunUrrpkjOfidIebOVzIyXIuMxfOTCwj8jM/V4OAg2ZecLNOhLPj59ZO169dJRFQEFJ0Ayc3OwXOoWHcFAvwDdKfWBaZENPv08PSSQchw74JnAwsVqtOnuShUqbsQfFY1gUVFRYWyYQhsPvsBTkNi60n2v0sImLJwCRL7wAg4DwE+2ErxUB6XkICH/3F9IKt0hSbywe7h4Y7fWjWzLx/AXN2ePXuWCmFUGhwP+fMQ4s6fr3Kejt3klpSB4cGDB7ByVowIRFV4MY2BYFslbRA4A7CbwK12Kg8dKeScnZ2lL7TS0jJdNR8cPFgmJk6U8eMTEDEpviPVdItjqqqqxQumbwNhQsWVxQKsxm3btk1eeukluf+++2Xjpk1QkIJUUGHo1wFc6cPK4jmYClCwT04+IJ995LNQanfJvfffB2Z1KsRQmIH+qopABeZpIlYxT506Ibt37dT5S64UOsZjpZDmYYdTDkszHM5HI4xsQUGhCgWLl9wur698Q77+7NckF2ZSDXBKb8MxjRBkaL5kxQj0fAK8i0SF/WY8y7jyTjPHEigI1diV3rc/WTzwDomGop3/odDMe4vPMO4ENuOe2blzh4SFh+q9ewLKAQMu8JnI3cIBA/ywEDUEySZPfQwlr9HY1CBZp6BM4JrLl90pO7C7wHv5LBYItu3YKf2wO8HnB3cOBw8erDsWNJl97LHH5Pvf/74sWrRI88q4QbGnKRCVBb6vuNsrfdqgOJyW++6+V85jx7CkpBFKRaX0wc4hdz24GHYC5qK5ednyxBNfxG5whC4W1FTX6jPmMMJb++E4BqNg6Gs+k3zxHLsbkeYchc8X9sNhtluP3QsqVlYuT8CUhctzsU+NgFMQ4Orr5x59VB/uu3ftgIDVHpOfjXOYdfjBV2HOnDlqGlJT064QcHWJjrjZ2dm6hcsVH5pq9JZy4kQmHvxlHypXogJnZGSUvPHGm7qyHQChNiQ8TBYvvv2akPAle/jQIa2XK3fcLucLbv78eTJlymSswEddU33OfnAEXsIUxLnCyC16Kl00RWpqbNadlCPHjkp9XYN4YveA/h6T4JBYjblG87hx8J9JS01DpKdG6QuTohjsEnBHhwpHfl6+7gww6pSrq5sUnT2jK6LDhsXKvffeJy+++FdxhZmEK17mtMeOQXI6CiFpePnX1FXr6iLNF95Z9a4qbfTlofMlBYOMzEw1dXB2ttY+I9BZAnjMSwj8Be665x4pLimWddhhaIT9/bEjx6SirEK42l5TU6cmle4urtgFbJDpM2eoKc6+fcnY0asRN+wCVmKVnfftkCGDca96YtFjvGzdth1mPYkSGBQku2HedHGhqY8vFldioodJNXYB8rA7sXjxIuwivCteHh4a/Y07fb6+PurzxchvNCukIzE/p3ktF1X4XKmDaRR3SFhcXF3Ey7sv7ukC6Yt/77vvXhX4uQPCnDNueFbw8zA8u3kOg1Lwnh8xYriaVLlhgyAlPU0yjmfAHGuu+o7RzIrPhszMDFm7dg122N3RjvZdB+4msHBHshU/fI5YuTwBUxYuz8U+NQJORYB2nnzItqJVtCk9BIGV9t408aAiwO3Xs1iRCfCfp+2mX8MZ/M0tZuYJoEDL83pLycrKFgq6ZVgposJFc5ajsOONjYuVmbNmqqLATMsdKaewlU+eVM5o7kL/Eb6Uh8A5mathS5YuVidmmh/1tDIGOzB0LjwLx8Qd23dIEFYIQxDudRYYvvLq33W1byIECkZwagYf7s64w6mb7GnWED0sWv0PuOK/bu1aqYNykAgnRG9vL+wcHIdzpIcMhiNiFeyluXsRO3yEIqSPRxRMIfr69FV/kmAILHQW7wPTguE45gTG5O233pZ58APp189PVxq52kjBgSYMfVG/FSPQ0wnQvycyMhLPd95Xibqjxufd2bOnYSpYJqEhobgnffXdUVRUJA0wax2MeykQvlT8vgw/w6JioJhzh1qE9xkVet7PvMfpRxSMez4UTsQu2EFwFG9vb+x2j4eJ0G1SXFoir7/6mqRhpZ7vm3AoL9Fo0wD4DnFn/BzMDk9hZyIQCkNkWDgWF+pk2fLleIcdFk+YJkXj2TxoUPuzc0D/AdIf974X6ufiTlLSXqlm2GmYOk2bfhucnmMlD74OuYX5Uoy2T5k6BX56dVJVU6t19cdCRgDq4nOFigD7QZPQKJgvRaBNbyJwAusNh7IxBM8dmizy3cpFECow9O+wcnkCfaAhQhezYgSMgDMT4K7AD37wA3nks59VAZXOuTUQYIfhwfeXv/xF7VHpDPrTn/4EQlb0JSvcW2EnygfiypUrNcKEM/e1M21zOOht2bJFzViOZcCUBatks2fPkdnX4WBMhYvsS0vKJBdb6AcOJMs5vBzvuGOZJE5MlBkzZnSmud3i3A0bNohPXx/1R+DLnWniGN0pBbsG3NUaDDMkmhcEwvnYEy9nvlIoNIRCaKhrpM+Npzz7zD/II5//nAzDy94XK4NUvgbArrgB/g4eMAGrh0kDV/XopDgsIkr9cXwgNPhCaKjC6ifzU/j59pPWpmZVRPLy82GeUCWxmP+MfkIBwgu2yri4DPIPkNKKMpk7t11x7haQrZFG4DoI0ITIB+Y2DfUNEhcXpyv1gxCogb5udPinMMwFJi509EEktiYcx4WjwaEhsB5CjpiySnGFKWsrhHF39/bcLqexMMAobRTYc3Ff0UzHHSv6Prg/HeZ9fCb44zrlWIwJDw+XkuISmCt6q1LCeptwPU8o91Uwf6U/AL8L8BsIJeaMTL5tqi64FEJ54c5DH/w3ZcqUC72nH1PS3iS8w6LVB6wE93L/flA8oABwp2PNmjXiit2CaiyW3QuzIipBuUUFMipuuPpVvff+e6ow1EH4Z94aR2FUt8wTJ6UBihWfEVzYQFPlPBikHz0C5ULkySefdBxu/36CgCkLnwBifxoBZyTA1W1u2dLJkw85OpfmwTwkHsIXzDtlD5J80Q5/PFZtHQ7QF/eDwjMFX0alYTi6nlj4EqTDN1f7ud1NW3e+JMnueiIRcSdmz549sgoh9ehEzogeCeMRmhYrdV/4/Bd6IsIb0ifufDEz9bTp09SZcQz8DqwYASNgBK5E4ARMPNug3HAnmCa1N7JQ8WG51uAWN7JNzli3KQvOOCrWJiPwCQJ0VtbVoQ8fnFy9pS0mHXO5w+DYHuSW6+Uerr1BWdiLiDsvvPCCzMNqEnMaTJkyVSnSfMXhxPYJrFf8k4rGSy+/LL/77e90a/oxOOUx1OBUhCjk1ja3+q10nAAjj7BwHDgeVoyAETACVyJAc0L6UPTH++xGF5ot0tGZJlNWrkzAntpXZmPfGAGnIcDY8VcqjEBjRdSmnv4ETKRGXw4qTtdaGNHn8OFDiPbzssYcn4eQfzRfGg4HOm7vX27X5lqv0RuPv56x6I2crM9GwAiI7gzfDEWBrM2puWMzzpSFjnGyo4yAEXBCArRXzYBJFiNzzJ03V21fmSnUYVvb0SYzSdBxRNBg1I1MRNOh89tXv/pV3blhZtTeIuzSaX7Xrp3t+QrgTExHRodzPHexGKq3ublVfQ24GkcllmZGjCbClTkeQ/MtJlGi8yV3EuhLw50wms/xHK7k8Xi+pBn9hCuIdFx27NbQn4GF57IuOiCyXu6kccWRuz7cPevXvx921Wq0Ln7vjra1NLfo8dy9YNtpu83283u2z/G354dtpcMn2+LYLXK0lQ7WdMrmtdh2RnJhndzh47X9EVqyDo6XzPFAkzfWzegsDA3LazmuzfZfcm30g7tUjFrD4AOsty92qhhv3rFjyDrZbv6w32xfO5e2dm6IbFMLX46WlvZQkjyPXHker83CceFG5ED4htB5k2NCJZp1OdrK6DJMUFVRUa510U6d7SGX9mt74HjsXiKiDnnwfPaH1+JOZ1/YorNwjGA1ov4nrJ/XZuGY81rkxLa0r9720fYwIo0fODfiXHJmlBrOAY4Rf9hv9oXfXZhPqI+RezgPOH84FmTsGEOewznMwrpa0Wba87ePoZce/8mVZMcY83jWw2sxQpcnEpkBq/bVwbF9rjdd4MjjeT6ZcM5wB41t84FjPj+rgeMtObKtHBuOAwsd/HkN1se2kROPI0feI7w2jejZVl7bF/46jfDNYVhgOhq3z7dW5eSY6457hdfhvcNzWacXmLhjTBh5jOFOOYZsa0lJyYVrs01kzrazbo45k7SRL+9x1s3vWdgXx33Ia/PeoIO1o+28Npnw2nwGtD8zmvV7HXP0lSFVWQfHi5xYP3/4N3/IiXlUOP5sLznxeHJi4dwnH37Pe4ltZfH3H4hrt88fto11cZ6SRft866/PG44b20bObDfbyt/JfuHCRVqX/e/jBD6MH/XxD+0vI2AEjIAzE2CmT4bpe/PNN+UthENlFA8Kci6ufeDQPEGF/au1n1mIX3vtNfn5f/9cXnvl73CcW6sve2YTZqZsviSnT5/eaxQF8qLwSoGbOShq8cKnUEEHxAoIso1wLvZFtBFGOyrH39UQhBiBiEIvv3fF5/37wQxOXKQC5/PfIUNDNbRiRXml1uVPp2YIBechLDAE68AB/pr0rQZCNn/vj2golRAMqqEEUCCnAMm6eG0e7wbBohyCQS2uzegqfOkzf0gLJFU6YVOyqoCwSKFqIASH9rZVIqJTi9bdiON5PgU1JnpqQL3noZy4urpr4qoq/M5Y8dyto4BWX9+I0I4N6kTqj3jxZTiX7RuK6DDu7l4q9DSg/4zi4g6hRq+NazC2PIVnHt8InurMjX6Xw+GTAlhf9IVtYrZbOnUHBgQqT16bwhMF1waMBfuOgJJQjKCUgUllZZVy6Ifr1dTWq5M3BW46uTKuPhNv8VoDwLIcgivPGRoyVPtbieR6bRiVgeDKhHnkUA9OIUPDIGA1ShnaQi7Myt0MJYRt49j384OABWGL53M8+sHZlEoR+9oucHlhrtSrMsM5QBNA9oM/VOgo7NVgLtUgxK53X1/pi7byO54TDKWcYXfprM7+BgYy6lW7oOoChWjQoCDwwnzC/KKjLsOEckzKcb4HBG5fjmFjM/pZrWFC2bfyivM6PzlfPOBcT8GV7Wc7mImcygRZkbGvN5Q09IvX90NULc4vCrKcoxwjbzjjcwx5zFDMZbaB9wYdhzkfeDz7ws+HDg3RttEZ3xsCdQDGtAnzi5woUDOUNZUuJiD0Rt1U4nhdcuZiB/tNhbAOygqVWf6wL7xXmHiMgiz7qW0DR1cXNxWS+TfvUwCQUrSlHkqBvz/uDYwh71PWG4BrYyi1HzRZZZb6qioEDkDfOLd43zWCI+9pbzBh23ltzvXAwGDlwLnEMSNzd3CtwPecb5x/Lpg35ETOA3EtJlljv1ugrHnrfemiY8Z7KQhR4xowhvye94gGLsAvnI+c6/7oK8eYc98D91gg5gDDM1fiev1wbc7HmtoGqYXywnuYbS2DkzLnxGBEanNzo7JaLU24v3zRNiZpY9tqUUcwokCxnxxD5itipCg+O8ipBZ+w3VYuT8D1/6Jc/iv71AgYgZ5CIEeT8FRrZB8Kwt29MGspBRVGzmjEqhbNhSgcjhkz9sLq06f1kRmXT548gYhJGVhhK9XVVQpVEyaMR8zukYh2dIdG3eHKVG8qFMy4s8LVTkY14WoiIxbhV5Q2/ZsZm/k7hReuADZAuKEAzJCLjNuu3+N8rugxGSBX7XgsV2wpqHEFkfVxRVlXGJlMCh9wpb59BbFZj69H/HUKerq8i+vpiiH/RnHF6iqVGa4Ksi6uerOtrFObimN0ZVWvpQdo/czcysRVXKWkwsEVUR7fokrHh23FyiyvzR0PKk8UrsiA0WVaIUxwhZLf0VeIfUTmE627DoKSthV9JweuzrNfcAzUlVBdFcbfPEdXXi+0DRmswZFZcRkX37Fqq3+jcS3gw7q5Qt/OEXHqcW22javMZFBTg7agT7w+j9W24m+uMlMA5Qo3PEZxTKu2rQ7tY7vJjmPCMXRl23ANrtpyrBxjSo5UbHgtto11sS3MgeFYWWcbqVg043Pu9rSgj7w2x4Pns23kzNVx1t8KAY311UCoo+DOHQAGamBbeTyZ8xwmDtM5gL/bPpxPrJMcyKcW514YwwvXbkE8fu7cNOg4ss3sJ4/nHGN0Hl6bK+01+jfbivmJvzmHOPdxNR2/2jqsYONv3RX4sC2sS+c6ru1oKzqkc125oW7OM85lXW3HCWwj+0Y+5Mo+aFI05YjcA/ibc47XbucEJRXzm2PEvjAXQR3axrawcD5yfrXhYLanHkJ8A47hubi8tqv9vm0fs2rMj7oP71uu2HMHhG3lfGNb2Fa2keCbsPvA+aNjDC4cr+qaqvYxRN28LtvjmD8MhUpubAfHpR5MHc8E3pc8Xu9TtI1951znM5u/Mykmx+TCfMPfnMtsC58/nONMykaeXAhiPcoN9ysLmXH+coy5w8C6+cPrcr6wbY77kvXxXLaNjBz3oePabbg3uEDB6E5WLiVgZkiXMrFPjIARcFIChw4dlNOnT+Pl0qSrcRER4fqAbw+ROqFDrX4Lsbb37duPDNgF6kAXh4gbwQj/GYwszHPmzOlQHT31IJog3I0ET1aMgBEwAkbACDgImLLgIGH/GgEj4NQEUlJSVMivxUpUXFycJu959tlnr9pmKhdpaWm6UsdV7Q3rN2h259i4GLkbcbrpk2DFCHSWwMmTJzU8MW26JyCE8acVZlYvKECWWtj8JyZO/LRDe9V3KSmHsVL8ka/FqFGjelX/O9rZo0ePSmlZKUx+Bsjo0RaKuKPcLnfcUeRYoKkW3ylWrkzAlIUrs7FvjIARuIUEuCWfnJysLYiJidF8CRkZx2FKdUy34zUJ11XaR0WBcbTzIZgVFRZqhCMXmNosvWOJTJ48GWZL9qK9CsIrfu0YH5oZjRgxQtnSvCEI/iN08KTwTDtx+oCwMBusmpTABMADJmS0zacZC00LWGjCQLMvmgV4ws44OjoaSl0pEjmdVZMBPejD4yiQ87pU/lhYV1hYmISEhOjfbMeJEycumJVwx4RO77TtzsrK0rbS1IFWHQ6H0HHjxum51/s/RuKKQTZa7lpdrCyw3zRzioUwEgA7d+ZHSUtLRUbZCJjGXJuNNHlpfTC7YD4R9oecmeyKfaEZxciRI5UpjyNT9ov2+Y5SiPuAP6zLC3b/E+Djw3Lw4EE14aBJTgRs2jm+PI6MabZDH4CEhARHNTfk30rYjjMjN+cB88Jcj7JAk5SU1BQ1h6KzNecRzWzOnTuLOdNuykVu8fHxiHx2WFlxfjCHDfk5SklJiZoq0oncy8sTHBOEQjrrogkL66bPDuciTRrbj/PS+U4TmxtZTpzI1PmUhznX1coCE1tyTrW0NOt9OGnSJDUZYn+OIZgE70n2n12kkE0OnCMOc0OyGjYs5kLkOM4hKsa8zzjneKzD+ZjPdfqGZWfznixuN0+CMRV9CUaOHCUHDxxQ/yNem9dhZvjByCjtKDRBar/P65Q/j+G4OqLW8br5SCxHX4R2Z2xPvU9oNsV5wvuDppLM6UDzxNiYWEfV9u8nCJiy8Akg9qcRMAK3ngBfPHwJrF69RubANIgvLz7Y+WKcMmWyPPTQQ1dtJF/2dIJ+++231W522bJl6rBMoZHRjShEWLl+AnzZHjx4QLJO5ahpWOaJ4/qiLisvQ+bW88LcHvQz+P73v6+sf/e738FenvbuLXIbErTdvmABBPds5Mb4kyoYFPTvufse+f0f/le+/e3vQDk8KQcPHZLM45mIeJUBu2k4ekLYjoVQ94/Pfk3eXf2+7Nu7T23RqfhRMJg9ezYcMgN1vjAKzB9+/wcpqSiVO5cuVwGUgjPr5XWZBZ1CYxyEiwcffPACCAr9FGgchUIRBXFGsAmCgySFfQrSLPyO5muM0kL76l27dslO/FCopnDEObYbf/f1bI8qRYWBGcHJ4ZVXXpE7li5zXObCv/n5+SpAsW0XFypVGchI/vbbb8rJE1ny1NNPqXLy/nvva5JGti82NlavyV24n//3LyQ8IkyFOCpsDoWBAi+9XTdv2aRRcxIgBFOBWo3Eeaew4xEQAN+f0e2KCB2yt23epA62i25frMdHRkaq4EXeDn8CttPBiYobhTrWSaGShUL1xf2hXTkjmfGeJiMK1+RKH5Y3ELRgMI6nwkU7fyoN5P2RAN6GAAZDVWin4M7rUpFhBDMW9bHAWPwE2ewf+MwDard+BgJwNtqTlpqG8Y7TqGlsUzYyjf/xD3+Qf/7ud9VX5+JdxtTUVMzvQ5KeniZPPPUk2GfIKTyHGDmNfk6z58zWPpDBfixqlOJ5Ez88TjlzHMiBgjLb4yhqp4++UHCNioqCkJytAjS/Zz/o3OtQWHgez2ffyYm29FScKejy2XjkyBHNtOyouyv+LcNuxebNm7XfRUWFmF/ROuaO/vCe5rXz8vI5hSRx0kS5a/ld+pylAkOmTz/5lHKaCCWjuLhYNmzcABYemFOjZMfO7Uh0mSQhGKsnv/SE9p8moCmHU+QMFN4k+KBReRifOEEF/H179krS4YO4dz3k/nvvU5+Di5WFHPjiuSHz9EsrXoYSUy7Tp07TaFnMh8NFh23btmL80nWcR2OX6rnnvi5nz5yTF17/oy4gRWHujRo+QpoxT7ds3ip94dDuWHDoCp49qQ6LhtSTRtP6YgR6CAGulK5Zs0Zef/01da6j8xpNhp544vGrKgoUMMrKyoS+CethcsSX9nPf+IZ881vfkkceeUSFEFMUOj9RKPiMiBsuKWmH5UUIvkWnzyFMozdWqsdrtBg6nx/FCm/xuTMq4GRBMFqwaKGuiB+B0HYg+QCi+1RohKVnvvqMPPzQw3CObpCkpP34nGFERcJCw+See+/VFWZGRFkwf4EsWboUQsA2WfG/f5RFCxfKokULZOvWLbpzdAArkSwU1Gni89DDD8n4cRPkt7/77QUFgIood5woPH/uc5+DQPkZdd50EKEARyEnJzdbSsqLpaq2Ws6VnpM9SPqXmZkJh1MXCEMnpCC/AEJ/tRyG6YwWtJchQhk5Jz+/ELsH6ToPqUwwUg6jHm3buQOOoa1yNP2IVFW2h4h1XJe7IQzdun7dWs1Ezt8vFsYpTDPKTjK47dmzG0IRnazrNLs4Ix/dsWy5ruhSmGOkmtQj6bJm7QeqJHFF2FEolBYXn5Oc7FxVxCi4JyEDPMeLylZF+Xk5euQoVnUPyX6MxW23TUcUohD5/e9/J0OHDNaVZdbF48tKy+R00WkpK6/QaDOFhaelGhGbKNQyy3xBYZGcw7Uc48LzqIhx1+NYRiZW6jOUNe9X7iKWI4TrqVNZ4NruyE6BmPH2C7A6zIhn3LWqhwMu69u6dTOEwFO6Gs0s7SxUThgVbcP69XIi84S8i4z1ZJONOpP3J8vwkcPl/s/cr5GJuCq9FcIvx3Tt+nXq+KqVfPg/V4wzr7sFwnNzY5NEQ0l9+ZW/SX/sPoxLGC+pKVAm4ENFIfk8rnH7ottl9XsfSBrGlv1nYZ+KS85Jbl4uOBTr/Oa/mRgjLmZwlT43J09yc3PUkXj//n16HhmlYNejEnxZH0PacsGEY8sVeEYOKsV3dFjvyrJ9+3YooiegpBTIUt5nW3fIbmSxp8LGEhUZJV/4whc0AEQMdg/cXd11MWbP7j2y/M47ZcnixeI/CLsznGQomzZtao+GBqUzE+OxZs16veeysJPw0ksvQZFtRL9OqWJJznFQshZDKZ2UOFkyoFT/6a9/lamTp8idy+6SmOgYfSaUYzGi/adcnZtffvFlqa9tlM89/Ii8887bMM8qk0NYZEjnPYZ78UBSsrghytLevXvk3Nlz8ov/+YWcgpIxZeoUmQOFbzh24qph+lZSXILQ2SnabvvfpQRsZ+FSJvaJETACt5xAH5k5c4YsXrJEo2JwN6CjZcOG9XhJH5T3sFIaHx8njz76qL74Onq+HdcxAhTIb5sxXebun6tJ7O64/XY1FdixYycEmhII6o/IWQhEr772BoSrCSpkr4MCyGg5M5HobixW3/dD4Cw8XYRdiG0ya9ZMhGH01VVilz6u2ojbUSd3Io5ydRACxkD/ARKKsKUfoJ6FCxYhTO54NR/Zv/8ABLBMhLNsNyPhyj6VAoZ5fPmlv2m0LK7mslB55A4FV23/9rdXZPKUSfL0U0/rd/zfnt27daWUQip3Cxj2kqElGXnlmWe+Iv/6y+clePBQCLzJMmnSBLkXK54sjihLXMF+46035RDMevwg3KdC6Gvq0wqh+zYITxvlHFY2GTmI0bu4YszC1WIKmPTHKTx9Bu3uD4YQMrHLsWhRe9x3CsLbt++QZVjJnTx9uuxM2o4wqX4yegxXbHfJ+4jwNQM7NuS1P2k3dhb+W9568y3Zjf5cvGI+b958XT1euHCBrpLz+qtWrZLwyDAZMTxe8qGUnIAAx/ZMTEyUh6FwUdF7GRnNuRI/aNAgngLB7wNV9hhSk6FtB0MpotDFzOkRVC5eeEHCo6PkHMb3y9gFcRTen9wxzIOypZF3qj+PFV0feekvfxVPb08IbWe4aI3S/v/TWOH+2c/+Qx774pPiBwWPwr0rFg+2bt2q/B7CrpDD7IQKFeflqZPZ8j//73/khRUvqJK2EErmmTNnlV8EVujvvedeScWOgRtMT36GHQhyYlSgi8usWbOxA+AOITMJY4tIO1BgGTJ2JtjTrIVRv9ZBsWN9nG/jEsbJ6LFj5AgE1Wm3tftB7U/eL3t27YGo2kfcvTxUOA4PD8MOTp788hf/Lf/2/X+T0PAIKDL7sIgxXuYj+zwLs9EXYIdpxZ9WSFhMpLz04ovyvX/5nrzxxhtSj/Crp6GAsx6Gqu3KQgXqLMy1+LzlLhx3Do6mHFalnNdZCGWfipi3h6cEYx6MGjNa/vznP3Py4z5fKR6ubvLdf/5n3Q3h8SVUkDC34zGvknGP+iOs6swZM9SHbPeu3XLn3S26A0ATsWIoQYcOHpb0tKMyf+5cST64Xzwxztu2bFUl6/EvPg5lIg4K00mtk6ZKNB86vP+gfO6Lj+mu8W9/+1s5jvnB+3sBdi7J0BuLBnv3JWH38CHMH1/ZvGEj7pkx8v77q7HTlCLzMDd8+jFUcYPudLDdVi4l0LUz7dL67RMjYASMQIcJ7E3aK6exEtmnufWC7S9XEz8yQbhyVevWrcOqWKZs3LhZhYmvfOXLuho5C4KpQ1C88tn2zfUQoODN2OvNEBazs7JVYKQJ0rq1a9W8gjHkG/A9V0WZeIz5BIoLznEJWM16aEJAf4f7HvqMBMEEgyunXJSkYE7hmoLf9u3bNGY68xVQKKUA5wETI67o8nvaKdMW2te33dad/aBDO+PNM4/GmDEjkbBv/gX794kTJ2l43DAoHachQNKciaY4MyDEsDDUI3cCFi9eKqmoh0mlpmIVctWqt+QoBJFSrOr+JwTxn/z4p2irywXBiDshLJFREfLA/VAg2lplL1bQGb7RDSvDaYfSEO/eX8aPTVA7ea72M8QjC01NCmGWQwdfmgmVYcW5D2KJkq+jUFlYjbZSgamGwHgOAuO0ydMgZCbKkMFDdDX17bfehmnTUlkHP520o8e0rjOnC3U3zVEPFRT+kB137FiGQPmpqUOuAgjFjNvP+4VKEsO9MvY+V25dXL0gVLUnxeJOBMdh3twFKjRTSI+HgMkxSc9IhTnWdrnzzjtk+oyZ8qvnn8dwfwgH12Lo1WqsNP/r974jSVDq31n1juZXiB0Rr2ZZNM9i6FVQ0V2oAweSIfjdrgJzJJSPZegfcznQTyALJnBlZRWaF4P9IKMDMB3aAtMpcqJPwjCYmjB87fwF82TEqBHYbXhXE+Axx8TmLZulFDs4eyBMTkSgAzeYy8yF2SMLnzlkRJ3FFz44HlBkGrASzp0Y2sVzd4f+FX19vPUzMuNuUFhoqJ7P//H40PBQSRg7Tk2XcrFT8chnH5Uf/ehHqijXVFdhR42mUtU61g7zNl6DK/qBGNfvfuufoLA9Iru27VC/rYcfflhN7hhylophVxZXCPvubh5SV92e4I87RwEX+XHQzK4I90wlxm9oeIjOIx4/Zepk+dITT2Dn9wnZBeV0IsyIWLibVg9zIC+Y99D0k0nhOKfZP08oT2TMW4DdSMR9+fAjj2DHMVn+8tJfsCgQrsrBN/7pW/I/v/yl7MQixOmiM7oDU1paomZcsbGx4hfAJG9VOmfJwwfjwfm9Fs8gKoihUObmzp8n69eul81QML0wlnfcsRxtniQ/+MEPhaZMvDZ3s6pg6mjl8gRMWbg8F/vUCBiBm0xg166d2NZPkfVYeXz4oQcl9KKX7pWaQrtpJlfbhu1zrojSMZJJ2aIhVCRiVZQrjo6V0CvVYZ9fHwG+mF/EimcVVlxp859fkKdmGe5QAGJgsnHbtGlqYrJixQoI3elqMnHXnctl1OhRatLjAVt7vtTPYAX7AHYY6LBO50gKfx98sAZmMAclDKFxx2IVMBsvdCoEFAYpYCyBg/rW72yTP/zhD/iMyc0qVYCbNm26dob+DdtgW74FZhCPP/G4Ou9yRZrKCO2UPSCw0NzoNFa9A5Eci34OjtICwZICjReEQ3d3V7WXpkkT2zrQb4BG4aISkp2TBUF0GNrjOJNCT4vOwzUQ6jOPZ8gy9HfNu+9JY32tREdGyeHUw8qEK9SMn09lg4UOtkxWRUG1AiY9UVFR6M/wC3OXdtd0QKZyRcGRDF586a8QOPcjmdxgcWlzkRY4Szc2NunqfxzMw5YsWaw+AH/8399jxfaQ3htUwGhqwl0DrszTP+K9996TBx74jDz/61/LSvSLOy6TIfwNxOpsemq6/Py/fq7Xmz5tCkyMzksIBGWaaVE4ZiIz1xoXzRLsh2RrlKw93BDhaVKc5jCpQz/pw3JxIXsP2KD//dW/o55y9R9gXdwdeQdmQ1SipqGdLMzQy+RlCxbMlz/96Y8ac/+pJ5+E8lIPNsFQkFKVadDgIM3ATl+CzZs2y+cff0xGjhgJnw34TmCcaSpGp+3C/ALMoxbYrZ9RJeFrz35dGfP6VD5iY4ZdaCrNrN7F2OXnF8r7762WL3/lKZk8cbJsh9DKoAlUUu+7735VBnlNmj9WwyxtAUzjOD5aIARTmPbEvOY13KFgsU/MARAEvwsmqKOpTnZ2jvqbOE7zRN3DMf5vY8dnxYq/qB9DHJSpHdgx2gVzGpptcZW+D3xgurLweRk/YjgE67W6Y8CdgTvvvkv+8z//U+bOnaNKHU2+GMBg+rQZeg9NmjwRitMeeRU7T02Yg3xuq5KFhvVHUj6aSjVivCZPnCjbt22Vn/zkJ6qE333X3Xqfj4ajfhh8a3IwTu+++44mnqMCPHP2HFnxwh9kNXyLaLI1evRo9aeZNo27NvRhcdF5vGDBQtmI3YKCwjxNCBcaGq7mREHwn2BeC85x+rS0Ae5gKF/3YsySDuyTM8VnNSFbWFik7nZWQtHryDunK3l3p7osKVt3Gi1rqxG4TgJcPeHLjM6VzpqUjUIChTSaA1CoYXSbKxXaljLnwo4d2+XVV1eqcDUHghYFS5oEUFHg6h+d5azcGAIU3AvzCiCUjcDK7gC8kH0guA6VyPBIFcBCYYpCIZiOhYMg8AVDOJqMFfo4CCMUoAb2668ZfLlCTQGOygAj0jASEseNSb+YabYCduxMOhWLfBhDEAmFEXKKCgrhizAOAryrZo1mVJUlMFmjYy0LBV4m+mLGXjof07k2Fse4wbxp+PARaF+A2rZTkaTzL52Dh6LtLGdh1xwbN0z7RXOGqKhoRC6K1LweNNOhnTl3F47CJyARQg0jv9AHhvcYBVK2PSRkqP4ehYhHzK4cGxOn1yAPOqpSGUiAkMQswPQHoHDJHTQKMxTk2RbeAw6nYJoj+fsPUifeoUOH6Oc8nqumPMYFOwRhMEuZMXOmnhsPITIwcJAKmX4Q2HhPkC+vS6WJ59CWPzQ0DPdZuLaN7WD7GGWJJlJhIWFol8D3A5mOYfKxEEIwI+NQEKRzMs1LxsMJeRD6EIzMy1z17495EA5WCTDHoc04d5toWjUFdufcQWJhxl+ON7MA8x7n9RzOyewbWU6eNFkVI/5O51Y6S1NxZD+YQZy7Bjyfc4w/9JOhnX9MVIw6uI4dN0YXCiLBf+iQEOXqgazVzLxM4Zb96NuXDuFxGnknHOMWDGXNF2PF5wYLOdGpnHN6wID+aCfnG5K3Ibswx41O2Ay3ybHjHOG8nQ3+jI7EecxnWW5uDpTjkXqd4MHBajo0HIocHX6nwlQpD4LseSQ9484bOXC+kxN9U5gJetiwaL1X7oVgzTHmNbnrFYo2JWD+M2v5cNxPXVWoANF3Jgb98sB9OX36dB1frtxPnz5DlTwGDqBiyJ04Kj40XaJvUWNLo8yZO093YRhljhwKcJ96oc5i7ARMwH0WhvnKXYWJiZMwJsFQrlvBEBGIoKBz7vF+pWJO3xleZzhYNDY0YdzHwXk6SKZhAYLjw/lCR2fen3yvDcG8ccOuyB13LNPFiFYA4e4kM8ZzcYCZuBPGJ+g9wXsTugaeL64wfZylDs2MmMQFhmnoL520rVxKwJSFS5nYJ0agxxGgIOOMygJX6NbDBpamBtwV4MuHLwM+xC8uNDGi0xojlNA05FjGcTkAm3GuGlGwor07Xx4z8bLmChS3vK3cWAIUkvIL8tVWn8qZCrZ4CVOYo4kPI5LwxUthgvb8XGVk5mOaKVEQ4GorV+4p1PaHAOnr6wPhoVmFggD4HrTb9PdRBYBCJVftKYhTgOQKIFe3KZDwOArWFIQdhQLteTi68jieQ7tlCsvuEFyY2ZbRiDjf+B0VhsmTpzhOVedJCk1cpWc9rq7MYlurbWaYRQqctTDTCAkeAtvn0apsqIkFhFWaR/B3KggUaObMmaurolxNZ3QfxsUnn/Y2wbQFgvAnVzPJi8kGL57DFFILwJqKD+8NKkU1EG64Wk2WXOmlDTd3Zzgu5OI4jlFh2Hdy48oxGbOd3E2h4MTdHApnlRASef/RtGbE8JHaXraTplJUcOZAGXcU3mvMwsvxpJDO8aVzuhsEMGbXjkT7snPztC0cm1Bch0oVC+cJFR36lLAe2ulz7NhGtpvt4g4K/+X3FCIZhYoZt9l+Rr5ihmFKfJw7DBVLQZv9TkfMfCo2c+fO0zrp9+Hq2kfHmsJ7//5+ypB98oM/y9y5c9G3CKzUl6oAz2ePIxoRx54CJxUOzhHOW/oi0F+CwjIVFyqabDOzAvfDddk+CtGcPyxNYMR2ce7yX86582BGgZhKAUM6N8IpPiIkVCNbJaI+9ptKC+vi9R3zl/1mPZxLbCMVCu4qMTJUVxXOOfaHiiDn2kAof5xHdLSnkE9/I845mv9wDLlAwPYyyzKP5/lsJ4V4Fo4xTRFjcDwXFzhXHPVS8OeuIOseDiWcSiuzQlPR4lzjc533OOe2P1jQf4bK7cWF85X3GZ3ayYl8qdhQ+eDOUkhIiF6Xzx4qojNnzpKoyCh9JnEMOQ6cx5FQcHmf8361cnkCMOUDVStGwAj0aAIMeceIFtzmf/XVV52ir9u2bZUjsKumicRomKZERUfKncvvutA2vlxod0rTEb4MKDDx5SPSRyNelMLkYBpMI7jSdtddd+lL7MLJ9osRuAEEuKvAUJANEPAofFLIpkBi5SMCXJmmWUoJWLVCuKUAScHYkl59xIgCLc2cKAxTgGbekbHjxqri89FRPeM3mtDx3UMFioqHsxX633A8qMRMmfLRooGztfNWt8eUhVs9AnZ9I3ATCDiLssAVKyoJWGbT1cqkpH1yHLsEXKmKgb2w42XCXRA+xPk9o9NwBZcrfXzhcIWOghpXOxkK1YoRMAJGwAgYASNw4wiYg/ONY2s1GwEjcBEBrt5wxZErTSNh08pV2nCYq9DmnVvXjsJdBMZRL4cT3xtvvCnzsHpLUwaGCkxIGO84zP41AkbACBgBI2AEbgIBUxZuAmS7hBHorQTorEm7YdrB0ia5vr5ZVq9ZJ1FwNg2FrS0d4RyFES/oOEk/BEaK+a//+i+1//3S009q3G/HcfavETACRsAIGAEjcPMImLJw81jblYxAryLgsF2mox4jHdEZ0M/PW5564osyEmEB6YPAwuPoPMeY6IwdvnLlSo2DHgmnxyeeeFwdHHsVOOusETACRsAIGAEnImDKghMNhjXFCPQkAruRtOjQ4UOyds1aJGi6E7HcH9CILO1Oyu095e/MVsqIGsmIiLQG8fVHIIrFFx//IsLgLe1JOKwvRsAIGAEjYAS6JQFTFrrlsFmjjYDzE2CM8mGIe37fvffJV776FW0wM5w6TJMyEeXoOPwX9iAqSFNTs8bU/tKTX5IxCH3KhFRWjIARMAJGwAgYgVtPwJSFWz8G1gIj0GMIJCXthd/BaYSWrEeseR+ZgkywzPi5desWOYfweecQKvDQ4RRhhlJ3JNEJhdMyIxox5j6z79I0if4NF8eY7zFwrCNGwAgYASNgBLohAVMWuuGgWZONgLMS2L5jJ0KhZmBHIUqzgK7+YLUmXEMOJE28FYQkXffee68m4OqHDL7tSa9cNQEPQ6FaMQJGwAgYASNgBJyLgCkLzjUe1hoj0G0IMARq5vFMycvPU1+Efkhqw7CnzJFw5vQZKcJOAjN7hoaGSwQUAWbaZJ4E7hww+Q3/tWIEjIARMAJGwAg4NwFTFpx7fKx1vZxAbW0tchPslqxTWVIPH4ChIUMlPi4eGY9HKxlmN96/fz/Ck56Fk3CQrtp7e3vfFGrMypmamiqbNm2SqciDMBSZbPNy8yQEGZUjIiOkj0sfqaurk+ioaFUUpk+fflPaZRcxAkbACBgBI2AEuo6AKQtdx9JqMgJdToDCdltrm+xCMjOGF6XA7eXppcrC8ePHNXlZcvIBVRb6Qkmgn8CsmbPE39//krYw83FnS3LyfikrLZOm5ib4ImTJ+o0b1OwoNj5O/Q6ioiLVpIjhUrlzEBg4CLsIUzt7WTvfCBgBI2AEjIARuEUETFm4ReDtskagIwTa2trkzTffVNv+iLBwSU5OluCgID2VycuoABw6dAhKxDRZt26tLF62VJjcLCcnR82BWnF+H2lT8yBGJ+pMOXjwoCoI58srpBjZl8srKzTk6bBh0TIHWZb9+vnJtNumSTD8EqwYASNgBIyAETACPYOAKQs9YxytFz2YQFZ2tjz19NMSh6zHv/r1r5EJuUl7y4zIVVVVMmToEHka31NByM3OkVHDR0pLS4vQmfg0fAdasTPBTYWsrFOdolQGJSQDydVWrXpHPLC7kTA+QebMmi1R0ZFy9933dKpuO9kIGAEjYASMgBFwTgKmLDjnuFirjMAFAm7u7lLXUC9V8F9gqa2tk5MnTwp3Criz0AKlgbsMzVAQ3BCOlKWmplYyjmfAROg4chg04acRpkrnpB4hTTMQreh6SkFhoV5j4qRJMmbMWOwgBMq4ceO0quut83raYecYASNgBIyAEbjZBBjam2G9gz7c3b/Z17+V1zNl4VbSt2sbgQ4QiEIY0g/eeUd8fHyhNDTBJyBUlQH/gACpqa2RYigB25DH4Eh6mjz66OdUgZgzZ/bHat62bavuMvzLv/yLfOc73/nYdx39g7sVnp6eGtEoKWmPKiGvvPJKR0/v0cc1NjaqqRhfJl3hG9ITYXEnjIWM+GNFdAeQ9xWjhFn5dAKtra3YVW0Wdyye9PZ7jCxookoOdi99+rxxfEteXDjrzPxhFL9hw4bJgw8+6Ki21/xrykKvGWrraHckwJfBl2Fi9OzXn5Nzaeny3De/KTGxsbJ2zRoIGs2yfPkySZuSJi/9+a8y7/bFMn3aNPVZ+GRf3dzcZf78+ep8zN2F6ykrVqxQf4QuASdjAABAAElEQVRpuAYdqPnwtdJO4Ic//KFMnDhRbkNUKDp3W7mUABXL8+fPy6JFizTU7qVH9K5PGGI4PS1Ndu3cKc8891zv6vw19rYRQt4xmEC+8ve/y7P/+I/6HLvGKnrU4fv3J2M3OU9i8S4YM2ZMj+rbjepMMRKCvvDCnzViYAgi97m5Xbv4GxgYKGfPnr1RTXTqeq+dllN3xxpnBHoWAQqejIj081/8XAYgjwH9F/x8+8qIEfG6ouTj4yNL71gqdy5bJiHIhlxdXSMREZGXQEhISJDy8nIIaVEQ8i/5ukMf0HGZ9TA06/Dhwzt0Tm85iC+fCRMmSP/+/TE2I3pLt6+pn0y6xxVRbuEbI4E54DG5bfJkycE9bTw+fSqVlZUJd1L37N0r3GmNjo7+9BN6+LeMRNcecc7b5k4Hx9oXkQJjYmJl1qxZ+k4NwHy61sLFO86/3lhMWeiNo2597jYEuMUcGhqqkY2qETo1MTFRBVJXVxfsLLTqd7ShLCjIl0/LgEylgj+dKTSX4DYusy6HhYV1pqoedy7NkGgiwXCxxubyw8u5Q0ach8ZIJBcBCc4jiSF9j4zH5eeM41M+c85DqeLCCYW83s7LBTlsGhoasfDj1etZOObI1f5lzqIG+P5xwWLQoEH67rzaOfb9RwRMWfiIhf1mBJyWwCdX8ocMGXqhrb6+vljpv/Gr2czAzB+zkb2A/sIv8fHxMnjwYGNzgcilvzi2/t3cXC/9shd+wlXKgTDnow20lasTYIZ4BlSw54/oogQFXirgVjpGgPcb36NeXl4dO8GO+hgB1/+L8rFP7A8jYASMwGUJtKlDZmRkpOZXuOwhvfRD7ixQiKENMU2RrFxKoBJ5ObirMGLEcI0ocukRve+ToqIiCQ0LVfOI3tf7jveY9xaTUAbBZnzUqFFqCtnxs3vekdzldexIDR360cJRz+tp1/WIu1N1dbWIJlgDBT3GggpcI9o+cFK8Tgvma7ySHW4EjIARMAJGwAgYASNgBIxAtyJg8eu61XBZY42AETACRsAIGAEjYASMwM0jYD4LN4+1XckIdFsCBw8e0EhLDDdH2/OIiIhu25fONpymI9lwtmRUqNGjR8vhw4c12R23uWmGxGg/p5Atu6iwSE2Sxo4d29lLdqvz8/LyJDc3V0Pr0uyITvksexHJprGxAXHOPTQ+vMPhmSYmfrBHZzSpnloOHTqIbOvVasbH4ATBwYOFfi4VFRVy9OhRdbqcOnWqpKamSnVNtbi6tAcR+LSgBT2R1ZEjR4SRjxw5OXhP8ZnDOUJTPxbmpOB9xiSTJcgqz+8YyrknRpSqQVALzgnHfcM+MgoSTbLYf/ot8DOGJOZxdN5lLgDmw+mthc9jmhuFhITqM4gJS2lAQ98+Pq95L9bV1Wu+hZiYYYgSWKEsOef6wHG8n1+/Hv0sut55YcrC9ZKz84xALyHA7MwpKalSWlqmD9vKymO9UlkoRAbr0tJSfSl7eHiKr5+vcmCSn+07dmjs9/KKcokIj5A9e/bANrZWXOHMS6WCwk1vKFSkqBSUl1eq0BsXG6MOhVQMtm7Zqo6Zty9eAmHGQ5goMA25Q0IQ7Ss+Lq5H4zlz5qwqBYzRTodm/k1lgUpnGUIa5yAyEiNpleAeO3bsqNrmUxikoNybbNLPgU9xCe6xNAjImDOBgwJlzuzZEIoD5K133pbW5la5HXk6Dh06JLwfq6qq8F0glK7KHqcsMA9HSsphjXq3det2mTRpshw4cEBz3WzdulUVAz5b6L9w+vRpyYaCXgrliYLxpEmTdD716Jvqos6xz1S6qVBuxnNl4bx5cjzzuJSXleM5VCONyC00EooCFap6RJHasydJRo4cIZWIRsZnE+/B9PR0GTJ4iETFRJuycBFbx6+mLDhI2L9GwAhclkB2Tq68+OKLyBRdIlHI07B06WI8ZCuwaj7gssf31A/TkECrDKtQf1zxglRXnpennnxKJuOl/OMf/xj5L3KkEWH5/l1/z5YtEIwPHjwk0XjxuLq59xplIQ1CHsNbrlq1CspSnQyEQvXb3/xGfvSf/yGph1MkGC/j+OHxKuCsWvUOso4fkaWLlsiQwOCeOm20X1lZWfLXv/5VPFzxyoWXYML4BOVEIe+73/1n3Ev95O4775H//q9fSE5uljRhlfOLX/wilKm0XqUs1COMLBcn0lPTJC8vV7AFJYOR38Xb20vWfrAGCbGKNeTsnXfeJbt27ZKdSGhHAW/mzBlYUZ+sK+09ZSKdOHFCV7mf+YevqUC7Zs1a+elPfyKHDh6WjRs2apK6RCSCjEDACSrp//HT/xAfKA+n8/I1vDWTRPaWyD9UEjKw2/Laayslef8+GRIUKDNnzZGXXnpZXvnb3yQQO0/jJ06QrzzzD/Lct74pTY1N8u47q+Rf//Vfxcu7r7z1pxfkKO61xQuXIDSvJdW83D30/9t7D/CsritreKv3XhGoI4kOovfesSnGDcexPZlvJomfSeI4mSSTZGZiJ3Hm8/95Uux44t5iwA2MTcd0JJoEEiqAekMV9V7519ryK4MNNmDssV6dwyMkvbp13XPP2Wvvtfcx1ZCuhor5zCBgEOhD4LVXXxNPT3d59NFHhJ4/d0hG6I0ZaCUfafD5YxJiFRLpuSQRoWEyEt6qDViZODouFhNQm0oAUmAUcwGgdffeK86QTGRkpMvq1Wv68LTmH2jgzZ03T+YtmA9piLecy8zQFcef/dtzEhURLjNnzUL53WAYgkW6EuoweNcXLJgna+68w6pLYiYmJgqNv8VLl6pRu2bNGkRWDsp7mzdL0omTEj92PKJ2w2Tbli3y+G8eky6socLIAtdQGUgyNkbg5iCS4OXjJWGQOraBgP/DQw/BCzxS1q1bJ3WQKJFIVVZWwIMuct9998ng0MFqLFMeOWSI9az/wsgJyeKunbvkwMH9cuDAPo1SJiWdlMmTJ8rqNasRXbgkZzPPSmNTo0yeOEl+9vOfyUtwZqy8/XZEr8pUimPN443l3ii/KisvFx8Y+tVVF2X69Bkq3TqTniaTxk+QezAWv/32O4i2uMj+ffvkvXfflRREbShhs8FXaekFicBia0vhCLv7nnuseiyyYHaj302C840iZrY3CAwwBFhqLgjl+boxMdlDcsOBuaure4ChIDJjxgwZDuN2NAyXAF//PgxopJQXl0h3S7v0tHVId2cPSoS6a+4C5UotWFV7oLSpU6dJD2QRJ48fV0+6K4hlE/TDdQjzE5ONG9arFIDlL6dAo59fkC/PvfgCog/PWDVENIIXLFggh44clk0gCIwynElNlTTIIh544AFpbm9Wrb6Hj7e0dXGBv06hXp1RmoHYmO9zDkZwVFgEHBWeUlVVIVmQlRC3QLx73SAMrvCid3V2iCNyYJyc8TM+s6bGfA06ZOzsbeSRRx6RjMx07RPgSBKAaEtUbByMY7/efCkYvBFREcKy1iRTzZBAkkwNlMY8lkkTxsudIOHMX2HjHOXu6ia2djaYu7qlC/OWi5MrxiFP+fWv/lOSk5KksLgQsq4AmYmxvaysXJ5/6SX5KyKhpn0WAUMWPouJ+cQgYBC4DAEmhpUjzF0NLTF1tPTE2EFLPdAak3W5eiyTB3tsLom3n69k5+RI4onj8p//+R8yMj5eTiK5rqy8VNpg5JXAM9gMouXq7jFgoGKuBnX4UVHR8tBD35ECYHD0+AnkcYTJD37wLzJx4gTVmTug/4RjFfC1a9diMbtBkgrZiTU3H5CA6dOnye3w+PJ9ysrKUr10PRKcExMTJDX5lOw9cFCqkBNTD4lbZ0eXbkdN+kBru3fvhhFXrAbeOBiAtSCa1TV1yA+KkF9CNpJw/Jj+vQZ69JaWNpCsWumEDt0ecj9rasxp4UJi//5v/w7HA2V6trpOCfNYyspAnkCmqqsqxdWtN28hOydXctCv7CF1Y/4Ldh1QzcfHF1HcTJVg8caJUxMcNfxiJMoRv0+HM+M3GKsjIkN1DvOGlJZJ4oNCBsmqVSvFGxH0TCTZm/ZZBAbejP9ZDMwnBgGDwOcgwMS6559/Tl4695L4wkDmIDwUHq+B2phMR41sQ0MdjLoO1Uw/99zzkgXisG7dvVg0aoTqqV94/gUJxorXc+bOGTBQ1dTWaKJgGox/YuQForRo0SKpqqiUP/7pTwj3lyB5cILk5ObKcUQfGFmwsbGT2dCcW3NLTDyGhMtzUlJcIiHoE7GINISCLFFzngDd/e49e1Q6UgHpyIYNG7S6zdo779L3zZpxudq9kWyWl5aJL6r+sHoNIyw7odd/vaxUakCuvCBvW7BooRw9kigb33oLnmRuN1LzPq52vP76GQ3+IEQQdoE80SkRMniIjB49WmWg+yCl+eCDzRKL6MLq1as1sfmZZ/4qR0E8WVWMxvGUKVP7663f9HVzQUyOz21IaB4MAsA+tHXbNs3viEURhcqLFYjQZKgkMDg4WCVK2Vk5WmyhuLgIdMxGpoFQmPZZBEzOwmcxMZ8YBAwClyHAiccHEzInrqFDh6rxx4F3oDbq7Rnu9/Xx07KgLCPb3dMFr/lECUJOQyC+SKgiIiLhwYqQifCOhiG/YSC0QiTDcxLugeaeVY5mzpwBL6czcJqI6jYdWqXFBzp84kPiSckA+xIjDmGoImWtrRx6ag8QJ1Y2CkfuBnX59BzXglyRPA0CgejFIgaeYjftS/6IYlG+FIBViwdSO3v2rFbHCsB7NA/5L1VVVRplaYcByGTeMWNGy+BBIZoXxNWvmQOzZMkSGTdunNXBxNK6nd2d6DvusmL5cpWAMo/FFuV3Y2KGarQlGGV4GYFgFbZAvHt8l2bPnq1RUKsD5AtuiGV3WVqW71YpCCfLFA/Fas3Mf5kyeYqSc1Y+8oQ8cjGqalFWS3LBfQIC/LHfMBmPUs8DrWTxF8CqfzaRhetByWxjEBjACMxCUirL8zWFNGKCitWBeADDoTriXHjGWWmE3j8XfB+JPAaWUB0xYoSWU2U5RyYoUm89A8l2A6XRGKZxF4uEbzbe/7Rp0yTxaKKMQD14YsSJnJN6BUioH8iCt7cPSMUsq4aIUgcnJ0dNSKUhMnbsWL1fJliyZGNUVBQwmImys0dhKMcpmWLkwRrXDviiB03ySOkRJX9swcFBmgw/HNED4jV9+nT9GyNTXGeB5JzRT2tsNGI9kevDSJQbxhrm+pBYUtZWWVmlOHB9DuLg5HRS8zbmo2woJZMDsVVXX9Q1W6ogzwoJGawOLjp3mGfHtVw4XpMo0OnFn2NjYzBeXdTE8aCgQODqq+/hQMTui+7ZBqxqAKXBfBEc5u8GAYOAQcAgYBAwCBgEDAIGAYOABQGT4GxBwnw3CBgEDAIGAYOAQcAgYBAwCBgErkDAkIUr4DC/GAQMAgYBg4BBwCBgEDAIGAQMAhYEDFmwIGG+GwQMAgYBg4BBwCBgEDAIGAQMAlcgYMjCFXCYXwwCBgGDgEHAIGAQMAgYBAwCBgELAoYsWJAw3w0CBgGDgEHAIGAQMAgYBAwCBoErEDBk4Qo4zC8GAYOAQcAgYBAwCBgEDAIGAYOABQGzzoIFCfPdIGAQMAgYBL5xCOzfv18cHR2ls7NTF1mys7PXWvu3+kK5lsiBgweksbFJ13/gOhqTJk26ZafhqrsuLq5Y2bpdLqHueysWGVu2bNmXOv6ePbulG8XPnYCPDY40d+7cGz5eS0uLHDiwX1xc3bDqbYgukncjBzl48KCw/noXng8X27uZa7iR85ltDQIGga8fAUMWvn7MzRkNAgYBg4BB4DoRyMnJlqSkZF2oy9XFRQICgyQvL0/Wrl2riyld52E+dzMuEpeWliabN2+WhoYGue++dViIsOtz97nRPzY2Ncihw4ckIz1DF6eztbWRI0cSZOKkibJm9eobPZxuzxV+T5xM0pWeh0ZH39QxSJJSTqdKNBb+8sIietfbXn7lFcHyt7pgGFfFLSoukUlYPdg0g4BBwPoQMGTB+p6puSODgEHAIGA1CFy8WC1JyTCIsepqZGQkVjzOlPyCAl2llsZtXX29tLa2YVXWaEQe7HTl7K6uLvHFaqyTp0yW7du3Y3VbJxk/frwSgpqaal19OyAgUGbPnq3bnzt3Tmh4b3l/i0yZMkVaW9qkrbUd5GGTes093HtXfU1KStLVzElUuBr1zp07hZ55WM34ssFq1N4yZMgQSUlJ0etbsWJF33NobGiS5ORk6UJUYc7EWVJZXiEnT5yQnks9chu2++ijPVKNe3XByrLDhg0DaanX1WXb29vFEedi6GDVql5SsXv3bqmvr1Nik3L6tEZeorEK9Pnz5+XMmTOw4Xvk7rvv0XNv27ZNeAxtOIa/n7/4YuXszMxMXdWWK0e7uLrgfuwl82ympKWnia2NDVZLtutd8dbTQ5qbW0DWarDCrQ8iB/MkMTFRGPFxx7VyRWEbbO/q4oz9RFfn3rt3r64mvGDBAqywHIh7+wgRm0ZcAnDCtu5YlXjRokW912T+NwgYBL7xCBiy8I1/ROYCDQIGAYPAwEWAnm8al6NGjZLRo0bDCHeXP/zX/5V1994rPl7eUlBULAUFeZKVnSVRMJjd3NzkVPIpWQ1v/aGDh2THjp2ybMVy2fz++5KPiERnV6eEhYbDyG9VUGl0jx49Rn77u9/JxepqNaRramqlpKQYRKROjX+ePyMjQ7Jxju6uHiktLZURI0YowSAx6JVI2UtPT7d4gsBUXKwSX28fsbO3k5kzZoq7uzv+1gMD3FZGjxgpd8GQz0xPB3k4heNmquFdjehGyYUSqUdko7KyUslRU1OTHD58GMTHR43t9vYOXJ8PDP2zUlRUCMJAQlGlZOESvPwffPihFBYWSldHh1RUVEpcXJzeQ2pKKs7fa6iTCLjAsK8FOQoMCACxuCTVuG8nZyfIiBw0glMIMtbQ2CBTQZxiYubJcZCakuJikImzipsPSFFebi5IRLNEAnMXZxclL6NHj5YNGzbIWZAvypKKiotkxPARUl5eLsXYn/fj4OggQUFBKlmaN2/ewO3Y5s4NAv0IAZPg3I8elrlUg4BBwCAwEBGgF59fq0AA7lh7h9jAhZ0NeVJNXb20tbVKfn6eHDxwQMpgxNdBEnMYcp9Tp5I1orDpvffUs06ZEYkDJU0VMMY7YMyy0bhPSTmtBiwjE/7+/mr40ht+/PgJHL9djdz9+/ZLTXWNHvOll19W45pG/a5duyQrK0s9+ow05OXnK4lYv/5NHDNY9+V5SBRomOfm5MhOXEfi0aPi6OQoE+Lj1dtO+VMzCMyHH26VTBAT5mnwmpnrwGMmHjuOiEqRDAoeJK+9+iqM+jrkP3QiMnFJvfiMwJAc1YJ02NrZyvPPPydeIFNlZeUaXcnHMU6dOiV79uwB0SiWChjw7777roQOCQMmSZKamorrrtXchzQQmZMnTiopSsfPjCrU4XwvQXpUVXURZKZCr4+kwQ73dRYk4hBITSWIy1ZEMngcB0d7RGbel04QqMqqSuRFHNBzkCAx8uAGAmWaQcAg0D8QMJGF/vGczFUaBAwCBoEBjQAN7VoQAZXZwAClBMbJxQnGu6P4ePtKehqN2lp48mdIXGyc5h+Eh4fJqJEjEIHwksGDQiQyIlINdA8PDzV2GS0YOXIklDG2YgcyQgN94sSJSkAYoYiLGyYzp8+Q9Iwzkl9YIP/91H+rMf3ue+/iOtKkA/Ieb3j9p2MbevkpHZo5cwaShOPk8IGDUgUyMSg4WJ8bz9Hd1Q0Pe65ul5dXgAjHEFm+fKm0w+h3c3IRP/8A9biXlpXBs9+osqoY5BKsW7dO3n7nXTl/LkuiIyOkGFGPRx99VO+lGrIqEo0zaWfkIiIa//KjH0gnrusNkJX0jDTp6e6BFChY5syZo6Qj5fQpxSgAUYWf//zn0lTfoBEQSp1iY2I1ChAE6dAoRE4o3SKBIqFq82kRehcZdZjz4AMgQjskGMRqNCI+jIqQfFEelgFy8fZbb0kcpFSUdDEa04Zk7rDQMBk3bpw0NjWqLKkdn5lmEDAI9A8ETGShfzwnc5UGAYOAQWDAItDW2gpDuFr2o2pPOmQ7lAWFDB4sH37wgbz66muQD9VAfuShHnpPEIMoJPsmJCTKpk3vyz2Q/FCjPy5+nNy+8jaVCr355htyGkZzOfIGLK0V56DkKTQ0VPyg66fXPzAwAIZ8O3Ii2lVqk5Obg4iCo+Y8MI/hEqQ9jHj4B/hBz+/VmwvhH4htXVXzT4JjaTy2nZ2DLEEFpO8+/LAa75QGkSh4eLjL7yGDysnN1giEDbz13SBE3J/5FswVcMF3Ho6/84vRFUYLmDPB7Sl14ue5Wdlij4pRbu6e4gLCgwPptQcFBYqHu5smhftAysQ8BRKBHptLKpFiJSPeE6MjHZ3tMgIki/dWj+jNH//7j1KNaIEbKiYxx4KNkZI6kBQSBZIBqJvEDQnoXjhvSUkJiEmByprcXdz0PlhdSu8D300zCBgE+hcCJrLQv56XuVqDgEHAIDCgEKDHux4SGBKDIwkJahx/+1vfksWLF8tekAc3N1eNCDDJlrIc6uNHwtANDPRHedJ2mTFnFqRFfrLro92SjmgA8xBIHlxRxvTyikcOMJy9QTRoQDO5l1EGHx9v9fTTI56SfFr+9Kc/i5uHq4SGhWvOwsmTJxCRsIeh3JsQzH2Ym0CD2gl5AcxZsDQb20vijEiIv6+/+Hh6yd133SlvvPG6/Prf/0N+8MgPxQmGfS8RcFTjuruzW6/BBQY4iYYNpEU20oMcilDkWIySp59+BpGKLs0tmI9EYuZ0MFLy9DPPiCeM/vhRI2VYbJyUXigVWwfsi2vkvdkDT5IOEhUnGO4kCc5OziBHzrIJ1aBykYsQN2K4tCFSUFNdKzUgacTK0REJzMClBaSKLTg4SI5CGgVdk+ZsMHF66NAYGY9ys795/HFs7yTh4eFaqYlRF0tjzgIjOyQbphkEDAL9AwEbeC4+cX30j2s2V2kQMAgYBAwCAwQB6uq722G4woPtCG84jVRLlaHk5CRo8svEAZ70ViT1enh4SkxkpKSkpcrjT/wBCc+R8uZrr6uHfP/+A5pLUF9fKzGxQ7Xi0cKFvRV5mLDcDeP4MEqZLli4QDoQSTiXfR6VfoLlYtVFmYtEXOr6mTPQjBKoy5ct14hDMnIAHJEYfAnyIkYmXOF5Z1KxKzz4LJM6fepUXQMhEOVe9+z5SKMB9K7XI7nYFTIqJvruRS4ES442Qw5UUV0F776n5iGwyhArCDGJeDgkPTl5uch/aJSlS5bKyaST8N5f0AhLZ2cXcjJa5a677tJkaEZLOjvbZOniJXD/20lC4jGxd7IRext7jc7w/ENRWYokjNc/bcpUSJjSxdXNRfMgapHszPO2QcoUGhamxIQEjAnRXiAhra0tmtRchs+6QTh6cO8sA2sHMsNjU9507HiStDY3yaLFCzVZm1WagiDHYnSjHdiW4toHhw2RsWPHDpBebG7TINC/ETBkoX8/P3P1BgGDgEHAqhGgsUxD3FKetNco9dV7ZrlTlkm1NC4Qlo6k4PfefldiRg6XR3/yqEyeMFHJwqe3pSyG0h02RgNIRq7W6Nln/gIrHl3uIWd0grkCPD//Tr9bbxnVK4/C7ehF5748BhvPzSgE97+RxuPweMzNYLTB0kg8+NUBwmQ5JiMJ3Jb3zW3pzee19mJp2fNa3y9p9IHHuFpjiVg+F8v9WLZh+VUStsux9EK0hjKlvvKtH2/MiAaPY5pBwCDwzUfAkIVv/jMyV2gQMAgYBAwC14EA1x+gZ7sC3nV3T3cJhuee0hjTDAIGAYOAQeDmETBk4eaxM3saBAwCBgGDwDcIAdbyp2SGUQhn1P5n3X/TDAIGAYOAQeDLIWDIwpfDz+xtEOi3CHBlV8oamITIBaaOou47tcqUB8yfP/+m7osLMlG6wOONGTPmpo7xeTtRZkKtNhNTg6GBZpLrjbZXUCuepSCZEEp9OduxY8ekAGUfKTlZtWrVdR2SWvns7GyVn/Beqde+mZYE/TklHXPmzL3m7vv374P2G3p2SEmWL1/+me3ex4Jjdahaw8TeSUgwNc0gYBAwCBgEDAK3CgFTDelWIWmOYxDoZwicwKJLbe1tMm7sGNU05yGB0g6JojSkb7adOHFcggICdcXZW00WEhMTtdpLKirahA0ZAr3zjRnnJEJJSIjlYlsLQYaqqy/iNnvJQll5GSrntGkN+Ou990ascMvSksnJyRKNUp03QxaOHz+uC1pRz83qNNda0ZYrC7OOfQHKUV6tcZEtLqrligRgQxauhpD5zCBgEDAIGARuFgFDFm4WObOfQaCfI0BDlavc/uhHP9SVXrkiLL3rs2bNEkYdmNu4fPkKrCj7IZIxHXC3LE3ZocmgTOZkBILGclNTk5Z8XLJkieTm5ale3BlGK43vsLBQiY8fr3XXWdeeq+F6ennKDCxideLECfWos568Haq2MFJgMXRp2B/Aiq9MjGTiJktX0pNPw/wYyjWuXr2qr/Qir+nQoUNaQpKlJCk/YYSAnzOx0/Izf/dCQmXK6dMS4OenxndNTa1ERETgznCzLCeJmvRMED127KjWl2dpSV4TK9Nw9VvWj2fdfZaaJAbEcOPGjUqwQkJC9Hp5zVzVdjDWAZiMRanYiBG35X0xKdQZ1zdi+HAs0FWsq/RyMSs/LHDFxutklIeJqayf34N7aGttky58x7peuk9KSoqei1VoSJq4Yi5XIY6NjZGtW7dqImsgFtaaPn26HtP8ZxAwCBgEDAIGgZtFwJCFm0XO7GcQ6OcI9K586y37ULqRC1m1QArDKi2sUJKTkyN5MPxJFvagjvrtt90GQ9UOXvAzWr6Rt27v4CjhKK147uw58AjWbHdCdRkPqaqqlPNZ56UK9dkLCgu15GI5DP3CwiI1tINhRLPGSn5+oVRUVMBo75Bhw4bDwO1Ww5yVVPbt26cr9TbCyA6AEc1KMhUVlZKdxUWrbNR49wbpoPFNApFbkC9Z586LPYxrRjS46m0aquLw+JRU0evO0pdPPfUUSkS6SX5evnTC+GY5SFaW0Wo1WH2X10VDnaSAhry9vYM0tzTrKrzZ2TlKWPh7bGysjB0zVs6dO4cVbQu1vKafv59ecx2O54+VeHnNJBssD8mfhwweIpRRMYrBmvaNICWsnkMpE3HK/zhqQLLBfXitLIvpg4o2rP/fjFKUlF/t379fsrBPJ0iFG4jUQw89pNEJF9T15xoC54CDm7urlrLkczLNIGAQMAgYBAwCXwYBsyrKl0HP7GsQ6McI0DM+D4Y0DVZ67RlKcIHxyd/p1WdlGbYtWKjpHBZ7yszMlPff36xe/JMnT8prr70mGzZukKLiIixW9ScQDVfUfXeTutp61HO/qAY/F22qxM8kDxs3vqXJp4899piSCkYx/v73v6txXoY69yQvbPx8F879Nurr10Pq8wa2SUvPwOXZqqHPSAMXl2rGdVZVVcmIuOHyP1igaguuLRsLSlVUVqpxzmvcu3evsIY+JUwffviBHp//NcLgZ1Thvffeg7Geo97+nTt2KKlgxOQJ1OivgvTn7+vflCwcsxorBB9G3XySGBr5xUVF2C9LS2ZyIS3WnmfewGuvvqoRkwsXLiBQYQPCVNV3TmJS39hLTl595WWpQg5CeHiYRk4ccE7L/XMHRkSI1/r16yUP5+dCWbt27UJ9/STF57m//Y9KskpLy1D3v0kcQGooKXv77bdk8+b3FGcHkDnTDAIGAYOAQcAg8GURMJGFL4ug2d8g0E8RoE5+8uTJQvlMypkz6qWfhkWkaCwzwkD5DqMLrCHPmvCdIBeUtsybN1dlN2+u36Ba/XX33iubNr0nTTDsWcN9zOgxsmTJYjkNqUxWVo6cOJkkOTCseb5uyHxs8MWoA8lKZES43P/t++Xb336gD0Uaygkw7udjIazvffe70trQKLmIdIwaOUJlNowEUOJD2ROvzxkRjVkzZspRyJpYR94dEQfKfHh8JlszasDrd3PrralPmc/8uXNlAuRFXPCLhj3zNLQePhaWotzowoUS6cT1emKf+sqLcuDCfhCqCk1CfuihB3Gtl3Q/Lm7lAsnVwkWLJAERiWLkDjAyQNKFU+OaR+l98echoUPELdNVui71KE51iDaEDBqsC2QxwZlJ4Zc3riewGDiuXXuHkoWcnGzxcPOQqMhILCoWq4tmeWGFYTvcmy3JU1MLJGCVWMBrhAQFBqt06/LjmZ8NAgYBg4BBwCBwMwiYyMLNoGb2MQhYAQI0rLkY1cqVK1XDfzQhUb3Y9JSztba0wosNiQ1kQd0wvKnnp9FNrz6bLSxgP0hkKJOx/E7jnDIiB0QJ2uHp7u7pQOKvt3hhoSbuNQUG+mOPPy6xkAnx/L7IHfi0B5zH8PHy1twHXksDpEbOOB4JAgkAjX1+WZotFoK6+7518tOf/FTP+cTvfqs5Fzw+8w8yEBXJyc3ry3HowTFIVuxxH00w0h0dnTQHgVjYInrhiYpDJBhcXfd7Dz8sS1eskIjoSLmEv3fgnpiz0IioRgASuRntaG5uUc/+0sWL5CdYBGwCVuN9F959JlJT/sTG5OX1yG34zb//DqvgemqeAfM0SIz4RSJFSRVzGyyNuQ1cM4B4XwLB4Da29rYgORPlJz/+VxmPXJD/78kn5aUXX9ScBS4wtmDBAiUrlGCRrJlmEDAIGAQMAgaBL4uAiSx8WQTN/gaBfooAowc0VGtqqtWrHR8fr8Y4CcD4seM1Ufax3/9Wk5jpqW+G8e0A450GMg167s8EZzbmAdC77evjK2dgqP7yl7/UhOE1a1bKurvvlNQzGZKRli4vwrB1gxd/IkgDK/f0Jk5fCSA/+953vyePPfYbueOOO/SPDzzwgJZ45S8kLDh9X2tua5U//fFPkD5Vag5CTEycDENJ1MGImFC28+c//VlckfQcEByo+zCCsHPXTtm+YzvIij+SradjAS83lV/xnuYg6rBwySL54IMPEKFwlfvvv18WIHLAvIP3N78vH27bLuPHx8u//eIXsmDhQnn22WflD7//vfgF+mteRhXkRl6IAERHRem18qS83iBff1SKCoBEqAKfXALpQCK0g53mXxRC1rRz+3aJioiQSOzHRuOfidJsJC+MfpB0fLR3n7z68qtiZ8/cjWCUSx2peRe8rzVr1miuRUJCAohKiixbulT3N/8ZBAwCBgGDgEHgZhEw6yzcLHJmP4NAP0dg586dShKYzNvY1AhPerB6z9sho+lCIu0l/PP19ZNaaPvDYcR2w7Nej4Rg6vUpVaLXm+VH/WBw16PG/5ixY6QSScjNrc34ahUXeOwrkT8wFp/n5eVDwhSk8h6/QHjLoefn34Lxczm+L1q0uA9NetAZDaCBXI5k4CEok3oRkQB62FmelASnGvkETFym950lX7u6ES2oLMM1iiZqM8n57NmzGo2gke8GslCB/IGlMJ6Zi8H1CngeXjvbzp075P33NsuY+LHy9NNP9yV4M2G7q6tT5VbM2WA0oQGyKCYbjxkzWiMBDfWNWqUoKDhIr5MY+aBCEUkDSQWlW7zmAuRiUI7l5x+oERBvby8Y9iUaYQnANpRDTZs6BVWhBilOSUnJ+nyYMM574OfMXWACOqVhDZB9sRKSK4hcPSIojshRaECSNmVQIYNDhInXFrLVB675wSBgEDAIGAQMAjeIgCELNwiY2dwgYC0I0PilVCc0NFSN3traGkQWej3aLGPKikiMIFi0/7xv/kzjl3r6srJyzWsIQ0Wk8+fP67b0mOMQGlXgNz/IjGjs09gtRMUflfqgmhGrH+Xn5wuJSTDKkvKYlzfKjFhpqHf73oXjmKvA47DRyx4J7T4bDXHeSw9KsLKFhYUrqSgtK9UqRb3XL0o2RiKHgESE983G+zuNkqMsa1pbUycrVizXSALPy+34nefh+UpKilViRYxorDNfgcfhuS0Y8Tu/KNHyBrEhNpbGz3lMXq+lUerEa+Cqw0zcZhUnS7M8H+JHcsKEbBIFL1RGIpaWczLXIReEqR1laZl/QuyYTO3h4S5RUdGWw5nvBgGDgEHAIGAQuCkEDFm4KdjMTgYBg4C1ILB164e6xgGTk7m42oQJE6zl1sx9GAQMAgYBg4BB4EsjYBKcvzSE5gAGAYNAf0YgIiISicvt8MJHGaLQnx+kuXaDgEHAIGAQ+EoQMJGFrwRWc1CDgEHAIGAQMAgYBAwCBgGDQP9HwEQW+v8zNHdgEDAIGAQMAgYBg4BBwCBgEPhKEDBk4SuB1RzUIGAQMAgYBAwCBgGDgEHAIND/ETBkof8/Q3MHBgGDgEHAIGAQMAgYBAwCBoGvBAFDFr4SWM1BDQIGAYOAQcAgYBAwCBgEDAL9HwFDFvr/MzR3YBAwCBgEDAIGAYOAQcAgYBD4ShAwZOErgdUc1CBgEDAIGAQMAgYBg4BBwCDQ/xGw7/+38NXewYEDB8TW1la4uu2qVaulrq5WkpKSxc7eXkKxsipXcd22bZuuZMuVU5cuXaqr2ZaWlkprawtWgL0kzs5OEhw8SEaNGiUfffSRODo6SktLi3R1YxVZrAZrixVtg4KCdRVdB0cHcXJ06qv3npCQIG1Y5ZZf9jhnN/dB4wq7Dg6OUlFRoZ/b4BjdXd0yf/78zwCyf/9+XYnW2cUJ9eQ7Zd68eX3b1NXV6Qq0jY2Nuhqts7OzODk5ycyZM/u2+bI/7N+/T++zEyvXXrrUI0sWL9FDcpXZ5KQkXfE3NjZW69zzDzt37BQb4NLR3Sm33377DZ2e91NQUKAr2Hp5eSpG48aN02McOnQIGDcCyw654441Vxx3165d2NZBV9Fta2uVuXM/wejyDbdu3SqDBw/Gs21VvPgsufru6tWr+zbjeTo7O7HQl5+MG9t77r4/fk0/fPDBB/oceU9X6xNf02WY0xgEDAIGAYOAQcAg0M8RMGThCx5gc0uzFBcXS8KRIzAy28Xd3VP+67+ekO/843fE389Pdu/ZI4fxt6NHj8qsmbPExsZW/Px85bnnnpfKygpxc3OD4dghY8aMlTVr1khZWakkJ5+SlNRUHMtdjWeSg5/9/GeyfsN6GMyRMmnipL6rokGdmJgop0+dVoLhBOLh4ekh//Ef/yFnz56TEyeOS15entjZ2enqsyQP69at69v/3bfeluTTpyQ7J0ccnRwlPj5eWkBiVixfodvQqE1ISBQayyQjo0eNlOkzZvTtf0t+sLPFdZ6QhvpGHH9U3yF57ozMs/j9koSGhvZ9npObI+lp6RIRGf4ZskDyxsZ7sQXWU6dO1d8t/3V1dUlOfp688LfnZPS4sbJi6TIhWSoqKsJ9JoBIFIIQuMnhw4eUECxYMF+fA7dJSUmRxUuWSEzMUMvh9Htzc7PwvInYPzsnV37wwx+KF57B0cSjsnffXuHfz58/L//0T/8ke/fuky3vb5YSkMVJUyZLU2PTLSVeV1zY5/ySkZEhlRWVMi7++sjK7t275Bz6E/sJydCkSZO0r+zff0BSU1P6VjY+ffq0pKWlSUdHO7YbInGxcXImLRWEqQKk1w7EZJ6MGDFCSP6spfHdSE09o31o6NBoGT58uISEhMj777+vRDF+XLzEDYvTMaC09AJIpxMcAyOV/F4oKZETJ0+qw6F3DFgtHh4e1gJN33288847eJczpbamRsk/nRmjR4+SkuISYV9kX/nOd/5BjmCsZP9pbGiQGRhnwsLDpbCwUMcHOkKmT5+hzgwfH5++Y/fXH+i4oHOIYx8dENOmTtex++zZs3rP/v7+MnLkSJk9e7b85S9/hiOjWXjfHKPzMYbR6eGIvjQU4xEXDFy4cGF/heILr/vI4cOSCVyysrLUiTZy5CiJjorG3FskJ/H+eHp6yvLlyzGPjpE9H+2RbGzn5eUtw4YNU+cbx/difHl5+8p3v/tPX3i+b/IGR44Qi/OSnp6GOc5GIiOjZPLkSdqP2CdsMZ/GjxuvY1B2djbepzNwNgZi7F2APsN36Ticit2Yx2J0HJ8+ffo3+XZv+bXt27dPCjCmsI+wcT4aP368bNmyRZ2rdP4uXrxYemxETsFZWVdbJ8MwpkfD9iKGpl0dAUMWro5L36cxiBxkZ2Wjk1XJps2bJMA/EAZ/GaIFzvqy0sCkMUWDnkYoDU1vby85cyZVJk+YJPMWzpdcGL8HDx6WIEygHiAIebm5Yg/j/t5778Gk2Si+vr4yCJGH1JRU6erskvHx4/vOz/PQy+9g7yAvvPiCLFq0SCcXGmYH4MGura7WF4GDQyYma05QJCuLP/beu3l4SgiMvyFhYUo4jhxJkEuIdljIAk+UkZEpVVWVcs899+Dc8cIohaVxoj93/py0gyj19PRoRCUoMBDbV4HoXJKIiAg12IkDjQC2Hnzuh3uaNm0arsVPbHC+8tJyDPwlEuAXIK+9/roEBgao152GE19eGwyK27dvlxoYG5xMz2edFx/fzxoMJF+HMbHMnjMLhniz5TL1O6M5Z86kybvvvCdJmGByYNgPxYQTB8OV2DACsGLFCsWnA0Rl5MgRGgHYtGmTHD9+XJKSk8UBkQLPy4w5kq8UPN+ExAT8PQnELB9E5oz4+vgq4WvA8xsyJET2gDSGhYUq+SnFeWKHxsopkMJBgUFKwkhqiCUHdxoF7u6uiH5USyTwq6uvl/b2NjUIpk6dpqSF5KMdqwrb47k7gRgxOnC5AUUMOCBeutQtwYhK8XmzD2zdtlXq6+qV4NJQG4F7vJ7GPs7j1eu1dEho2BDZt69WSeTxY8fk4e9/Xxoa6iU9Ix39IQvPbiwmrHglFpnnzklUdDS23y+Dzg7S9+J6ztlftikoLJALFy7g/huluKQUk7Ud+mcW+kQi3qtQjSxOwfPlO8kIIp9xdnYOnpev9jkaw7NmzVJDhwTZGpsr3ksavulnzig5qsc4NBmE8+DBQ+pASU/LwFgRLrkgo83NLVJdU6tjJiOajL7y/fPBmNFzyQYkov8bN+wvHMc43tJZ5OntLTGxMYhA97735RhXSkAkm5ubNKJJUk4ywCgoI9AVGF/9/AMwbpbJGRBVbysgT5/X7+0d7KW9o00CAgJ6xxg4Luh4u3ChRKO4dJoVFhbBAVep/SYRDq65c+eqkdzR0aljT15+Phxtkz/vNP3ibw14J4iDN+ZOO7GRHTt3yepVq1RxEBIyGO/XcdgRnsCrXcehC5j3iMuoUWPEH9Fsd3e3vneKkW/Or592qvULIG7yIrswxmZhjqqAs3YsnLS0U2hXnDp1CraZt9pTEyZOlHfeflvOnzuvY7QT7CxPOABNuzYChixcGxv9S2xsHLw8BfCkdsjTTz+tht+PH3lE5syeo4bw2bOZ+tmcWbPFDi8lPbN8OWncjxg+QuZiQPPHoL9p0/tKEOhNooSJ2zTUN6gBzs9IKGiMf7rRGGdkgxONt7ePTJ0yVb3webl5iFAkySx458bCcKOBzv2379guq1av6juMvYMdjNgwCR4ULDWVVfDcnFdJU98G+IGTNWVRLfCC81o4WFlaFQah4qISOXosEQNYoF7zhAnjMdFdkFpIssaOHYNBvFC9igUYrD1BTsoryuXBhx5UjzvJgmDAIx5FGOwPdh2ER8hDvWUkRjTgGVk4jegHDf2LID8kU5T5MNJhaTSyPvzwQ0RFWoUSGwia4HGJlGMwZC0DYVNTkxqqh0Gi7r77bo0G8DPKqprxnQNqY2MD8BsiQbhOXvcQSMmyYOzS0J6NZ9iJ58xITULCERgtM3Uynzx5ipRh0qaXh956epVz8JxLYBCQHEZGRkjK6RRcc5t6EqdMmSJrVt8hjz32GyEpoYSNjYSsFkbUzh07ZFjcMDkDz9EMPM9aeFnpQSOpoWeIxyW5sbezlw4cc9xERIPwfCxkgZ4TkoV8eJns7e1kaPRQSKK6pQmGx0FETDpaO/T6SDJIwq6n0XjhgBoNckwj5vjxE/LIj36kz+cI8GxF9ISDbhvw57WGIxLE6E53TzfuP1wNHnt7W/XccDtragXAuaurEx6q4VKKyCAjBTFDozWaNwUG8f994g9qBLOvU/pGLyf79Wn0iTREXarRp8vwe0NjPWD5JIJmTRiRYLOncdKlAyAQxg77CXHo6urCO1CrZJjevVj0/YjICLkIg5jEmYSY40kDxp/goEHoZ/0fGZKgONzno48+qlG2NowrdApUYGx093CXKIxdiXBA0LHEsYfvHAkGx7JzGI98QQ78QDYZPT2dclojE/0flWvfAZ0kHH/Kysoxj9rpHMV3LRfz3Cg4PBihe+edt+WJJ57QcS4ZUmCO7cSO4zsjWbkYtxsb6q59kn7yl7DQMNx3rsRGR+F9cpG3YNS2o/94oa/YQ6YsXT3aHzguMapNByIj8R9+sEXnftoDdETROHZ1ddU5rJ/c+i25zCLMoXTWdoCkDxkcAgyc1TbiGMw+xnfsNLCpBgEtA9Ei2Rp2nU61W3KB/fQgJsH5Oh6ci4uLenu6MDDR88pQFY2wQzCizoPB0ugPCRkEI60Vhm4eDNBQnQCPnzgmL738EojCJhk0aBAIgo0aDswtqMbLXJRfKKUXStUwpGHK1mvcfWLgxcXF9YVaGX50xMA4EayYE3EXBhCGZanr52TNUDVlLzRoLY0DSSAiATnwdmaC2AyFB5hGtqXRlpwyZZIe5wTIx5tvvin00GdkpOsmvOf09AxIbo7pBHbo0EGhbp+Nn5MAcKI7dvQYBjB4wuEhomyDhvgnzeZjInQJL66LDvDMS/BByDgvL1cjF/TEHoOUqx25GR4w5EmmLm8ka7nYlnIhkrcD8MTl5eTq/pbtSJYokylH5IeyJnpVkhBm5OTLMCPlIychCdi4cYMa7BxoiTcjCiQJIXhGNMorQapqEZpk47Wk4JgkFfGI+LAvsHG7LgxG9OTQo8oIEI1CRiIGYeKiZ97VzVUNJZIxNk5s9HgcRL9xxKDPe33973/XaBDJB2UcxJJEIRf3xnMlJZ3EwHdG9+d/DDHz6wyiGzTcSRJ27dotrfDKlcEQ2bdnn2LsguuhoXG9zdvLSyeWMkzQJFVVlReFkxHD/EHBQXIJz4N3QeI5ceIEDLrVKs3j4Lt0yVJ9BxyRQ0PvMfubNTVGwxgJLC8vxeRyQaouVoF0NsKwDQIpXAPSYAvDpQHveJBGqmjsDAJm9BqzP5Bk1MFY3rF9hxIua8LGci+MnJAs0SAOgeRoKqKKNPrZz8PwLtLbyfctHLKjlpYmjDEXtN/X1tdKJ4gY+1VEeBi8pw5KOizH7c/fGS1sgCOA4w4jLYye0HHC6LK/H5xGdvYqpaGxuwxySZKqze9vUWcNyUI7pEud8B4zuk0njrW35ZDGMg/PGQYy8/wYWfbx8da+UoExuRRRhoKCfIzTIRhnInR8Zx/jfBYNw5r9zBoaI0uc1zkHZmIeXoSIU05Otkpn+FIRHzqSKG3zAPGcCmdWRESkFGMuXrlylbi7ecA+KEFkb7ISKcq1BlIrxTxIhxX7A987Ei/OafPguA3CmL1z507NaWTfCcacT1vBAXhyPjbt2ghcvzVx7WNY/V/o5U6DhMQZgzoNISY0szNWoANWwjt2EcYDv6rhQWYUgLkE9OpWgrmmp6crWaBcIRoeYBqMNGo5sVIbHgLZAnMXmHPwSaNZ9kmjhyUORhvlQ9yfjd47et7pxaShSc87vdb8jFKdyxu32Q5DpQGeGIbfSGwOwwNNw5sG/9KlS5Dwe4cMHzVSPtq7Vz02pZANsV3CPxIA6iZ//etf66TFievee+/VyAmlGZTX0DBicjf1t7wGmyumfF53F6QqURjwFqlWmXKpSniRaGQz6nAkMRFeE0eECGdAVhWvhqvlXnkdPGZrS+vHZOoS9rFX3bMXjFw2eu2pd925c4cEQOJEb1zvYEuJVZUSKUYbpk2fppPMu+++i0moTDEoBD6UCtDrRyOwBJOShewwHMyEcEoESBS7P47+OAATPjNGExge78RE7wYiREOAHi/Ky0hAaLD3EkBcJB4r9wkKCZZJkyfrJADVhcrRxiG/gkns50Fs6mvrkeA+EaR0roRFRiD0I32tE9EY9rseHGze/Hly151rVa50FGSNsgdGsShZok6TZOl6vfzhMPI54Z4DoWSEiFIzkmLeN71aPE4VJuwITMyrYSBT2sa+TYJEb/HfQXoCsA8ncWvT5I+EsecLaR+J6AWQ+yhMzIzysV8dOLBfbNF/KaGhV30rxoZO9PVw4EAdMZ0Eo0aNVmOYeUrW3DgOaATMz0cnYRo1jCjcvmqlRgQLiwpl/oIFeAdsIdFL1neNY2ERZF4jRw2XBehvafAIXjn69V/EOP54enqpHJPvE73j+fl5Oo5wHHCFJKkAhJxOnlVrVstkRCQPYVx2RFEC7ksJFyONjCpTamjNjUSKTiYWwPCEsXux6qLY2djA4J2o4zqLigwfNhza/Sk6JnFuILniuETpFudTRnEtjpn+jFU+xt/DRw7DKXRSDh86jHF4njqOmLtBh4wLnFBl5WVqADfDacX3jvmRtCcYdd6PvLk0jM2jR48WOoEovRlIjU422ijjIJMNhAy4saEJCohxMhdkgYVI6GxsxVzLiALzOiZMmCCNcPiWl1cMJJhu+F4/0Xnc8K4DYweGhqnZ3w4jYM6cOdr5nvrvp2T0mNGaMEtDcBIYfFh4qBqNOfCQb936AQz7brkTOQBMfOzuuqRGFb3GnEyZE8Ak5fiJn+QmpH5sSNAQzEIUgNpWHjsYHkpOKiQElHzYfOyl9vXx09BrEcjJDhjIJBJpaWk68TD0aGn87APId45hMKbnhkSCBn4gGPY5EAUmjdEwZt6E08fVgKi9VsuWB8HMjbiAenz4KwdpDj408vEHSKrsMCH6qaFEw4ChUjVQ8bdPGiiHLaRO9IR398BI6JUGuXoy+btTB32y+3x4jVqaW+FxrEeoGfkIuH9Lo/eNSd37QGboLfjWt76lko958+brJpx03d09NIHyjrVrcR2e6nHiBJSB+4yOjlZPzMyZs5TwnToF2RCeBckdoxaTYbxzQg4GkaIMKTMzQ5OWGdmxNBo2vH96Kfx8/RAZ8UEUo1y9g5z8h2JSZyIVDf6DSIjuaO/QXannZqMRZINjONo7KmFi1MDV1U2fMx8rZU4kGyQgJByXxFa9sZfnkDCPwQ33aUc9L/sT9N/0MhE/XldrGypwAWMSnsamxssh1Gu41n+Ojk7qdeGEE4ABduy4MX2busDoc8UATA8p+2nK2d5ke8qx2NeYg8Loh+a7YC8+C2vyhDohjE1cBkMvTOOPWvxWePXoKNgJPTGdAMT/L5ApMupDGYATiOMIRKPoaNiHydvN3Q3J5vF9mFrbDyTqfO7O6EdD4PmlwduE/sf+wfGM/asZv/Nz5mcRT0YZ+HMxCHBRCQoPOLqClFG22P+bi4uzSquYXErZZFFRiTpK+L4zp4VOCRICO7zjaWfSYNylSQsiEYzkcVzdgGIXR1BQgcYMtfvUX1tzo1F7CNHiBvSR6tpqlTh64V0bNChYo7qsYLcM+WaWKYFV3nr1+L1zBOdKRiMcnSDT6eeNkWVG7N9F0QDOJ/mYj5YgIZcRcd5nc2uzzmGcf2hTvPPuO3BOOmvO4cXqGnl70zuIpI+Qs7BbVq1cib5XqFUb+zks1335JN8FcEAkwyHh5OiMKH+oRngTjiSovRIIJw4dOpxra5E7RScgFRsW1cB1n2iAbWjIwhc8cGrii4uKEdpzkwcffACTn7uGsXbu2qmJqGPHjBNW1CFjZQL0nt175AN4WgfB6PSH5pT6dXrRX375ZZXDMKTMYyWfOi3/9stfwbDuxgTqLI89/hiM2whNZnsFkQRHeCtp0DO5+ac//akatAzJOrnBSEdbvWYVJtgCGCL75fXTp3TiofyJWf4kAJZGb3MJDGIaosePH8Uk1QDN3mTNrdgMeVRkZAS0oO9qNZ3HvgAAHDVJREFUQiYHnvnwYtDw4UDMpgYsrtfDo5eAsCoFjUcmnNFDyETmifD+1CPc/uKLL6pkhQY1pRh9DZOdt6cvIgnH5JUXXpAekCXiYomOcAJdtGihvInB8M03/y5tMIhJXmigfrrZYIJdgopFjCgw2mBp9DLRwOf1fRtEguSAUSDKAJKSTqlmnASHz4Leq4kTJ8gIRFJexjXHYNtvf/vbGhV57733JBFyqCpIuThgX04WWNbWB0RpyOAhGiVhaJxJUiRkM2fPAm5hsgj4//GppyQVxjPlYoySzAXJZNMJjVjii80eAxQ17vzcCXiTyI0CCaW28s2/vwFZUrrqmBmWtjRGDejRrgH+27dt10liGGQu05D7wGog20EMn3zySQyAdRKJ+6Ie/HoaCVNm5lmQIdEkQRoplkZJiTfIEQdVatBJDJg/waReTtqUwPG6WM3EC/hEoqqENTVK0rKzcvGcbGU4sGa0wD/AXyWEfL/uu2+dSvDcYBizVC4TD4nRAhBZJoLTOOT7dNvyZRpZsiZsLPdCospJ2AmeTxIBVtPiPfN9O3LkiCxftgzV4Naq55OSQ8oBOAZERkaAIPirt49GzX3r7tU+ZTluf/0eHs4ImycMuLvkjTfegGMnANG+YXCOdKnckBGG2KExOnc0t7RqVJDj5rfuuw/eYG91yJCc92B+OJOagrHhFleo+4YBa8mTy4FM097ZUebNWahkkhGHGhh0HK9HjhyJ96d3zCc2HC8tUUx+H85o6mVzwjfsFq/7cjiv8YvvBwnlCUhnSRroUMrISMNY7CszIPtj8Y4TwOcAHFOc74YPH6aRzRnTZ6ikhtWAKMFlPsdAamvhLKzD/HcSkRk6ENl3OjvbpRQy0gvIjZoD9cPq21fKEZ8jGJsOa27DJFSbYhl8066NgA28wHR4mnYNBKjPp++ChtJ9MEKp0T4Pxs4IAr3qsbFx6v1l1IGSBHc3d9Wck6VSJ0/Dm574zZvf04GOEQMaqxdhaFKrq+jjBEzwor6Zentq0Sl3oTfS1tZO7rrrLj0mPe+REZQ3BGvYlZdMrxU9ycyHYOI0q/1c3phXwXKG9KK3d7aBPbuhRFi0RgCKi0ugjRyN629B2cdEjWYEwAiaNu2TaiQsCUtjthxhzxUrbpNtwIODD5k4K/boC4YelIyEoezsLCURlKU889e/qpFMrT+TcYkHIw+8d+Ze0EMbHhauki1eL6VRGTD26XnswaRJnBrhXWe52etpSUknMUBiQADRWrv2Th1kud8mGP8kEJSJ0NOflX1On0dMTCy8drHyNoz9COilXWDojUc4kqUOOcBQY87ny5wPS2NCIj3+UZFROE/vc6JBRC02PaKs/sRGTWQLPqNUx5J8zc9ZMYvb5+bmIM9kJQzKVPUwUurE3BcmhfohfEqD/PDBg8IQ8/qNG+XBBx6QH/7wh2qE8Ths27dvU8OTJMkbpHQGPJiM0ny0e7caq7wH6n9ZJncZDDXTDAJfJQLs24ydTYehYppBwCBgEDAIWBcChix8wfOkAcYvykwohWGjlOjyRgOQngAabvTQXt4skiDq0SljudHG4/L43JfHYLMckz/zfDwv2+XXqB/gP8ogboQP8h55HEujt4vSFxIGGvyWe6eXnrjw7yx5ehqyng+3bVOis3TZYnnsN4+pUc79uD+3u7zRY8Jz8frYLj+eZbur3Y/lb5/+brlOfn45Plc7N7e52v3wmizPm9vwd16XpV2OJZ8JceX2bJdva9nuZrBkHgmlb6+88qrmwYyALOHPkLfwfJT9WNq1rtPyfCzbWfqm5Xfz3SDwVSDA94xj1eVjx1dxHnNMg4BBwCBgEPj6ETBk4evH3OrOyKhLQsIR1amzBCIThqhHNu3GEaBsg6F3RiXOQrtKKRMNMEZojCF243iaPQwCBgGDgEHAIGAQ+HIIGLLw5fAze3+MAHMY6BGnJ5t6UtNuHgGD5c1jZ/Y0CBgEDAIGAYOAQeDWImDIwq3F0xzNIGAQMAgYBAwCBgGDgEHAIGA1CJh1FqzmUZobMQgYBAwCBgGDgEHAIGAQMAjcWgQMWbi1eJqjGQQMAgYBg4BBwCBgEDAIGASsBgFDFqzmUZobMQgYBAwCBgGDgEHAIGAQMAjcWgQMWbi1eJqjGQQMAgYBg4BBwCBgEDAIGASsBoFPlsC1mlsyNzKQEeCaE7m5OViX4pKupcC1CbgoG1t1dbVwpVlnZyesHBt1BUwFBQW65gOWhcCqyt66Su8VG3z8S35+vq4bwYXU/LAQGxfp40JtYVjYzdK4Yi+vg+VOLSuMWv72dX3vvZ8WlLMNEF6raQYBg4BBwCBgEDAIGARuBgFDFm4GNbPPNxYBrlMQEBAkZVjJ2dfHBytEZ6KU6wglAidPntSFzXJzc3WFaC7MFhgYqKQiLy9P/+YBYnH27NkryAIXX6uqqtTVtrOyzsvkyVMkJSVFRowYISdOnAAx6RY3Nzfxwfm4nWVhvqSkJF3BmYvZfd0tLT1NV/rOy8v/zKreV7uWhoaGvgX8iIsDVtLmyuMXL1bpfXMffk4s+MXGBet43yRMls+4DXFgCV1raVx5nM+U98j7431/siJ572ckZOx7lkX6Lr/33v34ySf97fK/W8PP7AO898v7Ae/L8jt/JnaWxs/d3d117RD2Pa7+zG7FbYglFzns740LaVZV8f3pfV8+ff/8vRcSvlc9fffP94eLK7a3twEV9hobfZ/4uTU3OnMs708vNp+MN5bf2Te4HZ0x/Ix9iN8bGxsVZ3t7O3WQ9Gec+Owt98P7sNw7+xG/2Gc8PDz1ZzqqtH/hM/YTbnt5X6Kj7H9j/vnfxN8yXuuYggtxdnLWhVr5ueVdtIwvn2DaO657eXn9b176N/rchix8ox+PubibQWDTpk3yq1/9UqZNnyH/8i8Py6nTp6S1pU2ee+4FOXo0QSMCEydNkp/+6MeYhB1g3PrKxg0bZCtWoL533TqZM2f2FaflonONDU3y7N/+R/Z+tFd++9vfyqyZM2Tjxo3yzDN/lVasXrvmjjXyrz95VIoKi+QHP/yhnD93Ttbdf780tzTLbStuu+J4X8cvCUeOSFZWtixbtuy6Tnf40CGsk1EqBw4dlInjx8uiRYt04q6trZH16zfKnFkzZTjI0c5du2T/gQPi6uIqI4YPkzlz52LV7jZ59tlnpQXGzcMPPyzemKDG4xjW0s7hWaZnZEri0UQZh/saGhkp3l6esmvXbsnKyZGHHnhARo8ejYUJE+Q4yWN3j6xcebsEBwVpn+JnAf7+8vD3v68kzNfX11qg6buPXbt3y6nUVClChI4rl0dEREgkcProo4+kCySCn913333AJFDew/tZWl4uU/AODosbptG3V159VZqam+XHj/xIjxkE7Pp743opJVh75vm//U1qQCS/98/fU0Nv7769cj4nW/vMA/d/W+xsbOXJJ5+UcjgaFuO9Gzd2LBZmPCFn0e+6erpk8YIFMjhkMMaz6f0dks+9/g3r35S0jAxp7eiSVbffjjFnlpw+nSJvvPG6+AX6yc//9WfqmHjuuf9B9DhfAtFHiBXJ+7nz5+V8dpZMmjRBHv7uw597nm/6Hw9hLCaB3rR5s9jDabNs8WJZvXqNPPn/npRzWVni4+0rc2fPEk8YtjUwgLdt3SpecOz8n3/8RwkNDZXfPfEHqaiokEXoN2H4fcnSpd/0W76l10dnYEVlBcbnXdLR2SXDh8XJtKnTpLigSN567x1xhPPu948/Tk+GvPb661JcUqLzpJeHhywAZqZdHQG736Bd/U/mU4NA/0KA0YG6unr54x//JFnnz2l0Yc7sORKE6MHrr70mbW1t8tRTT8FoWSchwcESERWpEYadO3cKCQblQ/SIU1I0CYYMG+U8VVUX5We/+IWkgnTUYRCfg4H6TNoZNZrdMcDMmDFTjaJhQ2Plzbc2qod+7dq1wkE/BJN8M7w/UVFRcuzYUblQWibp6enS0FiPvx9WQ2n//n1qVOTC8IyOjpbDhw9LcXGxnDlzRoqKivC3YnHChEgvmqXxmjkonsckSaOEkwS9csdPHJdUGG3ZWTlSW1MrsbGxuqK2Zb9rfd+yZYukIlrS3tYuRSU4H7wxra0t8sgjP5Yd23fIKCy0F4ZVucvKysTF2UVqYfzw/IMGDZKtW7fRrSXx4+Jl1KhR6r3h59bSNqNv7NyxXUox2bQ2t4iTqwsm83olAsOHDZM3YOhOnTZVjWDik56RrlI1eoKbmprFw91NSvH5YRA4kjdXV1drgabvPi6gz4Ri1XF6fFNOnZIa9MnlS5eJn7+fksfnn38eBHKi7N+/H9h0SA28w42NDeLh5iGZmWdly5YPxMbWRo4cOoJI2PIr+nrfSfrRDzl4l1tbW+W3j/9WZY1xsTEybtw4jCUV0tzcJG6ubsLx6uTJEzIRK97n4D2OiYtT0h0TEwdSaS+eGFvK0W9OnkwWXz9/iY8f148QuPFL3XdgP8bqICnEmJufnycXSi7IkcQEyQSBqC6v1LG6s6tTXnr5FYkZOlTmzZwjoWGhkoxxeTeIO0nDsaPHJRzjVDDGd0ZH+2PjmM6xHBxSggOD5cUXX9L5KOfceY1mn8H4TgcWo+Kcsy7A2F13zz0Sh7Ge3vMSzB3eIBIffvAB8AlT4kHiPlBaamqKfIg5qQXOh5kzZoBQxgOvRnnhxRdl5MgRMiw2Tt+5Z//6Vzl96rTk5+VrJM/L20vGgnyadnUETGTh6riYT/shAhxgW1qb5djxRCEHfuvtdyQbHrwwTCjMHTh67Bi85G8iKjBThoSGSycMG4ZpKU+iIf7Qgw/BI1Gphvq+fftk/vz5KjGKjIyQRx/9MaIF5+X5F1/QsC5zFzhgjxw5Ur8OHz4ohUUFciwxUdasWSNr77wT13ECEY0WSFjaFc2WllahNOl1eDNGjR4jKZjkJsGAam1rkUIM8PPnzddjZoLo7Ny6XQ2GZgx4SxYukugfDe17Im+9/TYIxRE1NOixHQ0DnV6SCngmn/nrs9IJUlRdfVGCka9hCbf27XyNHygjodtz7vx58JZnSyIm6RUrfi9PPPGE/OoX/ybtwCoH5GA8DBsfv3zx8vGWwyA7DIOfgnHo5OgkVZAsTZo0UaVJ1zhNv/yYXm5H3F9haYmERkdplIDGsRekAPchEvXOxg3q8STJPH8+GxN2vfYrhrjnzZurhLMBMolCED9rbVy1vRlE6kxamhLIWBjHQcFBSgCaQZhIgidMHC87d26X2Xj/hsXFAqssqa6phiHsg35fp7Kbu+68S6UU/R0nkiZXkMoMOAbqYMAVo++MAVmgBbhs+XI5gbGhHo6HBtx3D/rJ6jvXyqYtm5VwxcVGw8BrlIuO1eINwtkDSZafv/VFoz79jPnsjxw5LO6QNvKdGz16FDznNVJUXARpmr/EwBjOTEtXoskxJzAgUEJbGtWBER4RLkvggV+/foM6SSgB669t6tSpiAyU6xhiD+fVhnfe0ijC/MWLILHyV2eQu5u7jrMcfzkv5WZlq2OI97xy5Up5BYQqCISJsiziOJBabm6e5GGuYnTGw9MDc7+7dHdfkgyQTkqTfPyLZdWqlerAO4R5lI6cma4zlJwPJJxu9F7BXU0zCFgHApwgjiYeVb0nPbz07CXBc8cchHHwyt191906cb/00kvy12eeVsOd26SmpKoOlgZdKXIdSuCpYYSCLSgoWPd3gdfK2c1Z7O16XxkaA0yippeYE5u9vb20QY5EvSk/c8MXvYOXsA1sAW00HuvqGvT67lizWmZD7pScelrmgZQMhlc2vyBfownZMDijomPkHxFWtsP5Ki5W9h4A/+8HicmEJIaSIU4KK29fKWmYQOnNTsNXddVF3W/m9Jni6uyKc1/fpDl4yGBxBPHYsWOHJCclSyc0+qWlF0Ci3MTBGfkHIBIkVgxvlyE6Qkxnz52jkZM2yI8e+s4/wIPqBWNwZ5/uuO+i+/kPlSBB3r4+kIFMw4Tipt67yMhozWP4y1+eRpSoEYnzVdpvKM2iIdzU2KTPmbkOycnJIKBFKtECjFbZwsMjpLCwUEnTEES54uPH6zvRDuK6e89uefDBBxFha5Tx+Dw7J1e2w/PH7etAuCuh6x8/Pl7fh5LyCxqZsgaQGMlkdG7dunsRXfGSQwcPYszoQV8okQIQRxL9FZAokmjxi62zqxv9CZEHvHf8uzO+OjBGVcGJYe2NhNIO46gLyAIdK1mQ3FC7Px3vXWxsHN6jU5KemSmRURGyHNGnAoyX+/bu1T7nAWcPo6suIPV0GvXnxsIZjL5RAroRzq27EKXmz8xH2A6pLMfiQYNDGMyV+XPnqmw28dhx2QBZ7DBEOhnddXBy7J2P0HcooxxIjXlCLi7OsmDhQuQt+srBg4d0Xg8ICpD77/+WlBQV90Xvh2G8ngwHFx16VZg7Tbs2AoYsXBsb85d+hADD/gzfboV+MyosQsrLKyQIlYDyshnOLlGPDKUizElYvGSJpEBGVFlRqVKS4gslCGG7SDcmauqHSzCZU2LDxgReSpKmTJkiPdDSWmxvhrwdHRxVtkOjpxXyHUqS/DHQ10Oiw6hDGwbq3uS0XiBJFhha9oZ3iMnDQ6Oi1SDgfpwgukFAaIy3YqIMhLabyda+2PZyc58GPSUwNjaXEIYOgIHuIV3dnYgG5KqHxBNaeu7nBs9Tb7Jb77m/6H+SFd6jEzxZNHAZvp40abImc9PosSHRgYc0E5M1CQU9WiNg4PD8vHZ6bOzs7PXaeJ/W1CrQT2whkRkWF6cTdCn6E8PZM+Ehr4NnmISSRIqRl0EhwZBABGmyMwnEli3vq/QmFgRiMCI9mOmtCZor7iUvL1cjaZRAREZGwtBrkJa2Vq1AFhMTg/41VUYAt6H4uRV9zAH5Qo6QilyArj8YsrVRI0dJ1rmsK47Zn39htI3vhg0iA3zqnR2dGrX8CAbumdQzMgTvHCumrd+wXl555RWVR3RBZsNx7OzZcxppoZOiA+MBnR/W3Jjb8vJLL+p75g5PcCWipCweUVdXKyMxzgQHDZJk/B4aOgTjjIPYod9UQ2bpAIzpbS9HDgxJaVllOaIx/TtJldK0k7jXLe9vgZyvWgk2nVrMvWPfYc4TpbXsVLZ2djIWEaumlmZIkrLkLchgX4TcJioyQnOFOKeRcA2kxv7AyAvn5+7ubqgNWlVZQHUBHXhdyGPg/FUAuRtzqKIRLWYU4iKi8aZdGwFDFq6NjflLP0KAFTJoojIf4J//+bsyC8lxzE2gsX3iZJIcgHchDX+jTvgiBmB6r7whpcmC5pNGNSVHS5cukYULF4irmyuM4gyhFOnyxoGno7NDw+I0hqgZPQ2dfxI8XvSqc9BmlODY8ePyIqIX9CIOweTmgEHL0kgI7PDLDGgpO+ABs0WYmB41Ria4vWq8vT3l3NlMHDcZXrNaNcIt+/NaORja2dpJYkKinMI2TvAiTZw4UaIjIrX6Cs+fnHJKZQ7c/noaoySNGEB5DfRO8XiWFoBwv6+/H+4lVJOmGeatgIY4HRENaq8XwoOzG8lklSA6JBi8F2tqoTDo7GGg8L5tgDvzQEiISAjZ6Sgr6QGLpGb4woUyTDyNmvfCEDiNvnJgVVlZjZyV41bjNf/08z0Ir3k13qtg9JWIiAjV53fBUElLy9BcBb5flPoRNxovjL5ZtOXEtwLGHmUCE5BAfp1d9tOX8I36nSSBCcqrkJh6+EiCei3HjBkDLbkPJBL5iEJd0P6Ujnt2QsJlgr7LpyG1iUa0bpBK2Y4dPyl5kDtGYnwIDw/7Rt3frb4Y9oVa9J/jR0+o55ckatq06RIeFi4FeQUg5bUyYdIEodzIE1Gak8CGDhfmLrA8NmWCGYi4RuP3CIzN/bnROXGxuhZzSyqKZ3TouEGJY2LCUUR7y7XfNELaR6cSZa0pSAL3ReTz9ttuU6P4JOa79PRMJaIci5k3N5Aao3SDcM/Z2TlSDiyZ5M1cxFGQDH/44VbtP4w8sJ9UV0PmhkiDn58/5KUBAwmmG75Xk+B8w5CZHb6JCFA6xLKl9fUNiBwslttRjYaGPS2P1rYOldhQIpSfXwDPeadMgxeduQzUTUdh0GD1GuYaNDY1IkLgqcY4P2disqXlM4IAWcFSRCYYDWDokt4thr1nzJiOAcdXDaJyGM008meDEAzBOZhsxwmNEQhYS9IOT8cKDOyF0L1fQuWc8fHx8ByWgwQEQL4Rr5rdbFxXfWOT5ORkq0d79uzZ6r1mqJ2eft7LxYs1atyPHTcW9xAlDvDs10M+1Yq/U74QHT0UHt4IoZHyRY2JlPTO0finB52TteXea+Hdo+ec0homDcahgg0nL3ppmBNBjTFlWdyHn5P8cCK3lsZ8Dhv8YwlC4k8tMJPKmUAeiehQDPT5y5DMS6LFyBNJaBSS512BCychRiH8fP004kBDmoaytTV6vgORnOqESZhEmv2An/FdCwsbon3QDl5QJmQyt8Ef5HPevHlKvOg1JenyR1lMYjVq1GiNuPVnjBiRpDyR0RVWgxo8eIiEIJLgDHwGBYdIRESkknxG8hhdoSOCBs3wEcO19DBxIy6s1DY0dqgSK+5jrY1FGRpBsulAoeMlTsegwfrOCaJ6jNYNQ1WbpXjPmjBGEzP2M0Z92dc4/nh7+2j+GA3kCLxn7G/9sdEJUY0xJw5Om6FDY4CBK/oH8+u8VWJE540tQtQYejUKbIOfSZpIKLlvO+SwdCDFxMSqhItzykBqnLfaENHswjsViDGFhQU4xzLSzzGa+VT33rtOsWO/4dzGfdjnSFpNuzoCUBdYmWbg6vdpPrVyBKjLzMhIh0HbLA88+IBGC3jLrPJDjzllQwzx0/vJn2n0sUzaa6+9rlKjcTC4OVgcOnwI+uAq1cwGwKBZelnp0W3bt8NArNFkO3r3qatltSJO7CGDgvtK1G3YsFHDnJQZDIKXkIMVWxqSPynVaMKkeOfdd2sZ0iZ4WSdPnqzynlaUICXhIBHYvm0HKi/Vw2uULN///sNy1113aV6DHgj/HUD5UpIPDn6sPLQU5fFocLz11lu6Pz0ntrYOMOBDNMpi2e/zvh9DAjgnmjlz5lxzM1Z4skzCJElz58695rbW/ofS0lKQuVzIkWYoaeL9HkBFF3o+WTr21KlkGHxtV8DAahv0sFtbYxTOAcYujTjK2dgo5WMfZVTh8sa+Swwuj16R7HP7z+t7lx+jv/58I+/PEVTPYqPcbaA0Vsui8TYBhRRupHFsJYEnAbWGxvvpXX9EdIznHHH06FF11vD+mM/C94fr/bACkrXc9618dgPx/bmV+H36WIYsfBoR87tB4H8RAZZRpXSF60HQc02PJCsr0fgkQTHNIGAQMAgYBAwCBgGDwNeJgCELXyfa5lwGgetA4CjKr9ra2GjOgX+APyIT8X2e6+vY3WxiEDAIGAQMAgYBg4BB4JYhYMjCLYPSHMggYBAwCBgEDAIGAYOAQcAgYF0IIEXGNIOAQcAgYBAwCBgEDAIGAYOAQcAg8FkEDFn4LCbmE4OAQcAgYBAwCBgEDAIGAYOAQQAIGLJguoFBwCBgEDAIGAQMAgYBg4BBwCBwVQQMWbgqLOZDg4BBwCBgEDAIGAQMAgYBg4BBwJAF0wcMAgYBg4BBwCBgEDAIGAQMAgaBqyLw/wPbQhXaV/wXJgAAAABJRU5ErkJggg==" /></p><p>bid: twice daily; od: once daily; CI: confidence interval</p><p><u>CAD with heart failure</u></p><p>The&nbsp;<strong>COMMANDER HF</strong>&nbsp;study included 5,022 patients with heart failure and significant coronary artery disease (CAD) following a hospitalization of decompensated heart failure (HF) which were randomly assigned into one of the two treatment groups: rivaroxaban 2.5 mg twice daily (N=2,507) or matching placebo (N=2,515), respectively. The overall median study treatment duration was 504 days.</p><p>Patients must have had symptomatic HF for at least 3 months and left ventricular ejection fraction (LVEF) of &le;40% within one year of enrollment. At baseline, the median ejection fraction was 34% (IQR: 28%-38%) and 53% of subjects were NYHA Class III or IV.</p><p>The primary efficacy analysis (i.e. composite of all-cause mortality, MI, or stroke) showed no statistically significant difference between the rivaroxaban 2.5 mg bid group and the placebo group with a HR=0.94 (95% CI 0.84 - 1.05), p=0.270. For all-cause mortality, there was no difference between rivaroxaban and placebo in the number of events (event rate per 100 patient-years; 11.41 vs. 11.63, HR: 0.98; 95% CI: 0.87 to 1.10; p=0.743). The event rates for MI per 100 patient-years (rivaroxaban vs placebo) were 2.08 vs 2.52 (HR 0.83; 95% CI: 0.63 to 1.08; p=0.165) and for stroke the event rates per 100 patient-years were 1.08 vs 1.62 (HR: 0.66; 95% CI: 0.47 to 0.95; p=0.023). The principal safety outcome (i.e. composite of fatal bleeding or bleeding into a critical space with a potential for permanent disability), occurred in 18 (0.7%) patients in the rivaroxaban 2.5 mg twice daily treatment group and in 23 (0.9%) patients in the placebo group, respectively (HR=0.80; 95% CI 0.43 - 1.49; p=0.484). There was a statistically significant increase in ISTH major bleeding in the rivaroxaban group compared with placebo (event rate per 100 patient-years: 2.04 vs 1.21, HR 1.68; 95% CI: 1.18 to 2.39; p=0.003).</p><p>In patients with mild and moderate heart failure the treatment effects for the COMPASS study subgroup were similar to those of the entire study population (see section CAD/PAD).</p><p><u>Patients with high risk triple positive antiphospholipid syndrome</u></p><p>In an investigator sponsored, randomized open-label multicenter study with blinded endpoint adjudication, rivaroxaban was compared to warfarin in patients with a history of thrombosis, diagnosed with antiphospholipid syndrome and at high risk for thromboembolic events (positive for all 3 antiphospholipid tests: lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). The trial was terminated prematurely after the enrolment of 120 patients due to an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. 59 patients were randomized to rivaroxaban 20 mg (15 mg for patients with creatinine clearance (CrCl) &lt;50 mL/min) and 61 to warfarin (INR 2.0-3.0). Thromboembolic events occurred in 12% of patients randomized to rivaroxaban (4 ischaemic strokes and 3 myocardial infarctions). No events were reported in patients randomized to warfarin. Major bleeding occurred in 4 patients (7%) of the rivaroxaban group and 2 patients (3%) of the warfarin group.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Banoriv in one or more subsets of the paediatric population in the treatment of thromboembolic events. The European Medicines Agency has waived the obligation to submit the results of studies with Banoriv in all subsets of the paediatric population in the prevention of thromboembolic events (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Rivaroxaban is rapidly absorbed with maximum concentrations (C<sub>max</sub>) appearing 2 - 4 hours after tablet intake.</p><p>Oral absorption of rivaroxaban is almost complete and oral bioavailability is high (80 - 100%) for the 2.5 mg and 10 mg tablet dose, irrespective of fasting/fed conditions. Intake with food does not affect rivaroxaban AUC or C<sub>max</sub>&nbsp;at the 2.5 mg and 10 mg dose. Rivaroxaban 2.5 mg and 10 mg tablets can be taken with or without food.</p><p>Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. At higher doses rivaroxaban displays dissolution limited absorption with decreased bioavailability and decreased absorption rate with increased dose. This is more marked in fasting state than in fed state. Variability in rivaroxaban pharmacokinetics is moderate with inter-individual variability (CV%) ranging from 30% to 40%.</p><p>Absorption of rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% decrease in AUC and C<sub>max</sub>&nbsp;compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when rivaroxaban is released in the distal small intestine, or ascending colon. Therefore, administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced absorption and related rivaroxaban exposure.</p><p>Bioavailability (AUC and C<sub>max</sub>) was comparable for 20 mg rivaroxaban administered orally as a crushed tablet mixed in apple puree, or suspended in water and administered via a gastric tube followed by a liquid meal, compared to a whole tablet. Given the predictable, dose-proportional pharmacokinetic profile of rivaroxaban, the bioavailability results from this study are likely applicable to lower rivaroxaban doses.</p><p><u>Distribution</u></p><p>Plasma protein binding in humans is high at approximately 92% to 95%, with serum albumin being the main binding component. The volume of distribution is moderate with V<sub>ss</sub>&nbsp;being approximately 50 litres.</p><p><u>Biotransformation and elimination</u></p><p>Of the administered rivaroxaban dose, approximately 2/3 undergoes metabolic degradation, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion.</p><p>Rivaroxaban is metabolised via CYP3A4, CYP2J2 and CYP-independent mechanisms. Oxidative degradation of the morpholinone moiety and hydrolysis of the amide bonds are the major sites of biotransformation. Based on&nbsp;<em>in vitro</em>&nbsp;investigations rivaroxaban is a substrate of the transporter proteins P-gp (P-glycoprotein) and Bcrp (breast cancer resistance protein).</p><p>Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration the elimination becomes absorption rate limited. Elimination of rivaroxaban from plasma occurs with terminal half-lives of 5 to 9 hours in young individuals, and with terminal half-lives of 11 to 13 hours in the elderly.</p><p><u>Special populations</u></p><p><em>Gender</em></p><p>There were no clinically relevant differences in pharmacokinetics and pharmacodynamics between male and female patients.</p><p><em>Elderly population</em></p><p>Elderly patients exhibited higher plasma concentrations than younger patients, with mean AUC values being approximately 1.5 fold higher, mainly due to reduced (apparent) total and renal clearance. No dose adjustment is necessary.</p><p><em>Different weight categories</em></p><p>Extremes in body weight (&lt; 50 kg or &gt; 120 kg) had only a small influence on rivaroxaban plasma concentrations (less than 25%). No dose adjustment is necessary.</p><p><em>Inter-ethnic differences</em></p><p>No clinically relevant inter-ethnic differences among Caucasian, African-American, Hispanic, Japanese or Chinese patients were observed regarding rivaroxaban pharmacokinetics and pharmacodynamics.</p><p><em>Hepatic impairment</em></p><p>Cirrhotic patients with mild hepatic impairment (classified as Child Pugh A) exhibited only minor changes in rivaroxaban pharmacokinetics (1.2 fold increase in rivaroxaban AUC on average), nearly comparable to their matched healthy control group. In cirrhotic patients with moderate hepatic impairment (classified as Child Pugh B), rivaroxaban mean AUC was significantly increased by 2.3 fold compared to healthy volunteers. Unbound AUC was increased 2.6 fold. These patients also had reduced renal elimination of rivaroxaban, similar to patients with moderate renal impairment. There are no data in patients with severe hepatic impairment.</p><p>The inhibition of factor Xa activity was increased by a factor of 2.6 in patients with moderate hepatic impairment as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 2.1. Patients with moderate hepatic impairment were more sensitive to rivaroxaban resulting in a steeper PK/PD relationship between concentration and PT.</p><p>Banoriv is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhotic patients with Child Pugh B and C (see section 4.3).</p><p><em>Renal impairment</em></p><p>There was an increase in rivaroxaban exposure correlated to decrease in renal function, as assessed via creatinine clearance measurements. In individuals with mild (creatinine clearance 50 - 80 ml/min), moderate (creatinine clearance 30 - 49 ml/min) and severe (creatinine clearance 15 - 29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4, 1.5 and 1.6 fold respectively. Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa activity was increased by a factor of 1.5, 1.9 and 2.0 respectively as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively. There are no data in patients with creatinine clearance &lt; 15 ml/min.</p><p>Due to the high plasma protein binding rivaroxaban is not expected to be dialysable.</p><p>Use is not recommended in patients with creatinine clearance &lt; 15 ml/min. Banoriv is to be used with caution in patients with creatinine clearance 15 - 29 ml/min (see section 4.4).</p><p><u>Pharmacokinetic data in patients</u></p><p>In patients receiving rivaroxaban 2.5 mg twice daily for the prevention of atherothrombotic events in patients with ACS the geometric mean concentration (90% prediction interval) 2 - 4 h and about 12 h after dose (roughly representing maximum and minimum concentrations during the dose interval) was 47 (13 - 123) and 9.2 (4.4 - 18) mcg/l, respectively.</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>The pharmacokinetic/pharmacodynamic (PK/PD) relationship between rivaroxaban plasma concentration and several PD endpoints (factor-Xa inhibition, PT, aPTT, Heptest) has been evaluated after administration of a wide range of doses (5 - 30 mg twice a day). The relationship between rivaroxaban concentration and factor-Xa activity was best described by an E<sub>max</sub>&nbsp;model. For PT, the linear intercept model generally described the data better. Depending on the different PT reagents used, the slope differed considerably. When Neoplastin PT was used, baseline PT was about 13 s and the slope was around 3 to 4 s/(100 mcgl). The results of the PK/PD analyses in Phase II and III were consistent with the data established in healthy subjects.</p><p><u>Paediatric population</u></p><p>Safety and efficacy have not been established for children and adolescents up to 18 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity, carcinogenic potential and juvenile toxicity.</p><p>Effects observed in repeat-dose toxicity studies were mainly due to the exaggerated pharmacodynamic activity of rivaroxaban. In rats, increased IgG and IgA plasma levels were seen at clinically relevant exposure levels.</p><p>In rats, no effects on male or female fertility were seen. Animal studies have shown reproductive toxicity related to the pharmacological mode of action of rivaroxaban (e.g. haemorrhagic complications). Embryo-foetal toxicity (post-implantation loss, retarded/progressed ossification, hepatic multiple light coloured spots) and an increased incidence of common malformations as well as placental changes were observed at clinically relevant plasma concentrations. In the pre- and post-natal study in rats, reduced viability of the offspring was observed at doses that were toxic to the dams.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:438px"><tbody><tr><td style="vertical-align:top"><p><strong>Active Ingredients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rivaroxaban</p></td><td style="vertical-align:top"><p>2.500</p></td></tr><tr><td style="vertical-align:top"><p><strong>Excipients</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Lactose BP 200</p></td><td style="vertical-align:top"><p>96.500</p></td></tr><tr><td style="vertical-align:top"><p>Avicel PH 101</p></td><td style="vertical-align:top"><p>80.000</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose</p></td><td style="vertical-align:top"><p>8.000</p></td></tr><tr><td style="vertical-align:top"><p>Sodium Lauryl Sulphate</p></td><td style="vertical-align:top"><p>6.000</p></td></tr><tr><td style="vertical-align:top"><p>Croscarmellose Sodium Type-A</p></td><td style="vertical-align:top"><p>6.000</p></td></tr><tr><td style="vertical-align:top"><p>Magnesium Stearate</p></td><td style="vertical-align:top"><p>1.000</p></td></tr><tr><td style="vertical-align:top"><p><strong>Coating Materials</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hydroxypropyl Methyl Cellulose</p></td><td style="vertical-align:top"><p>3.900</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide Pharma Grade</p></td><td style="vertical-align:bottom"><p>1.200</p></td></tr><tr><td style="vertical-align:top"><p>Purified Talc</p></td><td style="vertical-align:top"><p>0.240</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol MW 6000</p></td><td style="vertical-align:top"><p>0.600</p></td></tr><tr><td style="vertical-align:top"><p>Iron Oxide Red</p></td><td style="vertical-align:bottom"><p>0.060</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water BP</p></td><td style="vertical-align:bottom"><p>Qs.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months/2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reel PVC/PE/PVDC</p><p>Each pack contains 10 or 60 film coated tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Feb 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>